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ABSTRACT 
 
As part of our ongoing efforts to find new drug leads against infectious diseases, 
several terrestrial and marine macro- and microorganisms were investigated. Several 
bioactive molecules, presented below, were isolated from these natural products.   
The mass-screening of dozens of marine Actinomycetes was completed and 
several Streptomyces with interesting biological activity profiles identified. A few 
examples are the Streptomyces code H747 and the Streptomyces code H668, a 
bacterium from which a new (5) and two known polyethers, the antimalarial agent K41-A 
(6) and its C-29 analog (7) were isolated.  
Five new six-membered ring cyclic peroxides: plakinastreloic acid A (8), methyl 
plakinastreloate A (9), the C-12 epimers of methyl 13, 14-epoxyplakinastreloate (10 & 
11), and plakinastreloic acid B (12) were isolated from a marine sponge of the genus 
Plakinastrella. Compounds 8 and 9 exhibited antifungal activities against Candida 
albicans (IC50 = 6.5 µg/mL and 3.5 µg/mL, respectively), Aspergillus fumigatus (IC50 = 
4.0 µg/mL and 9.0 µg/mL, respectively) and Cryptococcus neoformans (IC50 = 4.0 
µg/mL and 9.0 µg/mL, respectively). A moderate antimalarial activity against CQ-
resistant and CQ-sensitive strains of Plasmodium falciparum was observed, as well. It 
was also established that 8 possesses anti-HCV (Hepatitis C Virus) activity.  
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Two other compounds were isolated from HCV active methanol extracts of Inga 
fagifiolia (twigs) and Diplostephium rhodendroides (leaves). These compounds were 
identified as 2,3,4,5,6-pentahydroxy-2-(hydroxymethyl)hexanamide (14),  the amide of a 
known molecule and 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-
yl)oxy] pentanoic acid (15). The bioassay-guided approach used for their isolation and 
structure elucidation is reported here. 
 The potential of scCO2 to inactivate bacteria trapped in the gut of oysters was 
studied. It was established that exposing oysters to CO2 at 100 bar and 37 °C for 30 
minutes and at 172 bar and 60 °C for 60 minutes induced 2-log and 3-log reductions in 
the APC loads, respectively. The decrease in the microbial load as a result of treatment 
with scCO2 was found to be significant (P = 0.002). A blind study allowing sensory 
analysis of treated vs. untreated oysters was also completed; no significant difference in 
the physical appearance, smell, or texture was recorded. 
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INTRODUCTION 
 
Each year, millions of lives are claimed by diseases of all sorts. Nine of the top 
ten threats to human life are disease related; the deadliest being coronary heart 
disease, stroke and other cerebrovascular diseases, lower respiratory infections, 
chronic obstructive pulmonary disease, diarrheal diseases, AIDS, tuberculosis and lung 
cancer. Several of the diseases that burden the world population presently are 
extremely old. There are for instance reports of malaria and tuberculosis going back to 
antiquity [1, 2].  Yet after centuries of fight to see to their eradication, many are still 
major public health issues.  
Malaria, for instance, is a leading cause of death and morbidity in third world 
countries; this disease claims the life of a child every 30 seconds. One of the major 
hindrances towards taking full control of this disease is the emergence and rapid 
spread of strains of the parasite that are resistant to major antimalarial drugs currently 
marketed. Tuberculosis (TB), Multi Resistant Staphylococcus aureus (MRSA) 
infections and AIDS are other major infectious illnesses that burden our world. 
Tuberculosis (TB) is a pandemic and the leading cause of death among people 
suffering from AIDS [3]. It is caused by Mycobacterium tuberculosis, which presently 
infects about one third of the world population. One of the major barriers to fully control 
the disease is the emergence of MDR strains; about 450,000 new cases of MDR-TB 
are reported worldwide annually [3].  Like tuberculosis, MRSA which can cause fatal 
2 
 
invasive infections constitutes a serious public health issue faced by countries all over 
the world. MRSA infections are of particular concern in hospital environments. The 
emergence of vancomycin resistant strains is cause for greater concern, as 
vancomycin is currently the drug of choice in the fight against MRSA related infections. 
The incidence of several of these diseases is on the rise. These menaces put an 
unprecedented amount of pressure on the necessity to discover new drugs/drug leads. 
Multidrug resistance is not the only concern that threatens public health today; 
pharmaceutical drug companies facing major problems with their pipelines is another 
matter. As research and development (R&D) spending has grown exponentially over the 
years, a steady decline in the number of NCE approved has been noted instead. It is 
important to point out that combinatorial chemistry had failed to solve this issue. It has 
been speculated that increase in attrition, longer R&D timelines, and increased costs for 
some key R&D components (novel technologies for instance) were, among others, the 
factors that drive R&D costs [4-6]. Because the decline in the number of approved NCE 
had paralleled the reduced interest of pharmaceutical industries in natural products 
related research, several experts believe that there is a correlation between these two 
events [4]. 
Because of the exceptional contribution made, nature stands out in the drug 
discovery arena. According to a recent report [7], of the 974 small molecules new 
chemical entities reported between 1981 - 2006, 63% can be traced to nature, either as 
a natural or a synthetic compound inspired from a naturally occurring molecule (Figure 
0-1). An impressive number of currently marketed antibiotics were derived from 
Actinomycetes.  
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The first project was to screen a set of marine Actinomycetes previously isolated 
by one of our collaborators, namely Dr. Russell Hill - University of Maryland, Center of 
Marine Biotechnology (COMB).  Several bacteria with interesting biological activity 
profiles were identified. One of these bacteria was a streptomyces code H747 which 
crude extract had outstanding anti-MRSA and anti-HIV activities. Four known bioactive 
molecules, three diketopiperazines (1, 2 and 3) and a pyrrolobenzodiazepine (4) were 
isolated from the crude extract of this bacterium. 
   
Another Streptomyces with outstanding bioactivity against the malaria parasite 
Plasmodium falciparum and MRSA was identified during a different screening program. 
The bioassay-guided approaches used for the isolation of anti-infective metabolites from 
this bacterium and several other marine and terrestrial organisms are presented below.   
 
 
4 
 
 
Figure 0-1.  All small molecule new chemical entities, 01/1981-06/2006, by sources 
(N974) 
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Background: As multidrug-resistant (MDR) pathogens continue to emerge, there 
is a substantial amount of pressure to identify new drug candidates. Carboxylic 
polyethers, also referred to as polyether antibiotics, are a unique class of compounds 
with outstanding potency against a variety of critical infectious disease targets including 
protozoa, bacteria and viruses. The characteristics of these molecules that are of key 
interest are their selectivity and high potency against several MDR etiological agents.  
Objective: Although many studies have been published about carboxylic 
polyether antibiotics, there are no recent reviews of this class of drugs. The purpose of 
this review is to provide the reader with an overview of the spectrum of activity of 
polyether antibiotics, their mechanism of action, toxicity and potential as drug 
candidates to combat drug-resistant infectious diseases.  
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Conclusion: Polyether ionophores show a high degree of promise for the 
potential control of drug-resistant bacterial and parasitic infections. Despite the long 
history of use of this class of drugs, limited medicinal chemistry and drug optimization 
studies have been reported, thus leaving the door open to these opportunities in the 
future.  
Scifinder and PubMed were the main search engines used to locate articles 
relevant to the topic presented in this review. Keywords used in our search were 
specific names of each of the compounds presented in the review, as well as more 
general terms such as polyethers, ionophores, carboxylic polyethers and polyether 
antibiotics. 
 
1.  Introduction 
Polyether antibiotics or carboxylic ionophores [8, 9] represent a unique class of 
compounds reported as potent antibiotics. They belong to the larger family of naturally 
occurring ionophores. First used in 1967, the term ionophore refers to the molecule’s 
ability to bind a metal ion and facilitate its transport across cellular membranes. This 
chemo-physiological property has made polyether ionophores a useful tool in the study 
of cation transport mechanisms and has been the rationalization for their biological 
activities [9, 10].  
Polyether antibiotics are believed to affect their targeted cells by modification of 
the permeability of cellular membranes to cationic metal species. Polyether ionophores 
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possess distinctive structural features that are crucial to their ability to interact with 
metal species. These features include an exterior alkyl backbone that confers their 
lipophilic characteristics, and an oxygen-rich internal cavity that can bind metal ions [8, 
11, 12].  
Naturally occurring ionophores are grouped into three categories with regard to 
the mechanism through which membrane permeability is altered. The first group is the 
mobile carriers that bind the metal species in an internal polar cavity, thus shielding their 
charge. The second group is the quasi-ionophores. These molecules form trans-
membrane hydrophilic channels that permit the flow of metal ions. The last group 
consists of the neutral ionophores that facilitate the diffusion of cations across 
membranes according to the membrane potential [8, 13].  
Naturally occurring carboxylic ionophores are relatively high in molecular weight, 
500 – 1,000 amu, and are lipid soluble compounds that display a high affinity for cations 
such as K+, Na+, Ca2+, thus yielding  mobile cation complexes that can freely travel 
across biological membranes [9]. With the exception of lasalocid, (16) all naturally 
occurring carboxylic ionophores possess an affinity for Na+ and K+. Lasalocid (16) forms 
dimers and divalent complexes with Ca2+ and Mg2+. This metal complex formation 
results in a paracyclic complex as a result of the head-to-tail hydrogen bonding.  
The normal physiologic steady state of most living cells is dependent on the 
establishment of intracellular and extracellular concentration gradients of Na+ and K+ 
[14]. These ion concentration gradients are essential for cell function. Carboxylic 
ionophores can easily penetrate cellular membranes owing to their lipophilic properties 
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[14-16] and perturb the intracellular cation balance. Carboxylic ionophores thus present 
significant biological interests not only for their therapeutic utility but also for the 
possibility of using these chemo-physiological dynamics in combination with traditional 
or current therapeutics [10, 16, 17].  
A total of 53 bacteria of the Streptomycetaceae family are reported to produce 
carboxylic ionophores. These microorganisms belong to three genera, Streptomyces, 
Actinomadura and Dactylosporangium. Streptomyces sp. are the main producers of 
these types of compounds and ~ 50% of the known carboxylic ionophores are derived 
from two Streptomyces species (Streptomyces hygrocropicus and Streptomyces albus) 
[9]. Industrially, these highly active molecules are produced via fermentation by 
microorganisms; the cost of production is generally low [10, 18, 19]. 
2. Biological activity 
Polyether antibiotics show a broad spectrum of bioactivity including antibacterial, 
antifungal, antiparasitic, antiviral and tumor cell cytotoxicity. In addition to the previously 
mentioned biological activities, several studies have investigated the herbicidal [20] and 
anti-inflammatory activities [21] of these molecules, as well as their effect on the CNS 
and immunoregulatory systems (Table 1-1) [22, 23]. 
2.1 Antibacterial 
The antibacterial potential of carboxylic ionophores is widely documented; 
reports on the discovery of these compounds typically mention their activity against 
some fungi and Gram-positive and Gram-negative bacteria. From these reports, it can 
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be gathered that carboxylic polyethers are molecules of outstanding potency against 
numerous pathogenic bacteria (drug-sensitive and drug-resistant). The fact that their 
potency against serious threats such as MRSA and VRE rivals that of clinically used 
drugs such as vancomycin and oxacillin, adds to their potential utility. At this point, it is 
difficult to fully assess the true value of these molecules as potential antibacterial 
therapeutic agents simply because none of these molecules has been tested on animal 
models.  
2.1.1 Activities against drug-sensitive bacterial strains 
A similar inhibitory pattern, namely, a strong selectivity towards Gram-positive 
bacteria, emerged from reports on the antibacterial potential of carboxylic polyethers [9, 
11, 15, 16, 19, 24-28]. Monensin (17), narasin (18), salinomycin (19), nigericin (20), 
lenoremycin (21), septamycin (22), carriomycin (23), X-14766A (24), noboritomycin A 
(25), alborixin (26), ionomycin (27), A23187 (28), X-14547A (29), lysocellin (30) and 
lasalocid (16) were all evaluated against eight Gram-positive bacteria, seven Gram-
negative bacteria, and four fungal species. All but ionomycin (27) showed potent activity 
against Gram-positive bacteria (MIC varying in the range 0.006 – 12.5 µg/mL). In 
contrast, not one of these compounds displayed activity against the tested Gram-
negative bacteria (MIC > 100 µg/mL). Several other carboxylic ionophores are reported 
as having a similar biological activity profile against Gram-negative and Gram-positive 
bacteria. These are grisorixin (31) [18], ionomycin (32) [27], octacyclomycin (33) [25], X-
14931A (34) [28], dianemycin (35) [16], ionomycin B (36) [19] and C (37) [19], antibiotic 
6016 (38) [26], inostamycin (39) [29], inostamycin B (40) [29] and  leuseramycin (41) 
[30]. 
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Not all carboxylic polyethers show this selectivity towards Gram-positive 
bacteria. Compounds such as septamycin (22), noboritomycin A (25) and B (42) 
stand out for their ability to target not only Gram-positive bacteria but also Gram-
negative bacteria. The reported MIC of septamycin (22) against Escherichia coli was 
0.1 µg/mL [31]. Noboritomycin A (25) and B (42) inhibited the growth of Neisseria 
pharyngi with an MIC of 0.01 µg/mL [32]. The MIC of mutalomycin (43) against the 
same pathogen was 0.3 µg/mL [33]. Not all carboxylic ionophores possess significant 
activity against Gram-positive bacteria. For example, laidlomycin (44) was reported 
as inactive against Staphylococcus aureus [34]. Although in general anaerobic 
bacteria are more resistant to carboxylic polyethers, a few Clostridium sp, 
Eubacterium sp, Propionibacterium sp and Peptococcus sp are reported as 
extremely sensitive to compounds such as nigericin (20), monensin (17), dianemycin 
(35), lysocellin (30), lasalocid A (16) and A23187 (28) with MIC values as low as 
0.049 µg/mL in many cases [9]. Carboxylic ionophores have a broad spectrum of 
activity against Gram-positive but not Gram-negative bacteria. Guyot et al. [35] 
attributed this overall differential selectivity to the presence of an outer membrane in 
Gram-negative bacteria. The outer membrane is believed to be impermeable to 
hydrophobic compounds. These authors came to this conclusion while using 
autoradiography; they could show that only Bacillus cereus, not E. coli, could 
incorporate the radiolabeled calcimycin (28) [36].  
2.1.2 Activities against multidrug-resistant strains of bacteria 
Carboxylic polyethers were reported as potent agents against a variety of 
MDR strains of pathogenic bacteria. Lycocellin (30), for instance, was reported as 
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active against a streptomycin-, erythromycin-, chloramphenicol and penicillin-
resistant strain of S. aureus , MIC 4 µg/mL [15]. The MIC for the Na+ salt of the 
antibiotic No 6016 (38) against a similar strain was reported to be 1.56 µg/mL [26]. 
Noboritomycin A (25) and B (42) were also reported as being active against several 
resistant strains: penicillin-resistance strains of S. aureus, MIC 0.01 µg/mL, 
tetracycline-resistance strains of Micrococcus sp, MIC 0.01 µg/mL, aminoglycoside-
resistant strains of Streptococcus faecalis, MIC 0.01 µg/mL and macrolide-resistant 
strains of Sarcina lutea , MIC 0.01 µg/mL [32]. 
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Table 1-1. Overview of reported bioactive naturally occurring polyethers (from 1967-1994*), sources, and their 
reported in vivo and in vitro testings 
 
Name (acronyms), 
molecular formula, 
molecular weight 
 
Organism from which 
it was isolated 
 
In vitro activities  
 
Tested in vivo  Availability  
of crystal 
structure 
 
Discove
ry (year, 
journal, 
authors
) 
 
Lasalocid A (16), 
C34H54O8 
590.8 
 
Streptomyces 
lasaliensis 
NRRL 3382 
 
Antiparasitic [37-39], 
antiviral [40], antibacterial 
[9, 41], 
antifungal [9, 42] 
Antimicrobial and/or 
antiparasitic effect 
[43-47] 
 
[48]  [48] 
Monensin A (17), 
C36H62O11 
670.9 
 
Streptomyces 
cinnamonensis ATCC 
15413 
 
Antiparasitic [37, 49-53], 
antiviral [40, 54], 
antibacterial [55, 56], 
antifungal [9], 
antiproliferative/apoptotic
[55, 57]  
Antimicrobial and/or 
antiparasitic 
effect [37, 44, 58], 
immunoregulatory 
effect [59], 
cardiovascular 
effect [60, 61], 
antiviral [62] 
 
[63]  [63] 
 
Narasin A (18), 
C43H72O11  
765.0 
 
Streptomyces 
aureofaciens NRRL 
5758 
 
Antibacterial [9, 56, 64], 
antifungal [9] , 
antiparasitic [37, 51, 52] 
 
Antiviral [62], 
antiparasitic [64] 
 
 
 [64] 
Salinomycin (19), 
C42H70O11 
751.0 
 
Streptomyces 
lasaliensis 
Antiparasitic [38, 51, 52], 
antiviral [40], antibacterial 
[9, 56], 
antifungal [9] 
 
Antimicrobial and/or 
antiparasitic 
effects 
,immunoregulatory 
effect [40, 44, 47, 58, 
65-68] 
 
 [69] 
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Nigericin (20), 
C40H68O11 
725.0 
 
Streptomyces 
hygrocopicus 
 
Antiparasitic [37, 53, 70], 
antiviral [40, 71, 72], 
antibacterial [9], 
antifungal [9], 
antiproliferative/apoptotic  
[57, 73] 
 
Antimicrobial and/or 
antiparasitic effect 
[37, 74-76], effect on 
CNS tissues [23, 77], 
antitumor [73], 
antiherbicidal/insecti
cidal [20], Antiviral 
[62] 
 
 
[78] [78] 
Lenoremycin (21), 
C47H77O13Na, 
873.1 
 
 Antibacterial, antifungal 
[9, 39] 
  [79]  [79] 
 
Septamycin (22), 
C48H82O16 
 915.2 
 
Streptomyces 
hygroscopicus 
NRRL 5678 
 
Antibacterial, antifungal 
[9, 31], 
antiproliferative/apoptotic 
[31] 
 
Antiparasitic[16, 31], 
antiviral [31] 
 
 [31] 
Carriomycin (23), 
C47H80O15 
885.2 
 
 
Streptomyces 
hygroscopicus 
antiproliferative/apoptotic
[57],  
antibacterial, antifungal 
[80] 
 
Antimicrobial and/or 
antiparasitic effect 
[72, 81] 
 
[82] [82] 
Antibiotic X-14766A 
(24), 
C43H62ClO14 Na 
861.4 
. 
 
Streptomyces 
malachitofuscus 
subsp. downeyi 
Antibacterial antifungal 
[83] 
 [84] [84] 
Noboritomycin A (25), 
C43H63O14Na 
827.0 
Streptomyces 
Noboritoensis NRRL 
8123 
 
Antibacterial [32] Antibacterial [32]   [32] 
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Alborixin (26), 
C48H84O14  
885.9 
 
Streptomyces albus Antibacterial [9], antiviral 
[85], antiparasitic [51, 52, 
86], 
anticocicidal [50] 
 
Antimicrobial and/or 
antiparasitic 
effect [37, 39, 87], 
cardiovascular effect 
[18] 
 
[88]  [88] 
 
Ionomycin (27), 
C41H70CaO9  
747.1 
 
Streptomyces 
conglobatus ATCC 
31005 
 
Antiparasitic [51], 
antibacterial, antifungal 
[9, 89],  
antiproliferative/apoptotic 
[90, 91] 
Immunoregulatory 
effect [92-96], 
effect on CNS 
tissues [22] 
 
  [89] 
Calcimycin (A23187) 
(28), 
C29H37N3O6  
523.6 
Streptomyces 
Chartreusensis 
 
Antiparasitic [51], 
antibacterial, 
antifungal [9, 36] 
 
 [97] [97] 
X14547 A (29)  
 
 Antiparasitic [51]    [98] 
 
Lysocellin (30), 
C34H59O10 Na.1/2H2O 
659.8 
 
Streptomyces cacaoi antiproliferative/apoptotic 
[57], antibacterial [15] 
Antimicrobial and/or 
antiparasitic effect 
[81] 
 
[99] [99] 
Grisorixin (31), 
C40H68O10 
709.0 
 
Streptomyces griseus  
 
Antiparasitic [51], 
antibacterial [18]  
 
Antimicrobial and/or 
antiparasitic 
effect [52], 
cardiovascular 
effect [100-102] 
 
[35] [35] 
Lonomycin A (32), 
C44H76O14 
829.1 
 
Streptomyces 
hygrocopicus  
Antibacterial [27], 
antiproliferative/apoptotic 
[57], 
antiparasitic [37, 51] 
 
Antimicrobial and/or 
antiparasitic effect 
[103], 
cardiovascular effect 
[104] 
 [27] 
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Octacyclomycin (33), 
C52H88O19  
1,016 
Streptomyces sp. Antibacterial, antifungal, 
antiproliferative/apoptotic 
[25] 
 
  [25] 
X-14931A (34), 
C40H66O11  
723.0 
 
 Antibacterial [28, 105], 
antifungal [28] 
Antiparasitic [28] [28]  [28] 
 
Dianemycin (35), 
C47H78O14 
867.1 
 
 Antiviral [40], 
antibacterial [16], 
antiproliferative/apoptotic 
[57] 
  
 
Anti-inflammatory 
[21] 
[106]  [106] 
Lonomycin B (36), 
C44H75O14Na 
851.1 
 
Streptomyces 
ribosidificus TM-481 
 
Antibacterial and 
antifungal [19] 
   [19] 
 
Lonomycin C (37), 
C43H73O14Na 
837.0 
 
Streptomyces 
ribosidificus TM-481 
 
antiproliferative/apoptotic 
[57], antibacterial [19] 
   [19] 
 
Antibiotic 6016 (38), 
C46H78O16 
887.1 
 
Streptomyces albus Antibacterial, 
antiparasitic [26] 
 [107]  [107] 
 
 
 
Inostamycin (39), 
C38H68O11, 
700.9 
 
Streptomyces sp. 
MH816-AF15 
antiproliferative/apoptotic 
[24], antibacterial [29] 
 [108]  [108] 
 
Inostamycin B (40), 
C37H66O 11  
686 M+ 
Streptomyces sp. 
MH816-AF15 
Antibacterial, antifungal 
[29] 
   [29] 
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Leuseramycin (41), 
C47H78O13 
851.1 
Streptomyces 
hygroscopicus 
TM-531 
 
Antibacterial, antifungal 
[30] 
   [30] 
 
Noboritomycin B (42), 
C44H65O14Na 
841.0 
 
 
Streptomyces 
Noboritoensis NRRL 
8123 
 
Antibacterial [32] Antiparasitic [32]   [32] 
 
Mutalomycin (43) 
S-11743 
C 41 H 69 O 12 Na, 
755.0 
 
Streptomyces mutabilis  Antiparasitic [33]    [33] 
 
Laidlomycin (44) AB-
78 
C37H62O12 
698.9 
 
Streptoverticillum 
eurocidium 
Antiproliferative/apoptotic 
[34, 57] 
antibacterial [34, 41, 56], 
antiviral [85] 
 
   [34] 
X-14885 (45 ), 
C27H31N2O7 Na·H2O 
536.57 
 
Streptomyces sp. X-
14885 
Antibacterial, antifungal 
[109] 
 [109]  [109] 
 
Cationomycin A (46), 
C45H70O15  
850.5 
 
Actinomadura azurea 
sp Nov 
Antiparasitic [51], 
antibacterial [9, 110] 
Antiparasitic [110]   [110] 
 
AntibioticX-206 (47), 
C47H82O14 
870 
 
Streptomyces sp Antiparasitic [111] 
 
Antimicrobial and/or 
antiparasitic 
effect [111-113] 
cardiovascular effect 
[114] 
 
[115]  [115] 
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K-41-A (48), 
C48H82O18 
947.2 
Streptomyces 
gypseum 
NRRL 11168 
 
Antiparasitic [116], 
antibacterial [117] 
Antiherbicidal/insecti
cidal [118] 
[119] [117] 
Hawaiimycin I (49), 
C36H64O12Na 
711.4 
 
Streptomyces sp. Antiparasitic [120]   [120] 
Maduramicin (50) 
C47H80O17 
917.1 
 
Actinomadura rubra Antibacterial  [121], 
antiparasitic [52, 122] 
Antimicrobial and/or 
antiparasitic effect 
[44, 87, 123] 
 
 
 
 [121] 
 
CP-82,009 (51), 
C49H84O17  
945.2  
 
Actinomadura sp. 
(ATCC 53676) 
Antibacterial [124] Antiparasitic [124] [124]  [124] 
 
CP-84,657 (52), 
C45H78O14 
843.1 
 
Actinomadura sp. Antibacterial [93] Antiparasitic [93]  [93]  [93] 
CP-80,219 (53), 
C47H78O14  
867.1 
 
Streptomyces 
hygroscopicus  
Antibacterial [125] Antiparasitic [125] [125]  [125] 
 
Kijimicin (54), 
C37H 64O11  
684.9 
 
Actinomadura sp 
MI215-NF3 
Antibacterial [126], 
antiviral[40, 127, 128], 
antiparasitic [129] 
 
 
Antiparasitic  [126]  [126]   [126] 
Endusamycin (55), 
C47H77O14Na  
889.1 
 
Streptomyces endus 
subsp. aureus 
(ATCC39574) 
 
Antibacterial [130]   Antiparasitic [130]  [130]  [130] 
X-14868A (56 ), Nocardia X-14868 Antibacterial,  Antiparasitic [131]    [131] 
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C47H80O17  
917.13 
 
antifungal  [131] 
 
X-14868B ( 57 ), 
C48H82O17  
931.2 
 
Nocardia X-14868 Antibacterial,  
antifungal [131]   
Antiparasitic [131]     [131]   
 
SF 2361 (58), 
C48H82O16 
915.2 
 
Actinomadura sp. SF-
2361 
Antiviral [40], 
antiproliferative/apoptotic 
[57] 
   [132] 
SF2324 ( 59 ), 
C52H88O19  
1017.2 
 
 Antiviral [40, 43], 
antiproliferative/apoptotic 
[57] 
 
   [133] 
 
SF 2487 ( 60), 
C42H63O12Na 
805 
 
Actinomadura sp 
SF2487  
 
Antibacterial [134] 
antiviral [40, 134],  
antiproliferative/apoptotic 
[57], 
antiparasitic [129] 
 
 [134] [134] 
Monensin B (61) 
C35H60O11 
656 
Streptomyces 
cinnamonensis ATCC 
15413 
 
Antiviral [9]     [112] 
A 28695B (62) 
C48H82O17 Na 
953.5 
 
Streptomyces albus 
NRRL 3883 
 Antiparasitic [16], 
Antiviral [62] 
 
   [16] 
A-204 (63) 
C49H84O17 
945.2 
Streptomyces albus 
 Antiviral [9]  [135]  [135] 
Deoxy-(0-8)-
salinomycin (64), 
Streptomyces albus 
ATCC 21838 
Antibacterial, antifungal 
[114] 
 [114] [114] 
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C42H70O10  
734 
 
CP-91,243 (65), 
C50H83O18Na 
995.1 
 
Actinomadurra 
roseorufa 
Antibacterial, 
antiparasitic, 
antifungal  [136] 
 
    
 
[136] 
CP-120,509 ( 66 ), 
C45H76O17  
889.1 
 
Actinomadura 
roseorufa 
Antibacterial,  
antifungal [137]  
Antiparasitic 
 [137] 
 
[137] [137]  
Iso-lasalocid ( 67 ), 
C34H54O8 
590.8 
 
Streptomyces 
lasaliensis 
Antibacterial [138] 
 
 [138]   [138] 
20-Deoxynarasin 
(68), 
C43H72O10  
748 
 
Streptomyces 
aureofaciens 
NRRL 11181 
 
Antibacterial, antiviral 
[82] 
Antiparasitic [82]  [82] 
20-deoxy-epi-17-
narasin ( 69 ) 
C42H70O10 
735.0 
 
Streptomyces 
aureofaciens 
NRRL 11181 
 
Antibacterial, antiviral 
[82] 
Antiparasitic [82]   [82] 
 
Moyukamycin (70), 
C47H75O13Na 
871 
 
Streptomyces 
hygroscopicus 
TM-581 (FERM-BP 
274) 
 
Antibacterial, antifungal 
[139] 
 
  [139] 
(Deoxy-(O-8)3)-epi-
l7- 
salinomycin (71), 
C42H70O10  
Streptomyces albus 
ATCC 21838  
Antibacterial, antifungal 
[114] 
Hypertention [140] [114] [114] 
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735.0 
 
CP-54,883 (72), 
C41H61O12Cl2  
838 
 
Actinomadura routienii 
Huang sp. 
Antibacterial, 
antiparasitic [141] 
 
  
  [141] 
X-14868C (73), 
C46H78O17 
903.1 
 
Nocardia X-14868 Antibacterial,  
antifungal [131] 
 
Antiparasitic [131] 
 
  [131] 
 
X-14868D (74), 
C47H80O17 
917.1 
 
Nocardia X-14868 Antibacterial,  
antifungal [131] 
  [131] 
Abierixin (75), 
C40H68O11  
725.0 
Streptomyces albus 
NRRL B-1865 
 
Antibacterial,  
antifungal [142] 
 
Antiparasitic, 
[142] 
 [142] 
Martinomycin (76), 
C49H84O17  
967.5 
Streptomyces salvialis Antibacterial [143] Antiherbicidal/insecti
cidal [143] 
 [143] 
Portmicin (77), 
C44H76O14  
828 
Nocardiopsis sp No. 
6270  
 
Antibacterial,  
antifungal [144] 
 
Antiparasitic [144] 
 
 [144] 
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X-14667 A (78), 
C44 H88NO12Na 
826.0 
Streptomyces 
cinnamonensis 
Antibacterial, antifungal 
[145] 
  [145] 
 
X-14667 B (79), 
C45H70NO12Na 
840.0 
Streptomyces 
cinnamonensis 
Antibacterial, antifungal 
[145] 
  [145] 
CP-96,797 (80), 
C47H80O17 
917.1 
Streptomyces sp Antibacterial, antifungal, 
[146] 
 
Antiparasitic [146] 
 
[146] 
 
[146] 
 
UK-58, 852 (81) 
C52H88O18 
1000 
Actinomadura 
roseorufa Huang sp. 
nov., ATCC 39697 
 Antiparasitic, 
antibacterial [147] 
 [147] 
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The sodium salt of septamycin (22) was also reported as effective against 
several MDR bacterial strains. These included a penicillin-resistant strain of 
Staphylococcus aureus (MIC 0.31 µg/mL), a tetracycline-resistant strain of 
Micrococcus sp. (MIC 0.31 µg/mL), an aminoglycoside-resistant strain of 
Streptococcus faecalis (MIC 0.1 µg/mL) and finally, a macrolide-resistant strain of 
Sarcina lutea (MIC 0.31 µg/mL) [31].  In 2007, Yoo et al. [56] published a report on the 
potential of several carboxylic polyethers, namely, laidomycin (44), monensin (17), 
salinomycin (19) and narasin (18), to inhibit VRE and MRSA [56]. In the case of MRSA, 
the MIC of these compounds varied from 0.5 to 4 µg/mL; in the case of VRE, it varied 
from 8 to 16 µg/mL against. Narasin (18) was the most potent compound. All these 
compounds were more potent than vancomycin and oxacillin. The MIC of vancomycin 
against VRE was 64 µg/mL and that of oxacillin against MRSA was > 32 µg/mL [56]. 
2.2. Antifungal  
In general, fungi are more resistant to carboxylic ionophores. Several authors 
have reported MIC values greater than the highest tested concentration [9, 15, 18, 25, 
27]. There are some exceptions: several species of fungi, namely, Paecilomyces 
variotii, Candida albicans, Saccharomyces cerevisiae and Penicillium digitatum were 
reported as moderately sensitive to some carboxylic polyethers. These included for 
example, grisorixin (31) [18], monensin (17) [9], narasin (18) [9], salinomycin (19) [9], 
lenoremycin (21) [9], carriomycin (23) [9], alborixin (26) [9], A23187 (28) [9], dianemycin 
(35) [11] , lysocellin (30) [9], X-14931A (34) [105] and leuseramycin (41) [30] , with MIC 
values varying in the range of 20 – 100 µg/mL. P. variotii, C. albicans, S. cerevisiae and 
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P. digitatum were quite sensitive to several other carboxylic polyethers (lysocellin (30) 
[9], A23187 (28) [9], lenoremycin (21) [9] and nigericin (20) [9]). The MIC values for 
these compounds were < 2 µg/mL. More recent studies about the antifungal capacities 
of carboxylic ionophores have focused on opportunistic infections caused by 
Pneumocystis carinii [46]. Lasalocid (16) and nigericin (20), two common carboxylic 
ionophores, were found to possess a significant inhibitory effect on the growth of P. 
carinii in vitro [42, 46]. 
2.3 Antiparasitic 
2.3.1 Plasmodium sp 
The emergence and spread of resistant strains of the malaria parasites to several 
of the antimalarial drugs marketed at present, especially CQ, constitute a serious 
public health threat [148-151]. To address this issue, combination therapy, i.e., the 
simultaneous use of more than one drug known to have different mechanisms of action 
(MOAs) is important. Such an approach slows the development of resistance to 
individual drugs, thus limiting the spread of resistant strains [152]. The success of 
combination therapy is dependent on the availability of molecules with unique MOA. In 
recent years, a great deal of effort has been dedicated to the discovery of new 
antimalarial agents. Among the potential candidates reported thus far are carboxylic 
ionophores. From the reports we gathered, it emerges that these molecules stand out 
as potential antimalarial drug candidates for several reasons.  
First, carboxylic ionophores are potent in vitro antimalarial agents, with IC50 
values in the nanomolar and picomolar range [51, 111]. Carboxylic ionophores are 
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typically organized into three subclasses. The first category includes compounds 
specific to monovalent cations such as alborixin (26), lonomycin A (32), nigericin (20), 
grisorixin (31), narasin A (18), salinomycin (19), cationomycin (46) and monensin A 
(17). The second group includes molecules that are specific to divalent cations; few 
examples are calcimycin (28), X14885 A (45) and X14547A (29) (Figure I-1). The third 
category includes molecules that show no particular specificity; among these are 
lysocellin (30), lasalocid A (16) and ionomycin (27). Of these three subgroups, 
carboxylic ionophores specific to monovalent cations are reported as the most potent 
with IC50 values in the range of 0.6 – 1.5 ng/mL. Cationomycin (46), IC50 = 35 ng/mL, is 
an exception.  
Second, carboxylic ionophores are also reported to have potent activity in vivo. 
The in vivo antimalarial potential of alborixin (26), ionomycin A (32), nigericin (20), 
narasin (18) and monensin A (17) was recently evaluated using rats infected with 
Plasmodium chabaudi and Plasmodium vinckei petteri [37] . Alborixin (26), ionomycin 
A (32), nigericin (20), narasin (18) and monensin A (17) showed significant in vivo 
antimalarial activity, decreasing the parasitemia by ≥ 70% by day 5 in P. chabaudi and 
P. vinckei petteri infected mice. Overall, the ED50 varied between 0.4 and 4.1 mg/kg. 
Carboxylic ionophores that are specific to monovalent ions including alborixin (26), 
lonomycin A (32), nigericin (20), narasin (18) and monensin A (17) seemed to be the 
most potent. The therapeutic index using the intraperitoneal route of administration for 
lonomycin A (32), nigericin (20), narasin A (18), monensin A (17) and lasalocid A (16) 
ranged from 2 to 6 [37]. A similar study was completed by Adovelande and Schrevel 
who assessed the in vivo antimalarial activity of monensin (17) and nigericin (20) on P. 
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vincke petteri infected mice. The ED50 and ED90 values for monensin (17) were 1.1 and 
3.5 mg/kg, respectively. The ED50 and ED90 for nigericin (20) were 1.8 and 4.6 mg/kg, 
respectively. Monensin (17) seemed more effective at curing mice than nigericin (5); 
100% of mice that received 10 mg/kg of monensin (17) were cured. Only one-third of 
mice that received a similar dose of nigericin (20) were cured [74]. 
Third, according to several studies, these molecules act in a selective manner. 
The threshold of toxicity varies from one subclass of carboxylic ionophores to the next. 
Gumila et al. [51] reported the in vitro differential ionophore activity between P. 
falciparum and normal mammalian cells (Human Jurkat lymphoblasts and U937 
macrophage cell lines). It appeared that mammalian cells were only affected by 
compounds such as nigericin (20), alborixin (26), lonomycin (32), narasin (18) and 
monensin (17) at concentrations that are significantly (i.e., at least 35-fold) higher than 
the IC50 against the malarial parasite [51]. While the IC50 of narasin (3), monensin A 
(17) and nigericin (20) against the malaria parasite varied in the range 0.6 – 1.5 ng/mL, 
the LD50 against against U937 macrophage, varied between 23.5 and 305 ng/mL. The 
LV50, LD50 against Jurkat lymphoblast, varied between 45 and 500 ng/mL [51]. Gumilla 
et al. [37] assessed the acute and subacute toxicity of these compounds using rats 
infected with P. chabaudi and P. vinckei petteri and determined that alborixin (26), LD50 
= 1 mg/kg, was the most toxic. Overall, carboxylic ionophores such as alborixin (26), 
lonomycin (32), nigericin (20), narasin (18) and monensin A (17) that are specific to 
monovalent ions appeared to be more toxic; the reported LD50 values for those 
molecules were in the range 4 - 30 mg/kg. The LD50 values for polyethers specific to 
divalent metal ions on the other hand varied in the range of 30 – 80 mg/kg [37].  
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Fourth, two carboxylic ionophores were reported to be significantly more potent 
than CQ. Adovelande and Schrevel assessed the antimalarial activity of monensin (17) 
and nigericin (20) alongside that of CQ and showed that in vitro, these were 25- and 
30,000-fold more potent, respectively [74]. 
Fifth, several carboxylic ionophores were recently reported as having outstanding 
activity against chloroquine-resistant strains of P. falciparum. Otoguro et al. [111, 153] 
published two reports in 2001 and 2002 in which the effects of several carboxylic 
ionophores were evaluated against chloroquine-resistant and sensitive strains of P. 
falciparum alongside several drugs marketed at present. These antimalarial agents 
were artesunate, artemisin, CQ, pyrimethamanine, amodiaquine, quinine and 
trimethoprim. These studies revealed that carboxylic ionophores such as X-206 (47), 
lonomycin A (32), nigericin (20), narasin (18), salinomycin (19), dianemycin (35), 
monensin (17) and lysocellin (30) were extremely potent against CQ-resistant strains of 
P. falciparum with IC50 values varying in the range 0.15 – 6.4 nM (most potent). These 
molecules seemed to be more potent than the standard drugs mentioned earlier. The 
IC50 values for these drugs varied from 7.6 to values > 100,000 nM. Artemether (IC50 = 
7.6 µg/mL) was the most potent of these standard compounds. The cytotoxicity against 
mammalian cells, a human diploid embryonic cell line, was also assessed. Lasalocid A 
(16), octocyclomycin (33) and X-206 (47) displayed high selectivity indexes. The 
highest selectivity index was that of X-206 (47), that is, 3,673 against the CQ-resistant 
strain and 1,080 against the CQ-sensitive strain. These compounds showed higher 
potency and selectivity towards CQ-resistant strains when compared to CQ-sensitive 
strain [111]. Lastly, these authors performed a comparative assessment of the in vivo 
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effect of X-206 (47), artesunate and artemether in Plasmodium berghei infected mice. 
X-206 (47) showed a narrow therapeutic window and had an ED50 = 0.53 mg/kg but 
this compound was toxic at 3 mg/kg. In 2002, these authors reported another 
compound, K-41 (48), as active in vitro against a CQ-resistant strain of P. falciparum. 
K-41 (48) (IC50 = 8.5 nM) showed an activity similar to that of artemether and 
artesunate and was more potent than artemisinin, CQ and pyrimethamine. K-41 (48) 
had a moderate selectivity index in vivo; it was active orally against the CQ-resistant 
strain used; the ED50 (7.0 mg/kg) was close to that of artemether, CQ and artesunate. 
As far as acute toxicity of K-41 (48) is concerned, an LD50 > 100 mg/kg was reported 
[153].  
Finally, carboxylic ionophores are believed to affect the malaria parasite by 
means of a mechanism that is distinct from that of drugs available at present. It is 
important to point out that there is some conjecture over this subject. Adovelande and 
Schrevel believe that the mechanism of action of carboxylic ionophores is similar to 
that of CQ [74]. The latter acts by increasing the internal pH of the food vacuole and by 
binding to ferriprotoporphyrin, thus preventing its crystallization into hemozoin. 
Hemozoin will then accumulate to a toxic level inside the vacuole [74, 154, 155]. It is 
generally accepted that carboxylic ionophores act via anti-transport of cation with H+ 
after inserting themselves in cellular membranes, acting as ion channels. According to 
Adovelande and Schrevel, this anti-transport of cations with H+ will result in the 
alkalination of the food vacuole of the parasite in a similar manner as CQ [74]. Gumilla 
et al. [51] have a different point of view. According to these authors, the anti-transport 
of cations with H+ cannot justify the outstanding potency of these compounds, for the 
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simple reason that changes that occur in the plasma membrane of infected 
erythrocytes reduce the efficiency of ion shuttling across the membrane. These authors 
believe that carboxylic ionophores are completely internalized [51, 156]. Once inside 
the cell and in close proximity with the parasite, they can inhibit its development either 
by altering its ion content or by disturbing the pre-established ionic gradient between 
the host and parasite cytosol [51]. The parasite is reportedly more sensitive during the 
shizont stage [37]. 
A polyether isolated from the marine Streptomyces sp. H668 and named 
hawaiimycin-I (49)  [120] reinforced the critical role of certain key structural features 
including the terminal carboxylic group on the bioactivity of carboxyl ionophores. 
Hawaiimycin-I (49) is close structurally to a set of carboxylic ionophores reported as 
potent antimalarial [37, 153], that is, monensin A (17 ), K-41 (48), nigericin (20), 
lonomycin (32) and grisorixin (31). These molecules share a unique skeleton: five 
interconnected tetrahydrofuran and pyran rings. The key difference between 
hawaiimycin-I (49), established to have only a weak antimalarial activity (IC50 = 100 – 
200 ng/mL against P. falciparum) [120], and these molecules is the absence the 
terminal carboxylic group. Crystal structures of this type of compounds reveal that the 
terminal carboxylic moieties can either be implicated in ion coordination or be involved 
in hydrogen bonding with distant OH groups [8, 11].  
Toxicity concerns remain the primary hindrance in the development of carboxylic 
polyethers into antimalarial drugs. Apart from this issue, it can be gathered from the 
literature that carboxylic polyethers posses a great potential as antimalarial drug 
candidates and leads for further optimization. Carboxylic polyethers owe their 
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outstanding potency, in vitro and in vivo, to their unique MOA. Studies published by 
Gumilla et al. [37] illustrate that it is possible through semisynthetic modification of 
these molecules to generate better drug candidates. These authors reported that the 
therapeutic index could be improved in the case of monensin (17) and lasalocid A (16); 
the therapeutic index of monensin A (17)  is 5 p.o. but that of its synthetic analog, 
monensin A methyl ether, is 12 i.p. The therapeutic index of lasalocid A (16) is 3.3 i.p. 
but that of its analog, 5-bromo lasalocid A, is 22 i.p. [37, 65, 123, 157]. 
2.3.2 Eimeria sp 
Eimeria sp are apicomplexan protozoan parasites and etiological agents of 
coccidiosis, a disease affecting cattle and poultry. In an attempt to control these 
diseases, anticoccidial drugs are generally added to the feed of these animals. Several 
carboxylic polyethers are among the drugs that are now approved for use as control 
therapeutics for coccidiosis. The first approved application of veterinary carboxylic 
ionophores was in the prophylactic and therapeutic treatment of coccidiosis in poultry 
[65, 123, 157]. Carboxylic ionophores are reported to also have a positive impact on the 
growth of these animals [59, 92]. Maduramicin (50), salinomycin (19), narasin (18), 
lasalocid (16) and monensin (17) are the most prevalent of the feed additives marketed 
at present [9, 59, 92, 93]. Several other carboxylic ionophores are also reported to have 
anticoccidial utility in chickens and turkeys. Although these are the most common 
additives used now, there are several other carboxylic ionophores reported to be more 
effective than additives marketed at present [65, 131].  
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Dirlam et al. [124] performed a comparative study of the anticoccidial activity of 
CP-82,009 (51), salinomycin (19) and maduramicin (50) in chickens infected with 
several pathogenic strains of Eimeria: E. tenella, E. necatrix, E. acervulina, E. maxima 
and E. brunette. CP-82,009 (51) at doses of 5 or 10 mg/kg of feed showed a broader 
spectrum and tolerance [124]. These same authors reported in 1990 that another 
carboxylic polyether, CP-84,657 (52) had outstanding anticoccidial potential. This agent 
at dosage ≤ 5 mg/kg cured chickens infected with different types of Eimeria sp. CP-
84,657(37) was more potent than several marketed molecules, such as salinomycin 
(19), narasin (18), lasalocid (16) and monensin (17)  [93]. CP-80,219 (53) was reported 
to have an anticoccidial effects against E. tenella in chickens at dosages of 30 and 120 
mg/kg of feed [125]. 
Kijimicin (54), tested along with monensin (17) and salinomycin (19) in chicken 
infected with E. tenella, was more effective than several marketed drugs. Its 
anticoccidial index (ACI) was 156.8 versus 144.1 for monensin (17) sodium salt and 
127.1 for salinomycin (19) sodium salt [126]. Endusamycin (55) showed a protective 
effect on chicken infected with E. tenella and E. acervulina at doses of 10 – 40 mg/kg of 
feed  [130]. The toxicity of this compound in rats was analyzed; when administered to 
rats orally, the LD 50 was 7.5 mg/kg [130]. 
Liu et al. [131] reported that X-14868A (56) and X-14868B (57) were potent 
anticoccidial agents for chickens infected with E. tenella . Doses of 7 and 15 mg/kg of X-
14868A (56) and X-14868B (57), respectively, were estimated to be protective 
quantities against coccidiosis. These agents are more potent than well-known 
coccidiostats agents; required doses for monensin (17), lasalocid (16) and salinomycin 
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(19) are 98 – 121 mg/kg, 75 – 125 mg/kg and 60 – 100 mg/kg, respectively [131]. Smith 
and Strout suggested an MOA for the coccidiocidal effect of carboxylic ionophores 
[157]. They suggested that anticoccidial agents act, either by inhibiting the development 
of intracellular parasites or by inducing destruction of intracellular sporoizoids [157]. 
2.3.3 Cryptosporidium parvum 
Cryptosporidium parvum infections in immunocompetent individuals are generally 
self-limiting. In immunocompromised patients, particularly in AIDS patients, these 
infections are severe and are becoming increasingly prevalent [158-160]. Although 
many drugs are used for the clinical treatment of C. parvum, effective treatments for 
infected AIDS patients are scare [158, 159]. The screening of several anticoccidial 
molecules has led to the in vitro and in vivo examination of several carboxylic 
ionophores [38, 39, 44, 53, 58, 161]. Monensin (17), maduramicin (50), salinomycin 
(19), alborixin (26), and lasalocid (16) were all evaluated for their respective activity 
against C. parvum [38, 39, 44, 53, 58, 87, 121, 161]. When compared with control 
anticoccidial agents, monensin (17) reduced the development of C. parvum by > 90% 
[53]. The administration of maduramicin (35) and Alborixin (26) to severe combined 
immune deficient (SCID) mice inoculated with 106 oocysts (bovine) oral gavage, 
beginning 4 weeks post infection at 3 mg/kg/day for 3 weeks, has resulted in a 96% 
reduction in fecal parasite load (p < 0.003) (case of maduramicin (50)) [87]; this 
correlated with significant reductions in parasite loads in cross-sections of small 
intestine tissue (p < 0.000002) and colon (p < 0.000006). Alborixin (26) showed less 
effective results with oocyst reduction at 71% after 3 weeks [87]; some toxicity was 
observed [87].  
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2.3.4 Toxoplasma gondii 
T. gondii is best known for its neurological effects and its particularly hearty cystic 
stage; it infects a wide variety of organisms [75, 162-164]. T. gondii’s most deleterious 
activity is its induction of toxoplasmic encephalitis, thus causing fatal CNS lesions. T. 
gondii is an opportunistic pathogen in AIDS patients [49, 70, 162, 164, 165]. Treatment 
for toxoplasmic encephalitis is typically a combination therapy involving pyrimethamine 
and sulfadiazine. However, this type of chemotherapy is not effective against the cystic 
stage of T. gondii, thus, reactivation of the bradyzoites is chronic, especially in the CNS 
[23, 76]. 
Previous data has demonstrated that several polyether antibiotics are highly 
active against the tachyzoite stage of T. gondii [49, 73, 77, 78, 164]. In vitro and in vivo 
studies on the bradyzoites stage revealed under immunofluoresence and electron 
microscopy that very low dosages, 0.0001 µg/mL, of monensin (17) significantly altered 
the cytological physiology, that is, swollen cysts and large numbers of vacuoles, of T. 
gondii [49]. Temporal, in vivo mouse brain T. gondii bradyzoites, evaluations of a 6- and 
48-h exposure yielded significant antiparasitic activity [124, 129]. Six-hour single dose 
treatment of 0.1 µg/mL of monensin (17) effectively eliminated the viability or lysed the 
cells completely. In a similar 48-h trial with concentrations of as small as 0.0001 µg/mL, 
the bradyzoites were swollen or lysed, and at a concentration of 0.01 µg/mL all 
parasites seemed permanently altered beyond viability under electron microscopic 
evaluation [49]. Apart from carboxylic ionophores antibiotics only two other drugs have 
shown activity against the bradyzoites stage, atovaquone [166] and 2′,3′-dideoxyinosine 
(ddi) [167]. In vitro and in vivo tests have shown that these other molecules take a 
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significantly longer time to have the same activity as monensin (17) [78, 129, 137, 164].   
2.3.5 Neospora canium 
The coccidian parasite N. canium is often misdiagnosed as T. gondii. The 
antimicrobial potential of several compounds, including, a few carboxylic polyethers 
against this pathogen was recently investigated. To examine the inhibition of tachyzoite 
multiplication, a 2-day treatment monoclonal antibody-based enzyme immunoassay 
(EIA), and a 5-day treatment cell culture flask lesion-based assay were developed. In 
this study 43 chemotherapeutics, sulfonamides, dihydrofolate reductase/thymidylate 
synthase inhibitors, macrolides, lincosamides, pentamidine analogues, eight 
miscellaneous antiprotozoal and six carboxylic polyethers were evaluated for use in 
treating Neospora canium infections. This assay determined that five out of the six 
ionophores evaluated, that is, lasalocid (16), maduramicin (50), narasin (18), monensin 
(17) and salinomycin (19), caused 100% reduction in tachyzoite induced lesions at 
concentrations of 0.000001 µg/mL in the CCF assay. Alborixin (26) was toxic to host 
cells at these concentrations [52]. 
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Figure 1-1. Structures of carboxylic polyethers 
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Figure 1.1. (cont.) Structures of carboxylic polyethers 
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Figure 1.1. (cont.) Structures of carboxylic polyethers 
2.4 Antiviral activity 
From the literature reviewed, it can be gathered that carboxylic polyethers 
possess several features that could qualify them as promising anti-HIV-1 leads. 
Although none of the reports reviewed assessed the potency of these molecules 
alongside clinically used drugs the reported IC50 values against HIV-1 targets are 
significant. These molecules are also reported to have the potential to inhibit the 
replication of the virus in key cells such as CD4-expressing lymphoid cells and 
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mononuclear phagocytes. In addition, carboxylic polyethers have proven to be effective 
against acute, as well as chronic infections in vitro. The effective dose and toxicity level 
varied from molecule to molecule but a few molecules have proven effective at nontoxic 
concentrations. As a group, carboxylic polyethers do not belong to a specific class of 
known anti-HIV drugs. Some carboxylic polyethers such as monensin (17) and kijimicin 
(54) were evaluated as protease inhibitors, with respect to their interference with 
posttranslational modifications of HIV-1 proteins. It is well established that HIV-1, which 
mutation rate is extremely high, readily develops resistance to protease inhibitors by 
altering the active site of the targeted protease enzyme. Whether carboxylic polyethers 
that interfere with posttranslational modifications of HIV-1 proteins will share this fate is 
not well established at this time due to the limited understanding of the exact sequence 
of events through which compounds such as monensin (17) and kijimicin (54) impair 
posttranslational modifications. None of the studies reviewed investigated the 
effectiveness of these carboxylic polyethers in an animal model. 
2.4.1 Activity against HIV-I-AIDS 
Several reports describe the potential of carboxylic ionophores: monensin (17), 
salinomycin (19), lasalocid (16), nigericin (19), dianemycin (35), alborixin (26), kijimicin 
(54), SF2361 (58), SF2324 (59), SF2487 (60) and Laidomycin (44) as anti-HIV agents 
[86-91] [40, 54, 127, 128, 168, 169]. 
Nakamura et al. [40] assessed the effect of 10 carboxylic ionophores, monensin 
(17), salinomycin (19), lasalocid (16), nigericin (19), dianemycin (35), alborixin (26), 
kijimicin (54), SF2361 (58), SF2324 (59) and SF2487 (60), on the replication of HIV-1. 
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All but SF2324 (59) showed a dose-dependent inhibition of the virus replication. Apart 
from SF2324 (59), the concentration that inhibited reverse transcription activity, viral 
replication, by 50%, EC50, varied in the range 0.40 - 0.040 to 7.12 - 4.4 µg/mL. The IC50 
and EC50 of SF2324 (59) in H9 cells (primary infection) was determined to be > 100 
µg/mL, the highest tested concentration. The IC50 of the remaining compounds varied in 
the range 6.98 ± 2.9 to 78.40 ± 4.7 µg/mL (Table 1-2). For these compounds, an 
inhibitory effect at nontoxic doses was observed. The ratio IC50 /EC50 varied in the 
range 3.18 – 76.72 (Table 1-2). The chronically infected cells, U937, were sensitive to 
all but SF2487, but a higher cytotoxicity was observed as shown by the low IC50 /EC50 
ratio, which varied here from 1.18 to 8.32 (Table 1-2) [40, 127]. 
It is believed that all carboxylic ionophores do not share a common MOA against 
HIV. These compounds target different stages of the HIV infective cycle, that is, the pre- 
and post-absorption steps [40, 54, 127, 128, 169]. Nakamura et al. [40] using a time of 
addition design partitioned these agents in two main groups on the basis of their MOA. 
These authors exposed H9 cells to these molecules before, during and after viral 
absorption. The first group, believed to inhibit viral absorption was made of lasalocid 
(16), dianemycin (35), SF2361 (58), SF2324 (59), SF2487 (60) and alborixin (26). The 
second group, believed to interfere with post-viral adsorption events, was made of 
monensin (17), salinomycin (19), lasalocid (16), nigericin (20), Dianemycin (35), 
alborixin (26), kijimicin (54), SF2361 (58), SF2324 (59) and SF2487 (60) [40]. Yamauchi 
et al. [128] working specifically with kijimicin (54), tested at concentrations of 0.08 – 10.0 
µg/mL confirmed its lack of ability at interfering with the absorption step, as well as early 
stage of the replication, such as integration. It was proposed that kijimicin (54) acted by 
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decreasing the infectivity of the virus, which was possibly accomplished by means of 
incomplete glycosylation of gp120 [128].  
A dose-dependent study of the effect of monensin (17) on chronically infected 
MOLT-3/HTLV-IIIB revealed a marked inhibitory effect on the proteolytic processing of 
gpl60 to gpl20, after 7 h of exposure at 10 µM [54]. This effect was specific as no 
change on the protein level of gag proteins Pr53 gag and p24 was noted. No effect on 
the expression of tat, vif and nef gene products was observed, as well. Monensin (17) 
also showed a marked reduction in the formation of syncytia at concentration > 3 nM 
when MOLT-3/HTLV-IIIB cells were co-cultured with CEM cell. Both effects were 
reversible upon removal of monensin (17) [54]. All these findings were later confirmed 
by a second group [169]. Laidlomycin (44) was also reported to induce a dose-
dependent inhibition of HIV replication. The MOA of laidlomycin (44) was proposed to 
be via inhibition of gp120 expression. Laidlomycin (44) also induced an inhibitory effect 
on syncithium formation at concentrations as low as 1 µg/mL [85].  
2.4.2 Activity against other types of viruses 
Many carboxylic ionophores are reported to be active against several other DNA 
and RNA viruses: monensin (17), monensin B (61), nigericin (20), narasin (18), 
lasalocid (16), X-206 (47), septamycin (22), A 28695B (62) and A204 (63) were tested 
against transmissible gastroenteritis coronavirus, Newcastle disease virus (NDV), 
infectious canine hepatitis virus and infectious bovine rhinotracheitis virus [9]. All these 
agents showed a significant activity against transmissible gastroenteritis coronavirus, 
MIC ranging from 0.005 to 0.25 µg/mL. Nigericin (20), narasin (18) and A28695B (62) 
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were effective against NDV with MIC ranging from 0.02 to 2.0 µg/ml. Only septamycin 
(7) was active against infectious canine hepatitis virus (MIC = 0.32 µg/mL). Monensin B 
(61), nigericin (20), narasin (18), X-206 (47), septamycin (22) and A204 (63) were 
effective against the infectious bovine rhinotracheitis virus, MIC ranging from 0.005 to 
0.08 µg/mL [9]. 
2.5 Cytotoxicity and anticancer 
Resistance to chemotherapy is a common clinical problem in patients with 
cancer. During treatment, tumor cells are often found to be refractory to a variety of 
drugs with different structures or modes of actions. These cancers are referred to as 
MDR forms. Most multidrug resistances are caused by trans-membrane xenobiotic 
transport proteins belonging to the superfamily of ATP-binding cassette (ABC) 
transporter efflux pumps [170, 171]. Carboxylic polyethers are interesting antineoplastic 
drug candidates for several reasons; they possess potent anticancer activity in vitro and 
in vivo. Some carboxylic polyethers such as nigericin (5) have proven to be selectively 
cytotoxic, inhibiting DNA replication of tumor cells in vivo. Another feature that makes 
carboxylic polyethers even more appealing as antineoplastic drug candidates is their 
ability to reverse multidrug resistance in human carcinoma. Carboxylic polyethers are 
reported as chemosensitizing agents. These molecules selectively increase the 
sensitivity of cancerous cells, but not normal cells, to several cytotoxic agents of which 
the clinically used anticancer drug paclitaxel [172]. 
Kawada et al. [57] evaluated the effects of several carboxylic ionophores on 
colchicine resistance in human carcinoma MDR KB-C410 [57]; these compounds were 
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inostamycin (39), lysocellin (30), laidlomycin (44), monensin (17), dianemycin (35), 
leuseramycin (41), nigericin (20), lonomycin A&C (32 , 37), carriomycin (23), desoxy-
salinomycin, antibiotic 6016 (38), SF2324 (59), SF2361 (58) and SF2487 (60). It was 
discovered that the cancer cells responded better to colchicine when some polyethers 
were added simultaneously. Laidlomycin (44), monensin (17), dianemycin (35) and 
leuseramycin (41) led to > 100-fold potentiation of colchicine cytotoxicity. The most 
potent compound was laidlomycin (44); at 0.3 and 1 µg/mL, it potentiated the 
cytotoxicity of KB-C4 cells by ~ 725-fold [57]. Compared to tumor cells, the potentiation 
of normal cells was negligible; the ratio of IC50 in the absence of polyether versus the 
IC50 in the presence of polyether only varied in the range 0.4 – 2.4 µg/mL. Inostamycin 
(39) was also reported to have a chemosensitizing effect on paclitaxel in Ms-1 cell, 
small cell lung carcinoma. 
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Table 1-2 HIV-1 infectivity and cytotoxicity 
 
Acute infection (H9) 
  
Chronic (U937) 
 
   
   
EC90 
(µg/mL) IC50 (µg/mL) IC50/EC90 EC90 (µg/mL) IC50 (µg/mL) IC50/EC90 
Compounds 
Monensin (17) 4.22 ±  2.6 13.44 ±  2.8 3.18 0.5 ±  0.25 0.59 ± 0.19 1.18 
Salinomycin (19) 0.4 ± 0.04 6.98 ± 2.9 17.63 0.09 ± 0.02 0.28 ± 0.05 3.14 
Lasalocid (16) 2.37 ±  2.9 48.80 ±  4.7 20.63 0.2 ±  0.2 1.35 ± 0.35 6.92 
Nigericin (20) 0.68 ±  0.46 14.46 ±  8.0 21.26 0.05 ± 0.33 0.4 ± 0.007 8.32 
Dianemycin (35) 7.12 ±  4.4 78.40 ±  4.7 11.01 1.1 ±  0.14 1.1 ± 0 1.00 
SF2361 (58) 0.64 ±  0.36 49.10 ±  4.6 76.72 1.35 ± 0.49 2.1 ± 0.14 1.56 
SF2324 (59) > 100 > 100 > 1.00 3.7 ±  0.71 10.1 ± 0.14 2.73 
SF2487 (60) 0.49 ±  0.18 7.8 ± 1.3 15.92 0.03 ± 0.15 1.85 ± 0.28 64.91 
Alborixin (26) 2.5 ± 1.1 13.50 ±  3.1 5.4 0.12 ± 0.04 0.80 ± 0.28 6.53 
Kijimicin (54) 1.63 ±  1.9 18.62 ±  11 11.41 0.1 ±  0.007 0.55 ± 0.07 5.79 
Dextran Sulfate < 1 > 100 > 100 NT   
EC50: Concentration that inhibits reverse transcription activity by 50% (viral replication); IC50: Concentration that decreases cell viability by 50%. 
From Nakamura et al., 1992 [40]. 
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This effect was specific to these types of cells and to paclitaxel, as no 
potentiation was noted with the other tested agents, driamycin, vinblastine, 
methotrexate, cisplatin, etoposide and camptothecin [172]. Inostamycin (39) was also 
reported to reverse multidrug resistance in these cell lines. Using radiolabeled 
vinblastine, Kawada et al. [57] established that MDR cells treated with inostamycin (39) 
(0.5 – 2 µg/mL) accumulated the drug. Inostamycin (39) (1 µg/mL) acted by inhibiting 
drug efflux [57].  
Baibakov et al. [73] and Margolis et al. [173] studied the antineoplastic MOA of 
nigericin (20) and established that nigericin (20) was a unique type of cytostatic agent. 
The compound (20) acts not by interfering with spindle microtubules or 
transcription/translation processes directly, but rather by altering intracellular pH [73, 
173]. Nigericin (20) showed anticancer potential (cytostatic agent) in Ehrlich ascites 
carcinoma cells. The proposed MOA related to its ability to acidify the intracellular 
environment, a consequence of its H+ /K+ anti-transport ability [173]. It is believed that 
by decreasing the pH, DNA synthesis is halted. Nearly 100% inhibition of the DNA 
synthesis was achieved at 0.5 µM nigericin (20), with the pH of the incubation medium 
being 7.0 [173]. An in vivo method, using tridimensional histocultures of human lung 
tissues, with normal cells present in the same histoculture, determined that this 
antineoplastic effect of nigericin was selective. At 1µM of nigericin (20) neither the 
histology of normal cells nor their DNA synthesis was negatively affected. In cancerous 
tissues however, the same concentration of nigericin (5) halted the DNA synthesis in 
67% of the cases, induced pyknotic nuclei and dystropic alteration in 27% of tumors 
exposed to nigericin (20) and necrosis in 13% of cases. Another carboxylic polyether, 
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ionomycin (27), is also reported to possess antineoplastic properties. It induced 
inhibition of the growth of a human bladder cancer cell line, HT1367, in vitro in a dose 
(0.1 – 100 µg/mL), and time dependent manner. The MOA here is reported to be the 
induction of apoptosis by means of the downregulation of Bcl-2 and upregulation of Bax. 
Ionomycin (27) was also effective in vivo, as it inhibited HT1367 tumor’s growth [90]. 
2.6 Cardiovascular effects 
Several carboxylic polyethers were reported to show ionotropic, chronotropic and 
hemodynamic properties. Because of the critical role of Ca2+ in cardiovascular 
contractile systems, this was predictable at least for those carboxylic polyethers that are 
selective for this ion, such as lasalocid (16) and A23187 (28). It is well established that 
lasalocid (16), also known as X-537A, is a positive ionotropic agent. In canine studies, 
lasalocid (16) was able to increase the contractility index of the heart by approximately 
threefold at 2 mg/kg [10, 13]. X-537A is also reported as a positive ionotropic and 
chronotropic agent in dogs. In barbiturated dogs, at dosage 2 mg/kg, it caused a 
threefold increase in the contractility, as well as a modest rise in aortic pressure and 
heart rate. It also induced a drop in total peripheral resistance followed by a drastic 
increase in blood flow through the coronary arteries of the left ventricle [10]. The exact 
MOA through which these carboxylic polyethers induce contractility of cardiac muscle is 
still unclear. Initially, it was believed that this could be the result of their ability to shuttle 
Ca2+ and catecholamine across membranes. This was refuted after the discovery that 
carboxylic polyethers specific to monovalent cations were able to induce, even more 
effectively, this type of response. Nonetheless, it is believed that catecholamine is 
partially involved because the effect of these molecules on the cardiac muscle is 
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suppressed by α adrenergic inhibitors. 
Several other carboxylic ionophores were reported to possess a cardiovascular 
effect. Monensin (17) reportedly induced an increase of arterial blood pressure, 
myocardial contractility and total peripheral resistance when administered intravenously 
to anesthetized cats at a dose of 0.075 – 0.375 mg/kg [60]. A similar effect was 
observed when 0.125 – 2.00 mg/kg were administered via the same route to 
anesthetized dogs [60]. Monensin (17) was also effective on isolated organs; it showed 
a vasoconstrictor effect on isolated rabbit aortic strips at concentration ≤ 7 µg/mL and a 
myocardial stimulation effect in isolated rabbit hearts [60]. 
Three other carboxylic ionophores, grisorixin (31), alborixin (26), lonomycin A 
(32), are reported to have similar effects. Grisorixin (31) induced a coronary vasodilator 
effect in dogs at doses of 60 µg/mL; this was associated with a marked increase in the 
coronary blood flow, which reached a maximum at this concentration. At doses of 125 – 
500 g/kg, further inotropic and hypertensive effects were observed [174]. Grisorixin (31) 
was also reported to have a cardiotonic effect on isolated perfused rat hearts [100]. In 
guinea pigs, grisorixin (31) and alborixin (26) 4 mg/kg/min i.v. are reported to increase 
blood pressure. The MOA is believed to be linked to their intrinsic ionophorous potential: 
the ability of the molecules to alter the blood concentration of cations such as K+ and 
Na+ [101]. Moins et al. [175] working with anesthetized dogs reported similar findings, 
as 2 mg/kg of grisorixin (31) and 1 mg/kg of alborixin (26) increased the ventricular 
contractile force and systolic and diastolic arterial pressures. This was associated with 
an increase in the plasma concentration of K+ followed by a decrease in the 
concentration of Na+ [175]. Because it has been reported that  compounds such as 
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grisorixin (31) are able to induce the release of catecholamine, the physiological 
response associated with the release of catecholamine was also proposed as a 
possible justification of the cardiovascular effects of these compounds[174]. Lonomycin 
A (32), another carboxylic polyether, was also reported to induce a coronary 
vasodilatation effects in dogs. Its MOA was proposed to be the stimulation of the Na+, 
K+-ATPase activity [105]. 
As stressed by Pressman, and despite their toxicity, carboxylic polyethers are 
important drug leads for control of various cardiovascular conditions. Their value lies in 
their outstanding ionotropic, chronotropic and hemodynamic potentials. These 
molecules could prove life-saving tools in controlling conditions such as failure from 
myocardial infarction and other similar forms of shock. Carboxylic polyethers such as 
lasalocid (16) (1 mg/kg) were proven effective at restoring dogs in cardiogenic shock. 
Similar data were reported for salinomycin (19) (0.15 mg/kg). According to Pressman, 
the narrower the transport spectrum of a molecule, the fewer the number of associated 
undesirable effects  [10]. 
2.7 Other biological activities of carboxylic polyethers: immunoregulatory, 
herbicidal and anti-inflammatory 
2.7.1 Immunoregulatory activity 
Two measures are usually adopted to protect poultry against a variety of 
etiological agents such as Angara disease virus (ADV) and Newcastle disease virus 
(NDV), and to promote growth. These include vaccination and addition of substances 
such as antibiotics, coccidiostat and vitamins to feed. Among additives currently 
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approved for use are several carboxylic polyethers (lasaloicid (16), monensin (17), 
salinomycin (19) and manduramycin (50)). There have been some recent concerns over 
the possible implication of additives in vaccine failure in poultry. A few reports have 
actually proven that therapeutic agents such as cyclophosphamide and corticosteroids 
possess immunomodulatory properties. Munir et al. in 1994 and 2007 studied the 
immunomodulatory effects of salinomycin (19) and monensin (17); specifically, the 
effects of these molecules on the protective immune response in NDV and ADV 
vaccinated chickens [59, 176]. These authors established that unlike 
cyclophosphamide, salinomycin (19), at a dosage of 0.1 g/kg, did not adversely affect 
the bursal, splenic, thymic and liver weight gain [176]. It was also established that NDV 
vaccinated chickens that received salinomycin (19), 60 mg/kg of feed, had higher 
antibodies titers at days 14, 21, 28, 35, 42 compared to unmedicated chickens [59, 176] 
or vaccinated chickens that were medicated with monensin (17) 12 mg/kg instead [59]. 
These salinomycin medicated chickens also gained significantly more weight, p < 0.05, 
compared to all the other groups evaluated. These chickens were challenged with both   
ADV and NDV after vaccination. No post-ADV or post-NDV challenge mortality was 
observed in vaccinated chickens that received salinomycin (19) and no clinical sign of 
the disease was observed [59, 176].  
From these studies, it seemed that far from causing vaccine failure, carboxylic 
polyether such as salinomycin (19) actually seem to have a boosting effect on the anti-
NDV and anti-ADV immune response [59, 176]. Another carboxylic polyether reported 
as having immunoregulatory potential was ionomycin (27), a calcium-specific ionophore. 
Ionomycin (27) interferes with physiological processes by increasing the intracellular 
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level of calcium, an effect that could have several implications on key cells of the 
immune system such as neutrophils and macrophages. They exert their action by 
production of microbicidal species such as superoxide anions via an NADPH-dependent 
process known as ‘respiratory burst’ in response to in situ triggers such as inflammatory 
agents. Ca2+ is documented as an enhancer of NADPH oxidase activity. Finkel et al. 
[177]  reported that ionomycin (27) at a concentration of 1 – 10 nM can prime 
neutrophils to release approximately sevenfold more superoxide anions during 
stimulation. Ionomycin (27) was also reported to induce T cell activation [177]  . 
2.7.2 Herbicidal activity 
It has been reported that nigericin (20) also possess herbicidal properties. A 
concentration-dependent study of the effect of nigericin (20) on the growth of the radicle 
of garden cress seed showed a dose-dependent inhibitory effect. A 50% reduction in the 
elongation was achieved at 1.3 – 2.0 µg/mL; the maximum inhibition was reported at ~ 
3.33 µg/mL. Nigericin (5) did not induce browning or necrosis of tissues in the process 
[20]. 
2.7.3 Anti-inflammatory activity 
Dianemycin (35) was recently reported as having topical anti-inflammatory 
potential on several animal models for cutaneous inflammation. In a croton-oil induction 
of ear edema, dianemycin (35) had a comparable activity to prednisolone, a potent 
steroidal anti-inflammatory. In the UV-induced erythema test or in the delayed type 
sensitivity test, no anti-inflammatory activity was observed. Additionally, no acute 
toxicity was observed with topical application ≤ 10 mg/ear [21]. 
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3. Toxicity 
Acute toxicity of the naturally occurring polyether ionophores is relatively specific 
to the affected organism. It is clear that minimal exposure to these very active 
compounds initiates some type of physiological response [13]. In the case of higher 
organisms and specifically mammals and birds, these effects are almost equally diverse 
[9]. For example, a common poisoning scenario is a horse consuming a small quantity 
of feed prepared with a ruminant’s polyether antibiotic and dying rather quickly, or wild 
turkeys consuming anticoccidial chicken feed and dying. Although the ionophoric 
specificity of molecules can be predicted, respective acute toxicity values are diverse 
and unpredictable. For example, LD50 ± SE values for an acute oral dose of monensin 
(17) were: mouse (m) 70.0 ± 9.0 mg/kg, (f) 96.0 ± 12.0 mg/kg; rat (m) 40.1 ± 3.0 mg/kg, 
(f) 28.6 ± 3.8 mg/kg; dog (m) > 20.0 mg/kg, (f) > 10.0 mg/kg; rabbit 41.7 ± 3.6 mg/kg; 
monkey > 160.0 mg/kg; chicken 200.0 mg/kg; cattle 26.4 mg/kg; sheep 11.9 ± 1.2 
mg/kg; goat 26.4 ± 4.0 mg/kg; swine 16.7 ± 3.57; horse 2 – 3 mg/kg; trout > 1000.0 
mg/kg [9, 13].  
Dogs given a daily oral dose of 0, 1.25, 2.5, 5, or 7.5 mg/kg of monensin (17) for 
1 year survived with no evidence of toxicity in the two lowest dose groups. Four 
generations of rats were continuously maintained on diets containing 0, 33, 50, or 80 
ppm of monensin (17)… except for a decrease in body weight gain, there were no 
compound-related effects on reproduction or observed teratogenic effects” [77]. These 
same dosing conditions were evaluated for a 2-year period, with respect to the skeletal 
and cardiac muscles, with no increase in chronic lesions or neoplasms being detected 
[77]. Despite these maverick chemo-physical qualities of the ionophores, considerable 
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numbers of toxicology studies have attempted to illustrate/translate the specific 
toxicology and pharmacology of the most common polyether ionophores to human 
health utilization [13]. 
4. Cardiac toxicity 
Whether a monovalent or divalent ionophore is used, these molecules will disrupt 
the Ca2+ concentrations, either forming Ca2+ complexes or depolarizing the membrane 
potential, changing the H+ concentrations in the mitochondria [12]. It is clear that Ca2+ is 
an essential ion in the physiological activities of composite functionality in the entire 
human body’s daily functions. Cardiac function is especially sensitive to the roles of 
Ca2+ owing to the intrinsic functions of the ion and its role in muscular contractions; so, 
expectedly, potent effects of polyether antibiotics have been observed in mammalian 
cardiac studies [10, 73, 78, 106, 126, 129]. Canine studies are accepted as the 
translative animal model for human cardiac response and for the effects of carboxylic 
polyethers. These studies have shown that as little as 2 µg/kg i.v. can induce coronary 
dilation [86, 106]. The concern for clinical applications of these ionophores is that 
people with coronary heart disease who have coronary arterial dilation, as part of the 
hearts own auto regulatory response to occlusion of coronary arterial vessels, will dilate 
the affected vessels further in the presence of an indiscriminate vasodilator. The 
unaffected vesicles would dilate further and the already maximally dilated obstructed 
vessels would divert the blood supply away from the ischemic regions of the 
myocardium. This phenomenon is called ‘coronary steal’ and has been observed in the 
administration of the drug dipyridamole, a thrombus inhibitor and chronic vasodilator 
[88, 101]. As a high percentage of the population is affected by coronary heart disease 
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these concerns have validity, although this phenomena was experimentally evaluated 
and the coronary steal was not observed [88]. Only recently have the in vitro tools been 
available for cardiac toxicity evaluations with respect to interaction on the hERG (human 
Ether-a-go-go Related Gene) gene and the associated Kv 11.1 potassium ion channel 
that depolarizes the IKr current in the cardiac action potentials. The polyether antibiotics 
have not yet been critically evaluated in hERG assays. The drug interactions related to 
hERG ion channel were not mandated by ICH guidelines until November 2005 
(mandate #CHMP/ICH/423/02). Consequently, the effects of carboxylic polyether 
ionophores on the QTc, with respect to the interaction with hERG have not yet been 
evaluated. 
5. Conclusion 
Carboxylic polyethers are broad spectrum antibiotics. They are active against a 
wide range of biological targets: bacterial, fungal, protozoan, viral, neoplastic and 
cardiovascular. A few authors have also reported carboxylic polyethers as 
immunomodulating agents. In vitro, these molecules have proven to be effective at very 
low concentrations. The malaria parasite (P. falciparum) is especially sensitive to 
several of these compounds with IC50 values in the nanomolar range. Based on the 
reports in this review it can be argued that carboxylic polyethers are highly selective.  
Unlike Gram negative bacteria or fungi for instance, Gram positive bacteria tend to be 
extremely sensitive to these antibiotics. Moreover, the IC50 values of several of these 
molecules against mammalian cells tend to be significantly higher, when compared to 
the IC50 against targeted etiological agents.   
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Despite these interesting features, the only current application for carboxylic 
polyethers is in veterinary medicine, where they are used as controls for coccidiosis and 
feed absorption efficiency.  The main obstacle for the use of carboxylic polyethers as 
drugs to control human diseases seems to be the issue of toxicity.  Carboxylic 
polyethers possess some interesting qualities against serious threats such as MRSA 
and VRE and have proven to be more effective (in vitro) than drugs that are currently 
used clinically, such as vancomycin and oxacillin. They have also shown to be effective 
against several other resistant bacterial strains including penicillin resistant strains of S. 
aureus, tetracycline resistant strain of Micrococcus sp, aminoglycoside resistant strain 
of Streptococcus faecalis, and macrolides resistant strain of Sarcina lutea. Carboxylic 
polyethers have also proven effective at nanomolar range against CQ resistant strains 
of P. falciparum and are more potent against these resistant strains than several 
currently marketed antimalarial drugs. Their mechanism of action against the malaria 
parasite appears uniquely different from that of the currently utilized drugs. This makes 
them possible candidates for use in combination therapy.  
6. Expert opinion 
On the basis of our assessment of the literature, polyether ionophores show a 
high degree of promise for the potential control of drug-resistant bacterial and parasitic 
infections. Many of these infectious diseases fall under the umbrella of neglected 
disease with limited options for therapeutic intervention. Furthermore, recent decades 
have emphasized the importance of combination therapies for the long-term control of 
disease and mitigation of resistance. The long history of the utilization of polyether 
ionophores as growth promoting antibiotics by the agricultural industry validates the 
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potential cost-effective use of these antimicrobial agents for other applications. The 
polyether antibiotics seem to provide reasonable oral availability, half-life, metabolic and 
general stability, absence of a UV sensitizing chromophore combined with significant 
potency. Despite the long history of use of the class very limited medicinal chemistry 
and drug optimization studies have been reported leaving the door open to these 
opportunities in the future. In many instances, the potency and in vivo efficacy for the 
control of bacterial and parasitic infections is truly remarkable.  
However, concerns about toxicity need to be addressed with further optimization 
and preclinical evaluation. On the basis of the available literature, there is still 
insufficient data to clearly classify these molecules as either too toxic or safe as a class. 
Several carboxylic polyethers have indeed been shown to be too toxic in animal models 
for malaria, but the results cannot be generalized to the entire class. Using an in vivo 
model for cancer, nigericin (20) was recently reported to be highly selective in targeting 
cancerous cells, broadening the scope of possible utility for this class [80]. As a result, 
an organized and carefully orchestrated identification and optimization of leads using in 
vitro models followed by an in vivo assessment of toxicity and efficacy would seem to 
yield viable drug candidates for the control of drug-resistant infectious diseases and 
cancer with a reasonable understanding of pharmacokinetics, stability and cost of 
goods. The reported toxicity for monensin (17) of > 160.0 mg/kg (LD50) in primates and 
frequent utilization of this drug in agriculture makes the polyether class an attractive 
group of molecules for optimization and development of human health applications for 
the control of drug-resistant diseases such as malaria and MRSA. 
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ABSTRACT - The antimalarial-guided fractionation of the crude extract of the 
marine Streptomyces sp. strain H668 led to the isolation of a new polyether (5). This 
new metabolite showed in vitro antimalarial activity against the CQ-susceptible (D6) and 
resistant (W2) clones of Plasmodium falciparum, without cytotoxicity to normal cells 
(Vero) making it a promising drug  lead. 
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Malaria is a tropical infection caused by four different species of protozoa of the 
genus Plasmodium transmitted to humans by the Anopheles mosquito. During past 
decades, CQ and other aminoquinolines have been utilized as frontline antimalarial 
agents. However, an increase in drug resistance in Plasmodium falciparum has made it 
essential to develop new chemotherapeutic agents in addition to combination therapies 
utilizing available antimalarial drugs with different modes of action [178]. Recently, some 
specific polyether antibiotics have been reported to have potent antimalarial activity [37, 
51, 111, 153]. K41-A, a carboxylic acid containing polyether antibiotic produced by 
Streptomyces hygroscopicus has been reported to exhibit nanomolar range in vitro 
antimalarial activity against the P. falciparum strains K1 (drug resistant) and FCR3 (drug 
sensitive) [153].  Furthermore, it showed high selectivity in vivo against P. berghei strain 
N and P. yoelii strain NS-infected mice, when administered orally [153].  Several other 
polyethers from this class (ionomycin A, nigericin, and monensin, among others) have 
been identified as potent antimalarial agents, as well [37, 51].These compounds are 
classified as ionophores due to their potential to interact with ions (cations); this is 
believed to be their putative mechanism of action [37, 51]. There are two main classes 
of ionophores: mobile carriers or true ionophores which bind cations into an oxygen rich 
pocket in order to facilitate their transport across the cell membrane and quasi-
ionophores which, instead, form trans-membrane channels through which cations flow. 
Compounds of the latter group possess a polycyclic alkyl backbone which confers their 
lipophilic character. They also possess a terminal carboxylic group which plays an 
important role in the formation of the oxygen rich internal cavity which interacts with 
metal ions [37, 51, 179].  
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Bacteria, especially Streptomyces sp. isolated from soil samples are reported as 
the primary producers of this type of compounds, with at least 21 producer strains 
reported thus far [180]. Reports concerning the isolation of these compounds from 
marine Streptomyces are scarce; a few examples include aplasmomycin [181], arenaric 
acid, and oxolonomycin [182, 183].  
H668 was isolated from Hawaiian marine sediments and cultured in ISP2 
medium. It was established that its crude extract possessed potent in vitro activity 
against P. falciparum and no significant cytotoxicity to Vero cells. H668 was identified as 
a Streptomyces sp.  by 16S rRNA analysis. A bioassay-guided fractionation of the 
EtOAc-soluble fraction of the H668 culture led to the isolation of a new polyether 
metabolite. In this report, we describe the isolation and structure elucidation of this 
metabolite. 
The antimalarial active fraction eluting with 70% MeOH in H2O using reversed 
phase C18 VLC was further fractionated by  preparative HPLC [Phenomenex C8 column 
(21.2 × 250 mm); flow rate 5 mL/min] using a gradient from 50% to 100% MeOH in H2O 
over 80 min. The active fractions were further purified by preparative HPLC 
[Phenomenex C18 column (21.2 × 250 mm) at 5 mL/min] eluting with a gradient from 
70% to 100% MeOH in H2O, to afford a semipure metabolite. Purification of this 
semipure compound by HPLC [5 micron C18 (10 × 250 mm); flow rate 3 mL/min] using 
an isocratic solvent of 75% MeOH in H2O gave 3.0 mg of the pure metabolite 5.  
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The 1H NMR spectrum of 5 indicated the presence of eleven oxymethine 
hydrogens (3.1 – 4.3 ppm), four methoxy groups (3.2 – 3.6 ppm), eight methyls (0.9 – 
1.3 ppm), and five methylene (1.2 – 2.2 ppm). This was supported by the 13C and DEPT 
NMR spectroscopic data. In addition, two oxygenated quaternary carbon signals at δC 
82.8 and 78.4, as well as two ketal (or hemiketal) signals at δC 100.9 and 106.2 were 
observed. Four independent spin systems were identified by a COSY experiment, in 
which a sequential correlation from H-12 to H-23 and two methyl signals at C-26 and C-
27, were observed, along with correlations for H-9 and H-10, H-3 through H-7, and H-1 
and one methyl group at C-1. Several ambiguous correlations in the methylene area of 
the COSY data were identified based on the analysis of HSQC data. From the HSQC 
data, each protonated carbon for the partial structures could be assigned as shown in 
Table 1-1. The HMBC data of 5 revealed correlations from H-12 (δH 3.89) to C-14 (δC 
28.2) and C-15 (δC 81.7) and from H-15 (δH 3.74) to C-12 (δC 81.9), suggesting a 
structure of a tetrahydrofuran ring (ring C). In a similar fashion, HMBC correlations 
assisted in identifying ring D. Ring E was deduced from the HMBC analysis, where both 
the methyl protons at δH 0.97 (3H, d, J = 6.4 Hz, H-27) and 1.01 (3H, d, J = 6.4 Hz, H-
26) showed correlations with C-22 (δC 74.6), and H-22 (1H, t, J = 10.0 Hz) exhibited 2- 
and 3-bond correlation with C-20 (δC 75.3), C-21 (δC 40.9), C-23 (δC 47.8), and C-24 (δC 
100.9), along with a correlation from the methyl signal at δH 1.30 (3H, s, H-25) to C-24. 
Moreover, the HMBC correlations from H-12 to C-11 (δC 82.8) and C-10 (δC 94.8), as 
well as from neighboring protons (H-10, H-9, H-7, and H-6) to the ketal carbon at δC 
106.2 facilitated the construction of a spiroketal analog linked with ring C. These results 
suggest that compound 5 is a polyether type metabolite. Comparison of the NMR data 
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of 5 with those of polyether compounds previously reported supported the NMR 
assignments for the rings A – D [146, 182, 184, 185]. However, the residual part was 
quite different from reported polyethers. The biggest difference was the lack of a 
carboxylic group in 5. COSY data confirmed the linkage of H-3 (δH 4.29, 1H, d, J = 10.0 
Hz) and H-4 (δH 4.10, 1H, br s), and of H-1 (δH 3.45, 1H, m) and H-32 (δH 1.02, 3H, d, J 
= 6.4 Hz). The HMBC correlations from H-3 to C-2 (δC 78.4), as well as to the methyl 
carbon at δC 11.6 revealed the connection from C-1 to C-3 bearing two methyl groups 
(C-31 and C-32). In addition, two methoxy groups at δH 3.54 and 3.39 were identified 
and attached at C-1 and C-2, respectively, by the HMBC data analysis. Taken together, 
the structure of 5 was determined as shown in Figure 2-1, and all the 1H and 13C NMR 
data were assigned as in Table 2-1. The relative configuration of 5 was determined on 
the basis of ROESY NMR data. NOE correlations were observed as described in Table 
2-1, which indicated that 5 has the same relative configuration in rings A-E as those of 
K41-A (Figure 2-2). 
 
 
 
 
 
 
Figure 2-1. Spin system 1H-1H COSY data (―) and HMBC correlations of 5 
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Figure 2-2.  Key NOE correlations of 5 
The antimalarial activity of the new metabolite (5) was evaluated against both the 
CQ-susceptible (D6) and -resistant (W2) clones of P. falciparum, and their toxicity was 
tested against Vero cells. Compound 5 showed antiprotozoal activity against both the 
D6 and W2 clones, with IC50 values ranging from 100 − 200 ng/mL. Although the in vitro 
antimalarial activity of 5 was significantly less than the original extract, no cytotoxicity 
was observed at 4.75 µg/mL, the highest concentration tested. The high index of 
selectivity (SI = IC50 Vero/IC50 P. falciparum) of 5 indicates that the polyether metabolite 5 is 
highly specific to the parasite. As discussed earlier, the mechanism of action for 
ionophores (quasi-ionophore as mobile carier) is via alteration of normal membrane 
permeability to cationic species [37, 51, 186]. Ionophores  (mobile carriers) possess 
unique structural features which are crucial to their ability to interact with metal species 
such as Na+, K+, and Ca2+ [37, 51, 56]; these include (1) an alkyl backbone (2) an 
internal oxygen rich pocket and (3) a terminal carboxylic group [179]. A few examples of 
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mobile cariers are: monensins A, B, C, nigericin, laidlomycin, grisorixin, mutalomycin, 
lonomycins A, B, X-206, alborixin, lenoremycin, dianemycin, carriomycin, septamycin, 
etheromycin, A-204A, K41-A, K41-B, and A-601612. All these compounds possess a 
terminal carboxylic moiety [186].   
The polyether 5 isolated from the marine Streptomyces sp. H668 clearly belongs 
to a unique class of compounds.  Although it is closely related to several members of 
the mobile carriers group, the fact that it lacks the carboxylic functionality, suggests that 
the mode of action against the parasite might be unique; this warrants additional 
investigation.  
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Table 2-1 NMR assignment of 5 in CD3OD 
 δCa δH mult. (J in 
Hz)b 
HMBC ROESY 
1 81.8c 3.45, mc C-2, 1-OMe H-3 
2 78.4 / / / 
3 66.6 4.29, d (10.0) C-2, C-31 H-1, 2-OMe 
4 61.4 4.10, br s / / 
5 32.2 1.40, mc C-7 / 
6 78.6 3.34, m C-4, C-8 H-7 
7 36.7 1.71, m C-5, C-8, C-30 H-6, H-29, H-30 
8 106.2 / / / 
9 45.6 2.06, m C-8, C-10, C-29 H-10, H-29, H-30 
10 94.8 3.43, d (9.6)c C-9, C-12, C-28, C-29, 
10-OMe 
H-9, H-28, H-29 
11 82.8 / / / 
12 81.9c 3.89, t (7.2) C-10, C-11, C-14, C-15, 
C-28 
H-13a, H-15, 10-OMe 
13 26.0 1.99, m 
1.83, mc 
C-11, C-12, C-15 H-13a, H-14b, H-28  
H-12, H-13b 
14 28.2 1.71, mc 
1.87, mc 
C-12, C-15, C-16 H-13b, H-14a, H-16 
H-14b, H-15 
15 81.7 3.74, q (6.4) C-13, C-12 (or C-16), 
C-17 
H-12, H-14a, H-16, H-
17a  
16 81.9c 3.99, q (6.4) C-14, C-19 H-14b, H-15, H-17b 
17 28.5 2.06, m 
1.83, mc 
C-15, C-19 H-16, H-17a 
H-15, H-17b, H-18a 
18 24.8 2.00, m 
1.91, mc 
C-16, C-19, C-20 H-18a, H-21 
H-17a, H-18b, H-20 
19 79.9 4.20, dt (6.4, 2.8) C-20 H-20, H-27 
20 75.3 3.40, mc / H-18a, H-19, H-22, H-
27 
21 40.9 1.25, m C-19, C-20, C-22, C-27 H-18b, H-23, H-27 
22 74.6 3.08, t (10.0) C-20, C-21, C-23, C-24, 
C-26, C-27 
H-20, H-26, H-27 
23 47.8 1.40, m C-22, C-24, C-25, C-26 H-21, H-25, H-26 
24 100.9 / / / 
25 21.2 1.30, s C-23, C-24 H-23, H-26 
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26 11.5 1.01, d (6.8)c C-22, C-23, C-24 H-22, H-23, H-25 
27 12.3 0.97, d (6.4) C-20, C-21, C-22 H-19, H-21, H-22 
28 24.7 1.37, s C-10, C-11 H-10, H-13b 
29 10.5 0.97, d (6.4) C-9, C-10 H-7, H-9, H-10 
30 12.0 0.95, d (6.8) C-6, C-7 H-7, H-9 
31 11.6 1.10, s C-2 H-32 
32 11.2 1.02, d (6.8)c C-1, C-2 H-31 
1-
OMe 
60.0 3.54, s C-1 / 
2-
OMe 
49.1 3.39, sc C-2 H-3 
6-
OMe 
56.9 3.28, s C-6 / 
10-
OMe 
59.6 3.41, s C-10 H-12 
aAssignments based on DEPT, HMQC, and HMBC NMR data (100 MHz). bAssignments based on COSY 
and HMBC NMR data (400 MHz) 
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Figure 2-3. 1H NMR spectrum of 5 in CD3OD 
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Figure 2-4. 13C NMR spectrum of 5 in CD3OD 
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Figure 2-5. DEPT spectrum of 5 in CD3OD 
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Figure 2-6. 1H-1H COSY spectrum of 5 in CD3OD 
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Figure 2-7. HSQC spectrum of 5 in CD3OD 
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Figure 2-8. HMBC spectrum of 5 in CD3OD 
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Chapter 2: ANTIMALARIAL, ANTI-MTB AND ANTI-MRSA 
METABOLITES FROM A MARINE STREPTOMYCES 
PART 2 - EPIGENETIC STUDIES YIELDING POTENT 
ANTI-MYCOBACTERIUM TUBERCULOSIS AND ANTI-
MRSA POLYETHERS IN A MARINE STREPTOMYCES 
SP 
 
 
ABSTRACT—Two known polyethers (6, 7) were isolated from a marine Streptomyces 
sp whose crude extract previouly showed potent antimalarial and anti-MRSA activities. 
It was established that metabolites responsible for these activities were the antibiotic 
K41-A (6) and its C-29 OMe (7) ether analog. It was also established that etherification 
at C-29 has a negative impact on the bioactivity of K41-A. In this chapter, we report the 
outstanding bioactivity of these molecules against two important pathogens: 
Mycobacterium tuberculosis and MRSA. Several other commercially available 
ionophores were assayed, as well.  
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1. Introduction 
Tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA) infections 
are both serious conditions that can be transmitted from livestock and other animals to 
humans. According to the WHO, about 1/3 of the world’s population is currently affected 
by TB [3]. In 2007, the CDC reported that an animal MRSA strain is currently 
responsible for >20% of MRSA cases reported in the Netherlands [187]. As the 
incidence of these two diseases continues to increase there is an unprecedented 
demand for the discovery of new drugs leads.  
Nature has played a tremendous role in the drug discovery arena for decades 
with a wide range of bioactive metabolites reported thus far. Among these molecules 
are ionophores, a unique class of compounds with outstanding potency. Polyethers and 
peptides are often classified as ionophores; the peptide gramicidin D, has proven to be 
one of the most potent compound of this class. Due to limitations associated with 
cytotoxicity, none of these molecules is currently utilized beyond topical applications as 
a treatment to address human illnesses. It is however important to point out that 
ionophores are widely used in veterinary medicine. They have proven valuable tools for 
the control of coccidiosis, a serious problem in poultry and cattle [188].  
In a continued effort to identify new drug leads, a bacterium (H668) was isolated 
from Hawaiian marine sediments. Based on the 16S rRNA analysis, it was established 
that H668 is a new species. It is related to Streptomyces cacaoi AB 184183 and 
Streptomyces violaceoruber AY999815. The ethyl acetate extract of the fermentation 
broth of this bacterium showed outstanding potency against MRSA, IC50 = 0.55 µg/mL. 
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Due to a frequent loss of bioactivity from batch to batch, a bioassay-guided epigenetic 
study was completed to explore which external stimuli had the most significant impact 
on active metabolite production. This was followed by a bioassay guided isolation of the 
active metabolites.  
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Figure 2-9. Growth pattern of H668 (A) and variation of the antimalarial activity of 
the crude extract as a function of the number of days of incubation (B) 
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Figure 2-10. Variation of the antimalarial activity of crude extract of culture of 
H668 as a function of the temperature of incubation  
 
Initial epigenetic studies involved the inoculation of 50 mL of ISP2 medium with 
an H668 spore suspension followed by incubation at different temperatures (20 - 30 ˚C) 
and for different periods of time (2, 5, 7, 12 days). It was determined that the best 
conditions for active metabolites production were long incubations (~12 days) and 
temperatures within the range 25 - 30 ˚C. These conditions were applied to generate 
enough crude extract for the isolation of bioactive secondary metabolites. The 
generated crude extract was first fractionated on C18 material (VLC) to generate a 
bioactive fraction (80% MeOH in H2O) which was further purified by HPLC on a silica 
gel column. This bioassay-guided approach revealed that the  bioactive metabolites 
were the polyether K41-A (5) [117] and its C-29 methyl ether (6) [189].  
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Figure 2-11. Structure of K41-A (6) and its C-29 OMe Ether (7) 
Though an OMe, instead of an OH, was the only difference between the flat 
structures of 6 and 7, their NMR data varied considerably. Based on the NOESY data, 
the main difference between both compounds resided in their 3D structure, instead. In 
fact, in the case of 6, long range correlations between atoms at opposite ends of the 
molecule were detected (Figure 2-12). This was not the case with 7 (Figure 2-13) and 
was interpretated as an indication of the chelation of a cation. It is important to point out 
that a new polyether was previously isolated from this same bacterium [120] 
 
 
 
 
 
Figure 2-12. Key NOESY correlations of 6 
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The effects of these molecules along with several other standard ionophores 
including gramicidin D were evaluated against several disease targets. These included 
Gram negative bacteria (Escherichia coli, Pseudomonas aeruginosa), Gram positive 
bacteria (Mycobacterium intracellulare, Mycobacterium tuberculosis and Methicillin-
resistant Staphylococcus aureus) and fungi (Candida albicans, Cryptococcus 
neoformans, and Aspergillus fumigatus).  K41-A and its methyl ether showed selectivity 
and outstanding potency against Gram-positive bacteria. The IC50s (µg/mL) against 
MRSA were 0.065 and 0.55, respectively for K41-A and its methyl ether. Corresponding 
MICs (µg/mL) were 1.25 and 5.00, respectively, for K41-A and its methyl ether. The IC50 
and MIC (µg/mL) values of K41-A against M. intracellulare were 0.15 and 0.31, 
respectively.  
 
 
 
 
 
Figure 2-13. Key NOESY correlations of 7 
K41-A, its methyl ether and several other ionophores (monensin, nigericin, 
calcimycin, gramicidin D, and valinomycin) were also tested again M. tuberculosis [190]. 
In the primary assay, the inhibition potential of all but valinomycin ranked between 99 
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and 100%. The MICs (µg/mL) of monensin, gramicidin D, K41-A and its ether were 0.88, 
7.68, 3.70 and 5.96, respectively. Pending further investigations, these molecules are 
interesting drug leads for the control of zoonotic tuberculosis and MRSA. 
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Table 2-2 NMR assignment of 6 and 7 in CD2Cl2 
 
 
Hawaiimycin B (6) Hawaiimycin C (7) 
 δCa δH mult. (J in Hz)b δCa δH mult. (J in 
Hz)b 
1.  174.9 / 178.7 / 
2.  72.9  4.82 br s 71.6  3.79, m 
3.  99.9   98.8 / 
4.  38.8 c 2.90, m 38.6 2.04, m 
5.  85.0  4.09 ud 85.0 3.29, br s 
6.  78.3 /  78.1  / 
7.  68.5  4.60, dd (1.8, 12.0) 66.5  3.80, m 
8.  33.5  2.31, m 32.6 1.54, m 
9.  61.7 4.70, m 61.3 3.93, m 
10.  32.5 c 2.84 , m 
1.89, m 
31.1 1.14, m/2.07, 
m 
11.  79.4 4.17, m 79.8 3.38d 
12.  37.6c 2.60, m 36.8  1.81, m 
13.  107.0  107.0 / 
14.  48.3 2.30, m 46.1  2.12, m 
15.  95.6  4.27, d (9.6) 94.6 3.53, m 
16.  82.4 / 83.4 / 
17.  84.8 4.43, dd (6.6, 9.6) 83.6  3.75, m 
18.  25.9c 2.66, m 
2.60, m 
25.5  1.93m, /1.77m 
19.  29.2c 2.76, m 
2.38 , m 
23.0  1.77, m 
20.  81.4  4.35, m 79.5 3.94, m 
21.  81.8 4.88, dd (6.6,  7.4) 79.4  4.43, m 
22.  30.5c 2.92, m 
2.47, m 
29.2 1.44, m / 2.00, 
m 
23.  25.4c 2.66, m 24.1  2.13, m / 
1.84m 
24.  80.2  4.99, dt (3.0, 7.2) 80.8 4.37, m 
25.  76.6 4.19, m 74.2 3.89, dd (2.0, 
10.0) 
26.  40.1c 2.04m 39.1 1.23, m 
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27.  83.3 4.06, m 82.7 3.32d 
28.  46.6c 2.80, m 47.0  1.42, m 
29.  101.5 / 98.3 / 
30.  22.2 2.07, s 26.7  1.26, s 
31.  11.7c 1.75, m 12.3/12.5/13.0c Interchc 
32.  13.6c 1.79, m 12.3/12.5/13.0c Interchc 
33.  28.5 2.29, s 28.2 1.60, s 
34.  13.6c 1.79, m 11.3 1.00, m 
35.  12.9c 1.76, m 12.3/12.5/13.0c Interchc 
36.  11.4 1.87, s 10.9 1.09, s 
37.  12.2 1.81, d (6.6) 11.8 1.03, d (3.0) 
5-OMe 61.4 4.31, s 60.7 3.52, s 
6-OMe 51.0 4.11, s 50.4 3.33, s 
11-OMe 57.8 4.07, s 59.9 3.44, s 
15-OMe 47.8 3.92, s 60.0 3.40, s 
29-OMe 60.7 4.17, s / / 
1’ 103.1 5.19, dd (1.8, 9.6) 102.6 4.42, m 
2’ 31.1c 2.70, m 30.5  1.39, m / 1.93, 
m 
3’ 27.9c 2.95, m 27.3 2.19, m 
4’ 80.9 3.54, dt (4.2, 10.2) 80.3  2.78, m 
5’ 75.1 4.02, m 74.4 3.24, m 
5’-Me 18.2 1.97, d (6)  18.1 1.20, d (6.0) 
4’-OMe 57.1 4.09, s 56.4 3.31, s 
5’-Me 
    
aAssignments based on DEPT, HMQC, and HMBC NMR data (100 MHz). bAssignments based on 
COSY and HMBC NMR data (400 MHz). cSignals partially overlapped. 
c 
 interchangeable methyl assignments, dberried signal
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Figure 2-14. 1H NMR spectrum of 6 in CD2Cl2 
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Figure 2-15. 13C NMR spectrum of 6 in CD2Cl2 
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Figure 2-16. NOESY spectrum of 6 in CD2Cl2 
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Figure 2-17. 1H NMR spectrum of 7 in CD2Cl2 
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Figure 2-18. 13C NMR spectrum of 7 in CD2Cl2 
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Figure 2-19. NOESY spectrum of 7 in CD2Cl2.   
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Chapter 3 : ANTIFUNGAL AND ANTI-HEPATITIS C 
VIRUS (HCV) CYCLIC PEROXIDES ISOLATED FROM 
A JAMAICAN SPONGE OF THE GENUS 
PLAKINASTRELLA 
 
 
 
ABSTRACT— Five new six-membered ring cyclic peroxides, plakinastreloic acid 
A (8), methyl plakinastreloate A (9), the C-12 epimers of methyl 13, 14-
epoxyplakinastreloate (10 & 11), and plakinastreloic acid B (12) were isolated from a 
marine sponge of the genus Plakinastrella. Their structures and relative configurations 
were determined. Compounds 8 and 9 exhibited antifungal activities against Candida 
albicans (IC50 = 6.5 µg/mL and 3.5 µg/mL, respectively), Aspergillus fumigatus (IC50 = 
4.0 µg/mL and 9.0 µg/mL, respectively) and Cryptococcus neoformans (IC50 = 4.0 
µg/mL and 9.0 µg/mL, respectively). A moderate antimalarial activity against CQ-
resistant and CQ-sensitive strains of P. falciparum was observed, as well. It was also 
established that 8 possesses anti-HCV activity. The percentage of HCV’s RNA inhibition 
at 10 µg/mL was estimated at 88%. Some cytotoxicity was observed, as well. 
 
Marine sponges have proven to be an excellent source of secondary metabolites, 
several of which show interesting bioactivity against a variety of disease targets. Among 
these compounds are cyclic peroxides, a group of secondary metabolites isolated from 
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sponges of the genus Plakortis and Plakinastrella [191]. Examples include plakortide F 
[192], plakinic acid F [193],  and epiplakinic acid F [193], plakortide Q and its analogues 
[194], ethyl plakortide Z, ethyl didehydroplakortide Z, and methyl didehydroplakortide Z, 
ethyl seco-plakortide Z, epi-ethyl seco-plakortide Z, and ethyl didehydro-seco-plakortide 
Z [195], andavadoic acid [196], nuapapuin A methyl ester [197], nuapapuin B [197]. 
Cyclic peroxides are bioactives molecules; they are reported to possess  antifungal 
(primarily against C. albicans and A. aspergillus) [193, 198, 199], antimalarial [199, 
200], antineoplastic  [194-197, 201, 202] and antiviral (HSV) activities [200]. 
 
Figure 3-1. Jamaican sponge of the genus Plakinastrella 
In a continued effort to identify new biologically active metabolites from the 
marine environment, several sponge samples were harvested from Jamaica (Rio 
Buenos Discovery Bay) using closed circuit rebreathers at a depth of - 40 m [203]. We 
previously reported the isolation of new peroxylactones from one of these samples 
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(Plakinastrella onkodes) [203]. Here, we report the isolation of five new six-membered 
ring cyclic peroxides from a liver sponge of the genus Plakinastrella (Figure 3-1) [203]. 
These include plakinastreloic acid A (8), methyl plakinastreloate A (9), the C-12 epimers 
of methyl 13, 14-epoxyplakinastreloate (10 & 11) and plakinastreloic acid B (12). 
Plakinastreloic acid A (8) was isolated as a colorless amorphous solid {[α]D = + 
38 (c.0.09, MeOH)}. The 13C NMR spectrum suggested that 8 contained 25 carbons. 
Inspection of the 13C and 1H NMR spectra suggested that the molecular formula was 
C25H36O4, indicating the presence of eight degrees of unsaturation. A molecular ion of 
399.9 was obtained by LCMS analysis under negative ion mode. 13C and 1H NMR data 
are provided in Table 3-1 and  
Table 3-2. Resonances attributable to five methyl groups were observed [δH 1.16 
(3H, d, J = 6.6 Hz), δH 1.67 (3H, brs), δH 1.36 (3H, s), δH 0.91 (3H, d, J = 6.8 Hz), δH 
0.93 (3H, d, J = 6.0 Hz)]. Compound 8 also contained 11 methine, four methylene, and 
four quaternary carbons. It was established based on the 1H-1H COSY spectrum 
analysis that 8 contained four independent spin systems; these spin systems are 
labeled A-D and shown in bold bonds in Figure 3-2; full tables of data are included. 
  
Figure 3-2. Key HMBC and 1H-1H COSY correlations for plakinastreloic acid A (8) 
and methyl plakinastreloate A (9)  
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These spin systems were connected based on HMBC correlations (Figure 3-2). 
First, several HMBC correlations were observed between the methylene protons H-2a 
(1H, δH 2.26, m), H-2b (1H, δH 2.68, dd, J = 2.4 Hz, 16.0 Hz) and C-1. Another HMBC 
correlation was observed between the methine proton H-3 (1H, δH 4.01, dt, J = 2.8 Hz, 
9.6 Hz) and the same carbon (C-1). When taken in conjunction with the molecula 
formula and the chemical shift of C-1, this suggested that 8 was a free acid. The 
connection of the first and second spin system was made possible by HMBC 
correlations between H-7a (1H, δH 1.21, m), H-7b (1H, δH 1.50, dd, J = 2.8 Hz, 14.8 Hz) 
and C-6, on the one hand and between H-5a (1H, δH 1.21, m) and C-22 on the other. 
The existence of HMBC correlations between H-24 (3H, δH 1.67, brs) and C-9 on the 
one hand, and between H-24 and C-11 on the other, allowed the connection of the 
second and the third spin system (Figure 3-2). Finally, the HMBC correlation between 
H-14 (1H, δH 6.36, d, J = 16 Hz) and C-15 allowed the connection of the aromatic ring to 
the third spin system. The structure of 8 was determined to be as depicted in Figure 3-2.  
A closely related molecule (13) and its methyl ester were reported in 1980 by 
Stierle and Faulkner [204]. These molecules were derived from a sponge of the genus 
Plakortis. Compounds 8 and 13 share the same molecula formula and skeleton; in both 
molecules, C-10 and C-11 are connected by a double bond. The only difference 
between 8 and 13 resides in the location of the second double bond. The second 
double bond of 8 connects C-13 and C-14 and in 13 C-12 and C-13, instead. Stierle and 
Faulkner reported 13 and its methyl ester as highly unstable compounds that 
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“decompose on standing” making data acquisition difficult. Several other reported 
peroxides did not share this feature [204]. 
 
Based on the NOESY spectrum analysis, it was established that the relative 
configuration of 8 is as depicted in Figure 3-3. A strong NOESY correlation was 
observed between H-3 (1H, δH 4.01, dt, J = 2.8 Hz, 9.6 Hz) and H-5a (1H, δH 1.21, m). It 
is important to note that no NOESY correlation was detected between H-3 and 5b (1H, 
δH 1.63, d, J = 4.4 Hz) and that the correlation between H-3 and H-2b (1H, δH 2.68, dd, J 
= 2.4 Hz, 16.0 Hz) was weak. Another important NOESY correlation was identified 
between H-22 (3H, δH 1.36, s) and H-4 (1H, δH 1.85, m).  
The strong NOESY correlations between H-11 (1H, δH 5.07, d, J = 8.8 Hz), H-9a 
(1H, δH 1.87, m) and H-9b (1H, δH 1.96, m) suggested an E configuration for the C-10 - 
C-11 double bond. It is important to point out that no similar correlation with H-24 (3H, 
δH 1.67, br s) was observed.  
Strong NOESY correlations were identified between H-13 (1H, δH 6.17, dd, J = 
6.0 Hz, 16.0 Hz), H-14 (1H, δH 6.36, d, J = 16.0 Hz) and the aromatic protons H-16/H20. 
This is only possible if H-13 and H-14 are trans-oriented, suggesting an E configuration 
of the corresponding double bond; the large coupling constant between H-13 and H-14 
(J = 16.0 Hz) confirms this assignment. No other proton had a NOESY correlation with 
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the aromatic protons. H-13 and H-14 both showed weak NOESY correlations to H-25, 
H-12 and H-11. 
Methyl plakinastreloate A (9) was isolated as a colorless amorphous solid {[α]
 D= 
+ 32 (c.0.03, MeOH)}. 13C and 1H NMR data for 9 are provided in Table 3-1 and 3-2. 
Analysis of its NMR spectrum revealed that it was similar to plakinastreloic acid A (8) in 
all but one point: the presence of an OMe signal (δH 3.67, δc 51.1); merged NMR spectra 
of 8 and 9 are included. This resonance showed an HMBC correlation to C-1 (δc 171.9), 
an indication that 9 was the methyl ester of plakinastreloic acid A (8). No difference was 
observed between the NOESY spectra of methyl plakinastreloate A (9) and that of 
plakinastreloic acid A (8), suggesting that these compounds had the same relative 
configuration (Figure 3-3).  
  
Figure 3-3. Relative configuration of plakinastreloic acid A (8) and methyl 
plakinastreloate A (9) based on NOESY correlations (↔) 
Two additional new molecules, 10 and 11 were isolated after further purification 
of the HPLC fraction which eluted with 6:94 H2O/CH3CN [C18 column, 21.2 × 250 mm at 
6 mL/min]. These two compounds eluted together, and because of a limited amount of 
material, their structures were solved as a mixture. The HRMS analysis (positive ion 
mode) of the mixture showed a single peak, an indication that 10 and 11 shared the 
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same molecular weight. 13C and 1H NMR data for 10 and 11 are provided in Table 3-1 
and 3-2. Inspection of the 1H and 13C NMR spectra coupled with HRMS data suggested 
a formula of C26H38O5Na for 10 and 11 [(M+ Na) - m/z observed 453.2617], indicating 
the presence of eight degrees of unsaturation in each of these molecules.     
A comparative analysis of the NMR spectra of 9 with that observed for the 
mixture of 10 and 11 suggested that these three compounds share a common moiety 
(C-1 through C-11) (Figure 3-4); full tables of data are included. The remainder of the 
structure of 10 and 11 was assembled through analysis of the 1H-1H COSY spectrum of 
10 and 11 as follows: H-11 was coupled to the methine proton H-12 (δH 2.63 and δH 
2.47, for 10 and 11, respectively); this proton was in turn coupled to H-25 (δH 1.06 and 
δH 1.1, for 10 and 11, respectively) and H-13 (δH 2.79 and δH 2.86, for 10 and 11 
respectively). H-13 was in turn coupled to a methine proton H-14 (δH 3.69 and δH 3.7, for 
10 and 11, respectively).  
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COSY
 
Figure 3-4. Structural moiety shared by 10, 11, 8 and 9 
The chemical shifts of C-13 (δC 67.0 and 66.8, for 10 and 11, respectively) and C-
14 (δC 56.9 and 57.9, for 10 and 11 respectively) are consistent with oxygen substitution 
at these positions. When taken in conjunction with the molecular formula of these 
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molecules, this suggests the presence of an epoxide ring at C-13 – C-14. The strong 
HMBC correlation between H-14 (δH 3.66 and δH 3.77 for 10 and 11, respectively) and 
aromatic carbons C-15 and C-16 allowed the incorporation of a phenyl substituent at C-
14. The aromatic signal (δH 7.1-7.3) integrates for 10 instead of five protons. This further 
suggests that we are dealing with a mixture and that the aromatic rings of 10 and 11 are 
mono substituted. It was established based on the 1H-1H COSY spectrum analysis that 
10 and 11 contained four independent spin systems; these are labeled A-D and shown 
in bold bonds in Figure 3-5; full tables of data are included. The planar structures of 10 
and 11 are identical and depicted in Figure 3-5.   
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Table 3-1.  13C NMR data for compounds 8 - 12 (600 MHz) 
 
8 (CD3OD) 9  
(CD3OD) 
10  (CD3OD)a 11  (CD3OD)a 12  (CD2Cl2) 
1. 173.7 171.9  171.9 171.9 169.8 
2. 36.0   35.8  35.7 35.7 69.6 
3. 83.7   83.7   83.7 83.7 43.8  
4. 30.3   30.4 30.3 30.4 45.6  
5. 42.7 42.8 42.7 42.7 84.4  
6. 81.5 81.8 81.7 81.7 51.6   
7. 47.0 47.3 47.3 47.3 28.8   
8. 26.0 26.2 26.1 26.1 39.0  
9. 49.1 49.3 49.1 49.2 27.2    
10. 133.2 133.3   135.6 135.8 29.6-30.0u 
11. 130.4 130.6  126.8  127.6  29.6-30.0u 
12. 35.6 35.7  34.5  35.5 29.6-30.0u 
13. 134.7 134.8  67.0  66.8 29.6-30.0u 
14. 127.5 127.6 56.9  57.9 29.6-30.0u 
15. 137.9 138.1 138.0 138.0  29.6-30.0u 
16. 125.6 128.3 125.3 125.4  29.6-30.0u 
17. 128.1 125.8 128.3  128.3   29.6-30.0u 
18. 126.5 126.6  127.8 127.7   32.1 
19. 128.1 125.8 128.3  128.3   22.9  
20. 125.6 128.3 125.3  125.4   14.1 
21. 16.1 16.2 15.6  16.2 31.1  
22. 19.9 20.0  20.0  20.0  28.1  
23. 20.9 21.0   20.7 21.0  21.7  
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24. 15.1 15.2  15.4   15.6  / 
25. 20.3 20.4    16.2  16.7  / 
OMe / 51.1  51.1   51.1   / 
u interchangeable assignments (methylene carbons of the aliphatic chain). a the structures of 
compounds 10 and 11 were solved as a mixture; assigned signals are thus interchangeable for any given 
position 
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Table 3-2. 1H NMR data of compounds 8-12 (600 MHz) δH,mult. (J in Hz)  
 
8 (CD3OD) 9  (CD3OD) 10  
(CD3OD)a 
11  (CD3OD)a 12  (CD2Cl2) 
1. / / / / / 
2. 2.68, dd (2.4, 
16.0)/ 2.26, m 
2.72, dd (3, 
16.2) 
2.28, dd (9, 
15.6)  
2.71, m 
2.26, m 
2.71, m 
2.26, m 
/ 
3. 4.01, dt ( 
2.8,9.6) 
3.97, dt (3, 9.6)  3.95,m 3.96, m 2.56, dd 
(2.4,16.8) 
2.39, d (16.8)  
4. 1.85, m 1.85, m 1.81, m 1.81, m 1.93, dd (2.0, 
14.0) 
1.77, d (14.4) 
5. 1.63, d (4.4) 
1.21, m 
1.63, d (6) 
1.21, m 
1.62, m 
1.25, m 
1.62, m 
1.25, m 
/ 
6. / / / / 1.62, m 
1.46, dd (7.0, 
15.2) 
7. 1.50, dd (2.8, 
14.8)  
1.21, m 
1.48, dd  (2.4, 
14.4) 1.17, m 
1.24, m 
1.57, m 
1.24, m 
1.57, m 
1.62, m 
8. 1.81, m 1.8, m 1.80, m 1.80, m 1.29, m 
1.17, m 
9. 1.87, m 
1.96, m 
1.82, m 
1.9, m 
1.82, m 
1.91, m 
1.82, m 
1.91, m 
1.27, m 
10. / / / / 1.27, m 
11. 5.07, d (8.8) 5.04, d (8.4) 5.00, m 5.00, m 1.27, m 
12. 3.26, m 3.24, m 2.63, m 2.47, m 1.27, m 
13. 6.17, dd (6.0, 
16.0) 
6.15, dd  (6.2, 
16.2)  
2.79, dd 
(2.4, 6.0) 
2.86, dd (2.4, 
6.0) 
1.27, m 
14. 6.36, d (16.0) 6.33, d (16.2) 3.66, d (2.0) 3.77, d (2.0) 1.27, m 
15. / / / / 1.27, m 
16. 7.32, m 7.24, m 7.20, m 7.20, m 1.27, m 
17. 7.27, m 7.30,  m 7.30, m 7.30 , m 1.27, m 
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18. 7.17, m   7.14, m    7.23, m 7.23, m 1.27, m 
19. 7.27, m 7.30, m 7.30, m 7.30, m 1.27, m 
20. 7.32, m 7.24, m 7.20, m 7.20, m 0.88, t (7.2)   
21. 0.91, d (6.8) 0.91, d (6.6) 0.86, m 0.86, m 1.34, s 
22. 1.36, s 1.33, s  1.26s 1.29s 1.52, s 
23. 0.93, d (6.0) 0.93, d (6 ) 0.81, d (7.0) 0.9, d (7.0) 
 
0.97,d (6.6) 
24. 1.67, brs* 1.64, s 1.64, brs 1.66, brs / 
25. 1.16, d (6.6) 1.12, d (6.6)  1.06, d (7.0) 1.1, d (6.0) / 
OMe / 3.67, s 3.67, s 3.67, s / 
u interchangeable assignments (methylene carbons of the aliphatic chain). a the structures of 
compounds 3 and 4 were solved as a mixture; assigned signals are thus interchangeable for the same 
carbon position 
 
 
Figure 3-5. Key HMBC and 1H-1H COSY correlations for compounds 10 and 11 
The next step was to attempt to determine what differentiated 10 from 11. 
NOESY correlations appeared to be identical around the double bonds in 10 and 11. 
The olefinic proton H-11 (δH 5.00 and δH 5.00, for 10 and 11, respectively) did not show 
a correlation to the methyl signal at C-24 (δH 1.64 and δH 1.66, for 10 and 11, 
respectively) but did show a correlation to H-25 (δH 1.06 and δH 1.1, for 10 and 11, 
respectively) and H-9 (δH 1.82/1.91 and δH 1.82/1.91, for 10 and 11, respectively) 
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leading to an E configuration of these double bonds in both compounds. 
 As for the configuration around the epoxide ring, H-13 (δH 2.79 and δH 2.86, for 
10 and 11, respectively), gave a NOESY correlation to the aromatic proton H-16 (δH 
7.20 and δH 7.20, for 10 and 11, respectively). This point added to the fact that there 
was no NOESY correlation between the aromatic protons and the olefinic signal H-11 
was an indication that the aromatic ring had an α orientation while the C-11 – C-12 bond 
had a β orientation (Figure 3-6). The major difference between 10 and 11 is the 
chemical shifts of H-12 (δH 2.63 and δH 2.47, for 10 and 11, respectively). This suggests 
that 10 and 11 differ in the relative configuration between C-11 and C-12. The epoxide 
ring present in 10 and 11 could have resulted from a nonselective epoxidation of the C-
13 - C-14 double bond of 9. 
 
Figure 3-6. Key identical NOESY correlations for 10 and 11  
A fifth compound, plakinastreloic acid B (12), was isolated as a colorless 
amorphous solid {[α]D= + 60 (c.0.06, MeOH)}. The inspection of the 13C and 1H NMR 
spectra coupled with the HRMS data suggested a formula of C23H45O4 [(M+H+) m/z 
observed 385.4380], indicating the presence of two degrees of unsaturation. The 1H 
NMR spectrum indicated the presence of four methyl groups [δH 0.88 (3H, t, J = 7.2 Hz), 
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δH 0.97 (3H, d, J = 6.6 Hz), δH 1.34 (3H, s) and δH 1.52 (3H, s)]. Complex signals were 
present between δH 1.33 - 1.20 (23 H, m), suggesting the presence of an aliphatic chain. 
Based on the HSQC spectrum, these signals could be correlated to complex carbon 
signals in the δC 29.6 -30.0 region. This was further confirmed by the DEPT spectrum. 
 Based on the HSQC spectrum, the methylene protons could be assigned as 
follows: 2H attached to C-9, 2H attached to C-19, 1H attached to the methylene carbon 
C-8, and finally, 2H attached to C-18. By simple subtraction, it was established that the 
remaining 16 hydrogens (eight methylene) belonged to the aliphatic chain. Based on the 
HSQC, three additional methylene groups were identified, including C-3, C-4 and C-6. It 
was established that the molecule contained three quaternary carbons as well as a 
methine signal. All these carbons add up to a 23 carbon molecule.  
Analysis of the 1H-1H COSY spectrum showed evidence for the existence of 
three independent spin systems; these are labeled A-C and shown as bold bonds in 
Figure 3-7; full tables of data are included.  
The peroxide ring depicted in Figure 3-7 was assembled based on the following 
HMBC correlations:  first, the correlations between the methyl protons H-21 (3H, δH 
1.34, s) and C-1, C-2, C-3, C-4 and then the correlations between the methyl protons H-
22 (3H, δH 1.52, s) and the carbons C-5, C-4 and C-6. Because of the existence of an 
HMBC correlation between H-6a (1H, δH 1.46, dd, J = 7.0, 15.0), H-6b (1H, δH 1.62, m) 
and C-5, it was determined that the spin system that extended from C-6 trough C-8 was 
connected to the peroxide ring. Another HMBC correlation was identified between H-8a 
(1H, δH 1.17, m), H-8b (1H, δH 1.29, m) and a carbon at δC 27.2 which is part of the 
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aliphatic chain that extended from C-8 to C-20. H-20 (3H, δH 0.88, t, J = 7.2) gave an 
HMBC correlation to C-19 and C-18. Based on these correlations, the structure of 
plaskinatrealoic acid B (12) was determined to be as depicted in Figure 3-7.  
 
Figure 3-7. Key HMBC and 1H-1H COSY correlations of 12  
Based on the NOESY spectrum, it was established that the relative configuration 
around the peroxide ring of 12 is as depicted in Figure 3-8. A NOESY correlation was 
observed between H-22 (3H, δH 1.52, s) and H-3b; no similar correlation to H-3a was 
observed. A weak correlation was also detected between H-23 (3H, δH 0.97, d, J = 6.6) 
and H-22. Another NOESY correlation was observed between H-6a (1H, δH 1.46, dd, J = 
7.0 Hz, 15.2 Hz) and H-4a; no correlation between H-6a and H-4b was observed. 
Finally, there were NOESY correlations between H-21 (3H, δH 1.34, s) and both protons 
of the methylene C-3 and C-4, suggesting spin diffusion.  
 
Figure 3-8. Relative configuration of 12 based on NOESY correlations (↔) 
  
 111 
 
 Plakinastreloic acid A (8) and methyl plakinastreloate A (9) showed an 
interesting bioactivity profile. The IC50 values for plakinastreloic acid A (8) and methyl 
plakinastreloate A (9) against Candida albicans were 6.5 and 3.5 µg/mL, respectively; 
against Aspergillus fumigatus, the IC50 values were 4.0  and 9.0 µg/mL, respectively. 
Finally, against Cryptococcus neoformans, the IC50 values were  4.0   and 9.0 µg/mL 
respectively. A moderate antimalarial activity against the CQ-resistant (strain W2) and 
sensitive strains of P. falciparum (strain D6) was also observed for 8 and 9. For 
plakinastreloic acid A (8), the IC50 values were 3.8   and 2.7 µg/mL, respectively against 
D6 and W2. The selectivity indexes were higher than 1.3 and 1.8, respectively for these 
2 strains. For 9, the IC50 values against the malaria parasite were 2.3 µg/mL and 1.8 
µg/mL, respectively, for the CQ-sensitive (D6) and the CQ-resistant strains (W2) of P. 
falciparum. The selectivity indexes were higher than 2.1 and 2.6, respectively for these 
two strains. No cytotoxicity against Vero cells was observed up to 4.7 µg/mL, the 
highest concentration tested. Plakinastreloic acid A (8) also exhibited antiviral activity 
against the Hepatitis C Virus (HCV) in a dose dependent manner. At the highest 
concentration (10 µg/mL), the percentage of HCV’s RNA inhibition was estimated at 
88%. It is important to note that a significant reduction in the level of rRNA replicon was 
noted as well (Figure 3-9) suggesting that plakinastrella A (8) acts in a non-selective 
manner (cytotoxic). The EC50 was 2.2 µg/mL and the EC90 > 10 µg/mL.   
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Figure 3-9. Dose-dependent anti-HCV activity of plakinastreloic acid A (8) 
 
2. Experimental 
2.1. General experimental procedures 
1D and 2D NMR spectra were recorded on a 600 MHz NMR spectrometer 
(Varian; 3mm inverse probe with variable temperature control (vtc). Chemical shifts are 
expressed in ppm with the residual solvent signal used as standard.  
Semi-preparative and preparative HPLC were carried out using a Waters PrepLC 
system; Reverse (C18, C8) and normal phase (silica gel) HPLC columns were used 
subsequently. The MW of 8 was determined by LCMS analysis under negative (Bruker 
Daltonics MicroTOF LCMS). The high resolution mass spectra (HRMS) for 10, 11, and 
12 were recorded on a Waters Micromass Q-TOF® Micro mass™ spectrometer 
equipped with a NanoLockSpray™ source.  
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2.1.1 Extraction and isolation 
 A bioassay-guided approach was used for the isolation of all compounds 
mentioned in this report. Targeted biological assays included tests against P. 
falciparum, HCV and a variety of microbial pathogens (Gram positive and negative 
bacteria, as well as, a set of fungi). The initial fractionation of the crude extract was 
completed by VLC on silica gel using a n-hexane/acetone gradient. The most active 
fraction was further purified by HPLC. The first HPLC was completed on a 100 × 250 
mm C8 column. The flow rate was 25 mL/min and the solvent system varied from 100:0 
H2O/CH3CN  40:60 H2O/CH3CN over 60 minutes and then from 40:60 H2O/CH3CN  
0:100 H2O/CH3CN over an additional 240 minutes. The fraction collection was UV–
guided (254 nm) and 62 fractions were collected. Two of these fractions that eluted with 
100% CH3CN, namely the fraction 44, from which 8, 9, 10, 11 were isolated and the 
fraction 58 from which 12 was isolated, were selected for further purification. The HPLC 
of fraction 44 using the same column (C8, 100 × 250 mm) but a different solvent system 
led to poor separation; solvents were set to vary from 25:75 H2O/CH3CN  20:80 
H2O/CH3CN over 40 minutes and then from 20:80 H2O/CH3CN 0:100 H2O/CH3CN 
over an additional 80 minutes. Nonetheless, the further purification of a fraction that 
eluted with 100% CH3CN by prep-TLC led to the isolation of 9. The solvent system for 
the prep-TLC was 80:20 n-hexane-EtOAc. A better separation was achieved by 
switching the column to Phenomenex C18 column (21.2 × 250 mm). The solvent system 
varied from 25:75 H2O/CH3CN  20:80 H2O/CH3CN (40 minutes) and from 20:80 
H2O/CH3CN 0:100 H2O/CH3CN for an additional 80 minutes; the flow rate was 6 
mL/min; using this second approach, 8 eluted with 14:86 H2O/CH3CN. The fraction that 
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eluted with 6:94 H2O/CH3CN was further purified using a Phenomenex C8 column (10 × 
250 mm). In this particular case, the solvent system varied from 15:85 H2O/CH3CN  
0:100 H2O/CH3CN (25 minutes) and 10 and 11 eluted with 0:100 H2O/CH3CN.  The 
amount of plakinastreloic acid A (8) derived from 30 mg of fraction 44 was 3.5 mg and 
the combined weight of 10 and 11, epimers of 13, 14 –epoxyplakinatreloate, was 1.6 
mg; the structure of 10 and 11 was solved as a mixture. The fifth compound 
(plaskinastreloic acid B) was isolated from the fraction 58. The amount of plakinastreloic 
acid C (12) derived from 40 mg of fraction 58 was 3.5 mg. The purification of 
plaskinastreloic acid B (12) was completed using a Luna 10µ silica HPLC column (21.2 
× 250 mm). The solvent system varied from 0:100 2-propanol/n-hexane  10:90 2-
propanol/n-hexane over 45 minutes and then from 10:90 2-propanol/n-hexane  40:60 
2-propanol/n-hexane (25 minutes). All these isolations were monitored by UV (254 nm) 
and 12 eluted with 14:86 2-propanol/n-hexane.  
Plakinastreloic acid A [8]. Colorless amorphous solid; [α]D = + 38 (c.0.09, 
MeOH); MS negative mode m/z 399.9 (very weak signal) [M-H] (calcd for C25H35O4, 
399.2535); 1H NMR (CD3OD)  
Table 3-2 and 13C NMR (CD3OD) Table 3-1  
Methyl plakinastreloate [9]. Colorless, amorphous solid; [α]D= + 32 (c.0.03, 
MeOH); C26H38O4, calcd = 414.2770; 1H NMR (CD3OD);   
Table 3-2 and 13C NMR (CD3OD)  Table 3-1 
Epimer of Methyl 13, 14-epoxyplakinastreloate [10 and 11] Colorless 
amorphous solid. The HRMS m/z 453.2617 [M + Na+] (calcd for C26H38O5Na, 
453.2617); 1H NMR (CD3OD);  
Table 3-2 and 13C NMR (CD3OD) Table 3-1 
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Plakinastreloic acid B [12]. Colorless, amorphous solid [α]D= + 60 (c.0.06, 
MeOH); HRMS m/z 385.3318 [M + H+] (calcd for C23H45O4, 385.6033); 1H NMR 
(CD2Cl2); 
Table 3-2 and 13C NMR (CD2Cl2)  Table 3-1 
2.2. Material and methods 
2.2.1. Antifungal and antibacterial assay  
Several strains: Candida albicans ATCC 90028, Cryptococcus neoformans 
ATCC 90113, Aspergillus fumigatus ATCC 90906, Methicillin resistant Staphylococcus 
aureus ATCC 43300, Escherichia coli ATCC35218,  Pseudomonas aeruginosa ATCC 
27853, and Mycobacterium intracellular ATCC 23068) were used in these assays. 
Positive controls were amphotericin B (for C. albicans, C. neoformans and A. fumigatus) 
and ciprofloxacin for the rest the remaining bacteria. This assay was completed in a 96 
well plate format [205]. 
2.2.2. Antiviral  assay  
The anti-HCV activity was determined in the HCV replicon (Clone B) system 
(Huh 7 clone B cells containing HCV RNA). Cells were seeded onto 96-well tissue 
culture plates (3,000 cells/well); the compounds were tested in a dose response at 
concentrations of 10, 3, 1 uM (triplicate). After addition of test compounds the plates 
were incubated for five days (37 °C, 5%, CO2). Afterwards the total cellular RNA was 
extracted using the manual Perfect Pure RNA 96 cell Vacki from 5 Prime. The replicon 
RNA and the internal control (TaqMan rRNA control reagent, applied Biosystems) were 
amplified by RT-PCR. The antiviral potency of the tested molecule was determined by 
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subtracting the threshold RT-PCR cycle of the tests compounds from the threshold RT-
PCR of the negative control (no drug): #CtHCV ( a 3.3 value being considered a 1 log 
reduction in replicon RNA level (in other words 90% reduction). The cytotoxicity was 
calculated using #Ct rRNA values and RS-446 (2-Me-C) was used as control to 
determine the EC50 and EC90 values [206, 207]. 
2.2.3. Antimalarial assay  
The test was based on the determination of plasmodial LDH activity. Suspensions 
of red blood cells infected with D6 or W2 strains of P. falciparum (200 µL, with 2% 
parasitemia and 2% hematocrit in RPMI 1640 medium supplemented with 10% human 
serum and 60 µg/mL amikacin) was added to the wells of a 96-well plate containing 10 
µL of test samples diluted in medium at various concentrations. The plate was placed in 
a modular incubation chamber (Billups-Rothenberg, CA) flushed with a gas mixture of 
90% N2, 5% O2, and 5% CO2 and incubated at 37 ºC, for 72 h. Parasitic LDH activity 
was determined according to the procedure of Makler and Hinrichs (1993). 20 µL of the 
incubation mixture was mixed with 100 µL of the MalstatTM reagent (Flow Inc., Portland, 
OR) and incubated at room temperature for 30 minutes. 20 µL of a 1:1 mixture of 
NBT/PES (Sigma, St. Louis, MO) was added and the plate is further incubated in the 
dark for 1 h. The reaction was stopped by the addition of 100 µL of a 5% HOAc solution. 
The plate was read at 650 nm using the EL-340 Biokinetics Reader (Bio-Tek 
Instruments, Vermont). IC50 values were computed from the dose response curves. 
Artemisinin and CQ were included in each assay as the drug controls. DMSO (0.25%) 
was used as a vehicle control [208]. 
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Table 3-3. Complete 1D and 2D data of 8 (CD3OD) 
 
13C   δ H mult. (J in Hz)   COSY HMBC NOESY 
1.  / / / H-2a, 
H-2b, 
H-3 
/ 
2.  36.0   2.68, dd (2.4, 16.0)/ 
2.26, m 
H-3, H-2a, H2b / / 
3.  83.7   4.01, dt (2.8,9.6) H-2a, H-2b, H-4 H-21, H-
2a, H-2b, 
H-5a, H-
5b, H-4 
H-21, H-5a, 
H-2a, H-2b 
4.  30.3   1.85, m H-3, H-21, H-5a, 
H-5b 
H-21, H-5 H-5a, H-22 
5.  42.7 1.63, d (4.4) 
1.21, m 
H-4 H-22, H-
21 
H-4, H-23 
6.  81.5 -  H-7a, H-
7b, H-5a, 
H-5b, H-
22 
 
7.  47.0 1.50, dd (2.8, 14.8)  
1.21, m 
H-8 H-23, H-
22, H-9a, 
H-9b 
H-9a, H-9b 
8.  26.0 1.81, m H-7a, H-7b, H-
23, H-9abm 
H-23, H-
7a, H-7b 
 
9.  49.1 1.87, m 
1.96, m 
H-8m H-24, H-
23, H-7a, 
H-7b 
H-7a, H-7b, 
H-23 
10.  133.2 / / H-12, H-
9, H-24 
/ 
11.  130.4 5.07, d (8.8) H-12 H-25, 
H24, H-
9a, H-9b, 
H-12, H-
14 
H-13, H14, 
H-25 
12.  35.6 3.26, m H-11, H-25, H-
13 
H-25 H-13, H-14, 
H-25 
13.  134.7 6.17, dd (6.0, 16.0) H-12, H-14 H-25, H12 H-11,H-12, 
H-16/H-20, 
H-25, H-14 
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14.  127.5 6.36, d (16.0) H-13 H-13, H-
12 
H-11,H-12, 
H-16/H-20, 
H-25, H-13 
15.  137.9 / / H-14, H-
13, H-17 
 
16.  125.6 7.32, m H-17/H-19m H-20, H-
14, H-18 
H-13, H-14 
17.  128.1 7.27, m H-18, H20/H16m H-19, H-
15 
/ 
18.  126.5 7.17, m   H-17  / 
19.  128.1 7.27, m H-18, H20/H16m H-17, H-
15 
/ 
20.  125.6 7.32, m H-17/H-19m H-16 H-13, H-14 
21.  16.1 0.91, d (6.8) H-4 H-5a, H-
5b 
H-3, H-2b, 
H-4 
22.  19.9 1.36, s / H-7a, H-
7b, H-5a 
/ 
23.  20.9 0.93, d (6.0) / H-7a, H-
7b, H-9a, 
H-9b 
H-5b, H-9a, 
H-9bW, H-
7a, H-22, H-
8 
 
24.  15.1 1.67, br s* / H-9a, H-
9b, H-11 
H-12 
25.  20.3 1.16, d (6.6) H-12 H-11, H-
12, H-13, 
H-14 
H-12, H-11, 
H-13 
*assigned as a broad singlet, slightly split at the top but has no COSY correlation,  
m merged signals  
wweak correlations 
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Table 3-4. Complete 1D and 2D data of 10 and 11 (CD3OD) 
 
13C 
10 
13C 
11 
δH mult. (J 
in Hz) 10 
δH mult. (J in 
Hz)  
11 
COSY HMBC  NOESY 
1. 171.9 171.9 /        / / OMe, 
H-2a, 
H-2b,  
/ 
2. 35.7 35.7 2.71, m 
2.26, m 
2.71, m 
2.26, m 
H-2a, 
H2b,H-
3 
/ / 
3. 83.7 83.7 3.95,m 3.96, m H-2a, 
H-2b, 
H-4 
H-21, H-
2a, H-2b, 
H-5b 
H-21, H-
5a, H-2a, 
H-2b 
4. 30.3 30.4 1.81, m 1.81, m H-3, H-
21, H-
5a, H-
5b 
H-21, H-
5a, H5b 
/ 
5. 42.7 42.7 1.62, m 
1.25, m 
1.62, m 
1.25, m 
H-4 H-4, H-3, 
H-21, H-
22 
/ 
6. 81.7 81.7 / / / H-5a, H-
22 
/ 
7. 47.3 47.3 1.24, m 
1.57, m 
1.24, m 
1.57, m 
H-8 H-22, H-
23w, H-9a, 
H-9b 
/ 
8. 26.1 26.1 1.80, m 1.80, m H-7a, 
H-7b, 
H-9abm 
H-23, H-
7a, H-7b 
/ 
9. 49.1 49.2 1.82, m 
1.91, m 
1.82, m 
1.91, m 
H-8m H-23, H-
24, H-7a, 
H-7b 
/ 
10. 135.6 135.8 / / / 
 
H-24,  
H-9a, H-
9b, H-12 
/ 
11. 126.8  127.6  5.00, m 5.00, m H-12 H-9,  
H-24,  
H-25,  
H-12 
H-25, 
H9a, H9b, 
H13, H14 
12. 34.5  35.5 2.63, m 2.47, m H-25, 
H-11, 
H-13 
H-25, H13 H-14, H-
24, H-25 
13. 67.0  66.8 2.79, dd 
(2.4, 6.0) 
2.86, dd (2.4, 
6.0) 
H-14, 
H-12 
H-25, H-
12 
H-16/H-20 
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14. 56.9  57.9 3.66, d 
(2.0) 
3.77, d (2.0) H-13 H-15, H16 H-16/H-20 
15. 138.0 138.0  / / / H-14, H-
16 
/ 
16. 125.3 125.4  7.20, m 7.20, m m H-14, H-
20, H-18 
H-14, H-
13 
17. 128.3  128.3   7.30, m 7.30 , m m H-19, H-
15 
/ 
18. 127.8 127.7   7.23, m 7.23, m m / / 
19. 128.3  128.3   7.30, m 7.30, m -m / / 
20. 125.3  125.4  7.20, m 7.20, m -m / / 
21. 15.6  16.2 0.86, m 0.86, m / H-5 H-2b, H-3, 
H-4 
22. 20.0  20.0  1.26s 1.29s / H-7a, H-
7b, H-5a 
H-42b, H-
4 
23. 20.7 21.0  0.81, d 
(7.0) 
0.9, d (7.0) / H-9a, H-
9b, H-7b 
 
24. 15.4   15.6  1.64, brs 1.66, brs / H-11, H-
9a, H-9b 
H-12 
25. 16.2  16.7  1.06, d 
(7.0) 
1.1, d (6.0) / / H-12, H-
11 
OMe 51.1   51.1   3.67, s 3.67, s / / / 
w weak signal, m merged 
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Table 3-5. Complete 1D and 2D data of 12 (CD2Cl2) 
 
13C 
(CD2Cl2) 
δH mult. (J in Hz) 
(CD2Cl2) 
COSY HMBC NOESY 
1.  169.8 / / H-3a, H-
3b, H21 
/ 
2.  69.6 / / H-21, H-3a, H-
3b, H-4a, H-
4b, 
/ 
3.  43.8  2.56, dd (2.4,16.8) 
2.39, d (16.8)  
H4b, H-
3a, H-3b 
H-21, H-4aw, 
H-4b, 
H-21, H-4a 
4.  45.6  1.93, dd (2.0, 14.0) 
1.77, d (14.4) 
H3b, H-
4a, H-4b 
H-21, H22, H-
3a, H-3b, H-
6aw, H-6bw, 
H-3a, H-21, H-
6a4 
5.  84.4  / / H-22, H-4a, H-
6a, H-6b 
/ 
6.  51.6   1.62, m 
1.46, dd (7.0, 15.2) 
H-6a, H-
6b 
H-22, H-23, H-
4a, H-4bw, 
H-23, H-4a6 
7.  28.8   1.62, m H-23, H-
8a, H-8b 
H-23, H-6a, H-
6b, 
/ 
8.  39.0  1.29, m 
1.17, m 
/ H-23, H-6a, H-
6b, 
/ 
9.  27.2    1.27, m -m -m -m 
10.  29.6-30.0u 1.27, m -m -m -m 
11.  29.6-30.0u 1.27, m -m -m -m 
12.  29.6-30.0u 1.27, m -m -m -m 
13.  29.6-30.0u 1.27, m -m -m -m 
14.  29.6-30.0u 1.27, m -m -m -m 
15.  29.6-30.0u 1.27, m -m -m -m 
16.  29.6-30.0u 1.27, m -m -m -m 
17.  29.6-30.0u 1.27, m -m -m -m 
18.  32.1 1.27, m -m H-20 -m 
19.  22.9  1.27, m -m H-20 -m 
20.  
 14.1 0.88, t (7.2)   - H-19-H-9m - 
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21.  31.1  1.34, s - H-3a, H-3b, H-
4a, H-4b, 
H-3a, H-3b, H-
4a, H-4b, 
22.  28.1  1.52, s - - H-4b 
23.  21.7  
 
0.97, d (6.6) - H-6a, H-6b, H-6a, H-
7/H6b, H-22 
m
 merged  
u
 interchangeable  
*stronger signal  
6Correlation to H-6a 
4Correlation to H-4a 
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Figure 3-10.  1H NMR spectrum of the plakinastreloic acid A (8) (CD3OD) 
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Figure 3-11. 13C NMR spectrum of the plakinastreloic acid A (8) (CD3OD) 
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 Figure 3-12. DEPT spectrum of the plakinastreloic acid A (8) (CD3OD) 
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Figure 3-13. 1H-1H COSY spectrum of the plakinastreloic acid A (8) (CD3OD) 
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Figure 3-14. HSQC spectrum of the plakinastreloic acid A (8) (CD3OD) 
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Figure 3-15. HMBC spectrum of the plakinastreloic acid A (8) (CD3OD) 
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Figure 3-16. NOESY spectrum of the plakinastreloic acid A (8) (CD3OD) 
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Figure 3-17. 1H NMR spectrum of the methyl plakinastreloate (9) (CD3OD) 
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Figure 3-18. 13C NMR spectrum of the methyl plakinastreloate (9) (CD3OD) 
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Figure 3-19. 1H-1H COSY spectrum of the methyl plakinastreloate (9) (CD3OD)  
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Figure 3-20. DEPT spectrum of the methyl plakinastreloate (9) (CD3OD) 
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Figure 3-21. HSQC spectrum of the methyl plakinastreloate (9) (CD3OD) 
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Figure 3-22. HMBC spectrum of the methyl plakinastreloate (9) (CD3OD) 
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Figure 3-23. Merged 1H NMR spectra of 8 (green) and 9 (red) 
 
 
 
 
 137 
 
1
5
.0
5
1
6
.1
4
1
9
.9
3
2
0
.3
2
2
0
.9
0
2
6
.0
1
3
0
.3
3
3
5
.6
3
4
2
.6
8
4
7
.1
9
4
7
.2
6
4
7
.4
0
4
7
.5
4
4
7
.6
8
4
7
.8
2
4
7
.9
7
4
8
.1
1
4
9
.1
6
8
1
.5
2
8
3
.7
0
1
2
5
.6
6
1
2
6
.5
1
1
2
7
.4
9
1
2
8
.1
4
1
3
0
.4
6
1
3
3
.2
1
1
3
4
.6
4
1
3
7
.9
2
  
Figure 3-24. Merged 13C NMR spectra of 8 (green) and 9 (red) 
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 Figure 3-25. Merged 1H-1H COSY spectra of 8 (gray) and 9 (orange) 
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Figure 3-26. Merged HMBC spectra of 8 (red) and 9 (gray) 
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Figure 3-27. 1H NMR of the methyl 13, 14-epoxyplakinastreloate (10 and 11) 
(CD3OD) 
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Figure 3-28. 13C NMR spectrum of the methyl 13, 14-epoxyplakinastreloate (10 and 
11) (CD3OD) 
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Figure 3-29. DEPT spectrum of the methyl 13, 14-epoxyplakinastreloate (10 and 
11) (CD3OD) 
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Figure 3-30. 1H-1H COSY spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 
11) (CD3OD) 
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Figure 3-31. HMBC spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 11) 
(CD3OD) 
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Figure 3-32. HSQC spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 11) 
(CD3OD) 
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Figure 3-33. NOESY spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 11) 
(CD3OD) 
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Figure 3-34. 1H NMR spectrum of plakinastreloic acid B (12) (CD2Cl2) 
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Figure 3-35. 13C NMR spectrum of plakinastreloic acid B (12) (CD2Cl2) 
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Figure 3-36. DEPT spectrum of plakinastreloic acid B (12) (CD2Cl2) 
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Figure 3-37. 1H-1H COSY spectrum of plakinastreloic acid B (12) (CD2Cl2) 
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Figure 3-38. HMBC spectrum of plakinastreloic acid B (12) (CD2Cl2) 
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Figure 3-39. HSQC spectrum of plakinastrelloic acid B (12) (CD2Cl2) 
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Figure 3-40. NOESY spectrum of plakinastreloic acid B (12) (CD2Cl2) 
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Chapter 4 : BIOASSAY-GUIDED ISOLATION OF HCV 
ACTIVE METABOLITES FROM INGA FAGIFOLIA AND 
DIPLOSTEPHIUM RHODENDROIDES  
 
 
ABSTRACT - Two new molecules were isolated from Hepatitis C Virus (HCV) active 
methanol extracts of Inga fagifiolia (twigs) and Diplostephium rhodendroides (leaves). 
These compounds were identified as 2,3,4,5,6-pentahydroxy-2-(hydroxymethyl) 
hexanamide (14) and 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-
yl)oxy]pentanoic acid (15). The bioassay-guided approach used for their isolation and 
structure elucidation is reported here. 
 
1. Introduction 
Hepatitis C, caused by HCV is a serious condition which, according to the CDC, 
currently affects about 3.2 million Americans. HCV targets the liver causing 
inflammation. HCV is a highly mutable virus; this property has made it difficult to 
address this disease effectively. Consequently, there is an urgent need for new anti-
HCV drug leads. 
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In a continuous effort to find new drug leads against infectious diseases, we 
initiated a screening campaign of plant and marine extracts from the National Cancer 
Institute repository of natural products. These extracts were screened for their ability to 
inhibit HCV. Two extracts with outstanding activity were the crude extracts of the twigs 
of I. fagifiolia and the leaves of D. rhodendroides.  
I. fagifiolia (Figure 4-0-1), also known as Mimosa fagifolia L., I. tetraphylla (Vell.) Mart, 
M. laurina Sw., M. tetraphylla Vell, Feuilleea fagifolia (L.) Kuntze or F. laurina (Sw.) 
Kuntze  is a well known tree belonging to the order Fabales, family Fabaceae and sub-
family Mimosoideae. I. fagifolia is a non climbing perennial tree and not an endangered 
species. The reported use of this tree is environmental, being used as a shade tree. The 
geographical distribution of this plant is wide. I. fagifolia has been reported in many 
countries around the world. These include the Caribbean regions, Central America, 
Indian Ocean regions, and South American regions. It possesses a variety of vernacular 
names; these include Pois Doux Blanc, Arbre a Miel, Caspiro, Cujincuil, Gina, Jina, 
Nacaspiro, Palal, Paternillo, Paternillo and Spanish Oak [209, 210].  Reports concerning 
the isolation of secondary metabolites from I fagifolia, especially those of biological 
importance are scarce. A few molecules have been isolated from this plant in recent 
years. These include a protein inhibitor of trypsin isolated from seeds [209], and three 
new galloyl depsides of tyrosine [211] that are abundantly produced in young leaves of 
I. Fagifolia. The primary structure of the protein was EVVVDSDGEMLRNGGKYY 
LSPANPIGGGAIISAAIRHGDHLCSLAVVS. The structures of these new galloyl 
depsides are displayed below [209, 211]. 
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Figure 4-0-1. Inga fagifolia 
 D. rhodendroides, on the other hand, is a flowering plant that belongs to a 
subgroup of Diplostephium with characteristic disk flowers. The latter are more or less 
clavate and merely bifid; corresponding branches are very short and ovate. D. 
rhodendroides has been reported in Ecuador and Columbia. Plants of the genus 
Diplostephium are believed to have evolved from Aster, another genus of the familly 
Asteraceae, by adapting to extreme paramos’ conditions. Among other evolutionary 
variations was the development of tomentum under leaves and on branches. About 110 
species (trees and shrubs) have been reported to belong to the genus Diplostephium. 
Plants of this genus are mainly distributed in Columbia. Several species have been 
Inga fagifolia 
www.les-vegetaliseurs.com 
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reported in several other nearby countries, such as Ecuador, Peru, Chile, Coasta Rica, 
Venezuela, and Bolivia [212, 213]. 
2. Results and Discussion  
The crude extract of twigs of I. fagifolia was received from the National Cancer 
Institute and fractionated using VLC on silica gel. The percentage of HCV RNA 
inhibition for the MeOH fraction was estimated at 99 but this fraction was also cytotoxic. 
HCV active and cytotoxic constituents of the methanol fraction were successfully 
separated by HPLC using a Phenomenex NH2 column (21.2 × 250 mm). The fraction 
that eluted from 100 -107 minutes was active against HCV and showed no cytotoxicity. 
This fraction was further separated on a smaller scale using a Phenomenex NH2 
column (10 × 250 mm) to yield two well resolved peaks. 
The fraction corresponding to the second peak was active against HCV and 
showed no toxicity (percentage of HCV RNA inhibition = 96, percentage of rRNA 
inhibition = - 54); this fraction contained compound 14. The molecular formula was 
determined to be C7H15NO7 based on a pseudo-molecular ion peak at m/z 226.9440 [M 
+ H] + obtained by HRMS. The odd molecular weight of 14 was interpreted as an 
indication that the molecule contains an odd number of nitrogen atoms (nitrogen rule). It 
was determined that the molecule contained two quaternary carbons, two methylene, 
and three methine (Table 4-0-1). A 1H-1H COSY correlation was observed between the 
diastereotopic methylene protons H-7a (1H,
 
δH 3.62/3.47, m) and H-7b (1H, δH 3.62 
/3.47, m). Another COSY correlation was observed between the methylene protons H-6 
(2H, δH 3.62, m) and H-5 (1H, δH 3.9, m). An HMBC correlation was observed between 
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H-3 (1H, δH 3.7, d, J = 10 Hz) and C-5. Another HMBC correlation was detected 
between the methylene signals H-7a, H-7b and the quaternary carbon C-2 (Figure 
4-0-3). The fact that H-4 was a doublet of doublet, suggested that it was positioned 
between the only two other methines of this compound namely C-3 and C-5.   The 
presence of a terminal amide group in 14 was determined based on the chemical shift 
of C-2, the degree of unsaturation and the molecular weight of the compound. All these 
points suggested that the structure of 14 is as depicted in Figure 4-0-2.  
 
Figure 4-0-2. Structure assignment of 14 [2, 3, 4, 5, 6-pentahydroxy-2-
(hydroxymethyl) hexanamide] 
This molecule was identified as 2, 3, 4, 5, 6-pentahydroxy-2-(hydroxymethyl) 
hexanamide (14). The free acid analog of 14, 2-hydroxymethyl-D-arabinohexanoic acid, 
was reported recently [214-216]. In fact, the potential of various salts of the free acid of 
14 to boost the immune response after immunization has been broadly studied. These 
studies, which also involved several other similar molecules, have resulted in several 
patents [214-216]. These compounds were investigated for use as components of 
vaccine adjuvants, a safer, less toxic alternative to cholera toxin [214-216].   
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Figure 4-0-3. COSY (↔) and HMBC (→) correlations of 14 [2,3,4,5,6-pentahydroxy-
2-(hydroxymethyl)hexanamide] 
       The crude extract of Diplostephium rhodendroides was also received from the 
National Cancer Institute and fractionated using VLC on silica gel; solvents included n-
hexane, DCM, EtOAc and MeOH. The methanol fraction showed promising HCV activity 
and was further purified using a 250 × 21.2 mm NH2 column. The resulting ELSD 
chromatogram indicated that this fraction was constituted of a large number of minor 
metabolites that elute early during the HPLC. The major constituents of this methanol 
fraction were simple sugar molecules, none of which possessed anti-HCV activity. Early 
fractions that eluted from 10-12 minutes and from 13.9-15.9 minutes were active against 
HCV and non toxic. It was determined that the 10-12 minutes fraction was constituted of 
a mixture of trace amounts of HCV active molecules predominantly distributed in the 
stem and twigs of this plant. The fraction that eluted from 13.9-15.9 minutes was further 
purified using a Phenomenex NH2 column (10 × 250 mm). The ELSD chromatogram of 
this fraction indicated that, aside from very minor metabolites, it also contained 15; 
about 1.5 mg of 15 were isolated from 400 mg of the methanol fraction; compound 15 
eluted at around 38 minutes. Based on a pseudo-molecular ion peak at m/z 295.0491 
[M - H] – (HRMS, negative mode), its molecular formula was determined to be C11H20O9, 
corresponding to two degree of unsaturation. The 11 carbons included a quaternary 
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carbon, a methyl group, a ketal moiety, six other methines, and two methylenes (Table 
4-0-2). It was established based on the 1H-1H COSY spectrum analysis that 15 
contained two independent spin systems labeled A and B and shown in bold bonds in 
Figure 4-0-5. The first involved protons from H-6 (3H, δH 1.52, d, J = 6 Hz) to H-2 (1H, 
δH 4.46, m) and the second involved protons from H-2’a (1H, δH 2.73, dd, J = 3 Hz, 18 
Hz) and H-2’b (1H, δH 3.02, dd, J = 5 Hz, 18 Hz) to H-5’a (1H, δH 3.67, dd, J = 4 Hz, 11 
Hz) and H-5’b (1H, δH 4.12, m).  
 
Figure 4-0-4. Structure of 15 [4, 5-dihydroxy-3-{(3, 4, 5-trihydroxy-6-
methyltetrahydro-2H-pyran-2-yl} oxy) pentanoic acid]  
 
The HMBC correlation between H-1 (1H, δH 5.24) and C-5 indicate a six membered ring 
involving carbons C-1 through C-5. Similarly, the HMBC correlation between H-1 and C-
3’ allowed the connection of this ring to the rest of the molecule. Based on these 
analyses, it was determined that the structure of 15 is as depicted in Figure 4-0-4. 
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Figure 4-0-5. COSY () and HMBC (→) correlations of 15 [4,5-dihydroxy-3-{(3,4,5-
trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy}pentanoic acid] 
Based on the NOESY spectrum of 15, it was established that its relative configuration   
is as depicted in Figure. 4-0-6. NOESY correlations were detected between H-5a' and 
H-1, H-3' and H-4'. Another correlation was detected between the methyl protons H-6 
and H-3; no such correlation was detected between H-6 and H-4. There was also a 
correlation between H-4' and H-5'b. Finally a correlation was detected between H-2 and 
H-3.  
 
Figure. 4-0-6. Relative configuration of 15 
3. Supporting information  
Compound 14. White solid, [α]D = -12 (c.0.03, MeOH); HRMS m/z 226.9440 [M + 
H+] (calcd for C7H15NO7, 226.0927); 13C NMR (400 MHz, D2O) Table 4-0-1; 1H NMR 
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(400 MHz, D2O)  
Compound 15. Clear solid; [α]D = -40 (c.0.02, MeOH); HRMS m/z 295.0491 [M - 
H] – (calcd for C11H19O9, calcd 295.1029); 13C NMR (400 MHz, pyridine) Table 4-0-2; 1H 
NMR (400 MHz, pyridine) Table 4-0-2 
3.1. Experimental Section  
3.1.1. Inga fagifolia  
 The crude extract of twigs of I. fagifolia was initially fractionated using VLC on 
silica gel and the methanol fraction showed promising activity. Next, HCV active and 
cytotoxicity constituents were separated by HPLC using a Phenomenex NH2 column 
(21.2 × 250 mm). Fractions collection was guided by an ELSD detector. The solvent 
system was 100/0 DCM/MeOH  75/25 DCM/MeOH (90 minutes), followed by 75/25 
DCM/MeOH  0/100 DCM/MeOH (30 minutes). The fraction that eluted between 100 - 
107 minutes was active against HCV and showed no cytotoxicity; this fraction was 
further purified on a smaller scale using a Phenomenex NH2 column (10 × 250 mm). 
The solvent system was 70/30 DCM/MeOH  30/70 DCM/MeOH (60 minutes), followed 
by 30/70 DCM/MeOH  0/100 DCM/MeOH (5 minutes) and the flow rate was 6 mL/min. 
The ELSD chromatogram showed two well resolved peaks; corresponding fractions 
were collected at 22 and 28 minutes, respectively. The fraction collected at 28 minutes 
showed promising HCV activity and displayed no cytotoxicity. The percentage of 
inhibitions against HCV RNA and rRNA were estimated at 96 and - 54, respectively; this 
fraction contained compound 14; 3 mg were derived from 300 mg of the methanol 
fraction. 
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3.1.2. Diplostephium rhodendroides  
The crude extract of D. rhodendroides was fractionated using VLC on silica gel. 
Next, the MeOH fraction was purified using a Phenomenex NH2 column (21.2 × 250 
mm). The ELSD chromatogram of this fraction indicated that it was comprised of a large 
number of minor metabolites that eluted early during the HPLC. None of the major 
metabolites was bioactive. Using the solvent system 50:50 DCM/MeOH (10 minutes)  
0/100 DCM/MeOH (18 minutes) followed by 0:100 DCM/MeOH (5 minutes), minor 
metabolites were combined in a few fractions and sent for assay. The fractions that 
eluted from 10-12 minutes and from 13.9-15.9 minutes were active against HCV and 
non toxic. The 10-12 minutes fraction was constituted of trace amounts of HCV active 
molecules predominantly distributed in stem and twigs. About 2 mg of a mixture of these 
molecules were derived from 400 mg of the methanol fraction. The fraction that eluted 
from 13.9-15.9 minutes was further purified using a Phenomenex NH2 column (10 × 
250mm). The solvent system used was 100:0 DCM/MeOH (10 minutes), followed by 
100:0 DCM/MeOH  75:25 DCM/MeOH (40 minutes) and 75:25 DCM/MeOH 0:100 
DCM/MeOH (40 minutes). The ELSD chromatogram indicated that, aside from very 
minor metabolites, this fraction also contained a metabolite (15); about 1.5 mg were 
isolated from 400 mg of the methanol fraction; 15 eluted at around 38 minutes.  
3.2. Anti-HCV assay  
Antiviral  assay  
The anti-HCV activity was determined in the HCV replicon (Clone B) system 
(Huh 7 clone B cells containing HCV RNA). Cells were seeded onto 96-well tissue 
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culture plates (3,000 cells/well). The compounds were tested in a dose response at 
concentration 10, 3, 1 uM (triplicate). After addition of test compounds the plates were 
incubated for five days (37 °C, 5%, CO2). The total cellular RNA was extracted using the 
manual Perfect Pure RNA 96 cell Vacki from 5 Prime. The replicon RNA and the 
internal control (TaqMan rRNA control reagent, applied Biosystems) were amplified by 
RT-PCR. The antiviral potency of the tested molecule was determined by subtracting 
the threshold RT-PCR cycle of the tests compounds from the threshold RT-PCR of the 
negative control (no drug): #CtHCV ( a 3.3 value being considered a 1 log reduction in 
replicon RNA level (in other words 90% reduction). The cytotoxicity was calculated 
using #Ct rRNA values and RS-446 (2-Me-C) was used as control to determine the 
EC50 and EC90 values [206, 207]. 
Table 4-0-1. 1D and 2D data of 14 
 
13C δ H mult. (J in 
Hz)   
COSY HMBC 
1.  / / / / 
2.  98.0 / / H-7a, H-7b 
3.  67.9 3.7, d (10.0) / / 
4.  70.1 3.81, dd (3.0, 
10.0) 
/ / 
5.  69.5 3.9, m H-6 H-6, H-3 
6.  63.7 or 64.1u 3.62, m H-5  / 
7.  63.7 or 64.1u 3.62/3.47, m H-7a, H-7b / 
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Table 4-0-2. 1D and 2D data of 15 
 
13C δ H mult. (J in Hz)   COSY  HMBC NOESY 
1 103.1 5.24 * / / H-5’a 
2 73.2 4.46, m / / H-3 
3 74.0 4.35, m / / H-6, H-2 
4 74.9 4.24, m / H-6  
5 71.4 4.13, m H-6 H-6, H-1  
6 19.8 1.52 d (6.0) H-5 / H-3 
1’ 178.0 / / H-2’a, H-2’b  
2’ 40.1 2.73, dd (3.0, 18.0) 
/3.02, dd (5.0, 18.0) 
H-3’ /  
3’ 70.3 4.74,  m  H-2’ H-1 H-5’a 
4’ 88.6 4.9, m H-5’  H-5’ab 
5’ 68.6 3.67, dd (4.0, 11.0) 
/4.12, m 
H-4’  H-1a, H-3’a, 
H-4’ab 
*buried signal, presence inferred based on the HSQC 
a
 correlation to H-5a 
b
 correlation to H-5b 
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Figure 4-0-7. 1HNMR spectrum of 2, 3, 4, 5, 6-pentahydroxy-2-
(hydroxymethyl)hexanamide (14) (D2O) 
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Figure 4-0-8. DEPT spectrum of 2, 3, 4, 5, 6-pentahydroxy-2-
(hydroxymethyl)hexanamide (14) (D2O) 
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Figure 4-0-9. HSQC spectrum of 2, 3, 4, 5, 6-pentahydroxy-2-
(hydroxymethyl)hexanamide (14) (D2O) 
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Figure 4-0-10. HMBC of 2, 3, 4, 5, 6-pentahydroxy-2-(hydroxymethyl)hexanamide 
(14) (D2O) 
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Figure 4-0-11. COSY of 2, 3, 4, 5, 6-pentahydroxy-2-(hydroxymethyl)hexanamide 
(14) (D2O) 
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Figure 4-0-12. 1H NMR of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-
2H-pyran-2-yl)oxy] pentanoic (15) (pyridine) 
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Figure 4-0-13. 1H-1H COSY of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-
methyltetrahydro-2H-pyran-2-yl)oxy] pentanoic (15) (Pyridine)  
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Figure 4-0-14. HSQC of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy] pentanoic (15) (Pyridine) 
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Figure 4-0-15.  HMBC of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy] pentanoic (15) (Pyridine)  
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Figure 4-0-16. DEPT of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy] pentanoic (15) (Pyridine) 
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Figure 4-0-17. NOESY of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy] pentanoic (15) (CD3OD) 
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1. Glossary (Definitions of keywords)  
“An outbreak involves two or more ill people” – CSPI. 
Action levels: “Action levels and tolerances represent limits at or above which the 
FDA will take legal action to remove products from the market” - FDA.  
Biological contaminants: in the context of this document, these are pathogenic 
microorganisms (bacteria, viruses and parasites) found in seafood.  
Chemical contaminants: in the context of this chapter, are regrouped under this 
denomination, all non-biological contaminants (deleterious chemicals) traceable to 
seafood. 
Environmental pollutants: seafood-associated deleterious substances traceable to 
the environment such as heavy metals and persistent organic pollutants. 
Etiological agent: a microorganism responsible for a given disease.   
      Food safety hazards: according to the Seafood HACCP Regulation, a “food safety 
hazard” is “any biological, chemical, or physical property that may cause food to be 
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unsafe for human consumption."  
Seafood-associated toxins: harmful chemical substances produced either by 
seafood-associated bacterial contaminants, cyanobacteria or toxic microscopic 
algae (dinoflagellates and diatoms) on which seafood feed. 
Seafood: edible marine plants and animals (fish and shellfish) are usually grouped 
under the denomination of seafood; in some contexts, these are referred to as “fish 
and fishery products” [217]
 
This same term is often given a broader meaning: all 
edible aquatic plants and animals.   
Tolerance threshold: maximum allowable amount of ubiquitous deleterious 
substance in seafood. 
  
2. Definition of the subject.  
In order to function properly, the human body needs a wide range of essential 
nutrients, which it gets from food that is ingested on a daily basis. Unfortunately, food 
also represents a vector for harmful creatures (bacterial, viral, protozoan pathogens) 
and chemical substances (organic toxins as well as toxic metals and various 
environmental contaminants). According to the most recent surveys of the Center for 
Science for Public Interest (CSPI), for more than a decade now, seafood has ranked 
first as the most likely source of foodborne disease outbreaks of established origin [218, 
219].  Based on these surveys, seafood-associated hazards that have caused the 
largest number of outbreaks are toxins (especially scombrotoxin and ciguatera), 
followed by bacteria, the most problematic of which are Vibrio spp, and finally viruses, 
especially norovirus. Though food safety is primarily the responsibility of regulatory 
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agencies, several other groups are involved. These include industries, consumers and 
the scientific community upon which rests the responsibility of developing cutting edge 
technologies capable of eliminating seafood-associated biological and chemical 
contaminants. The international community also relies on science for the development 
of revolutionary technologies for a faster, cheaper, easier and more accurate detection 
of seafood-associated health hazards; tools without which enforcing laws and 
regulations set forth by regulatory agencies is virtually impossible. In this chapter, we 
review different categories of seafood-associated health hazards as well as a few 
relevant regulatory and scientific efforts dedicated to reduce the incidence of seafood-
borne illnesses. 
3. Introduction.  
Seafood constitutes a significant portion of the world’s food supply and is 
renowned for its delightful taste. It is a critical component of the human diet because of 
its unique nutritional properties. Fish, for instance, is a good source of protein as its 
major components are proteins and lipids. All essential amino acids can be derived from 
fish consumption. Approximately 40% of the lipids found in fish are comprised of highly 
unsaturated long-chain fatty acids. Other outstanding nutritional qualities are reduced 
saturated fats and carbohydrates and plentiful essential nutrients. Some fish species 
are a valuable source of important nutrients such as vitamins A and D, phosphorus, 
iron, calcium, magnesium, selenium and iodine [220, 221]. 
There are numerous reports of health benefits associated with the consumption 
of seafood. Several of these health benefits have been attributed to seafood’s high 
content of vital nutrients, such as n-3 polyunsaturated fatty acids (PUFAs), specifically 
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eicosapentaenoic acid (EPA), and docosahexaenoic (DHA). These health benefits 
include a reduced risk of developing serious diseases such as depression [222], 
myocardial infarction, Alzheimer’s [223], dementia [224] and weight loss [225]. A 
number of reports have associated seafood consumption with a reduced risk of mortality 
among individuals suffering from coronary heart disease [226] and a reduced risk of 
developing diseases such as ischemic and thrombotic strokes, colon and intestinal 
cancers as well as others [68, 225, 227, 228]. These positive effects are counted among 
the factors that have driven current market trends. There has been a steady increase in 
the world’s per capita fish and fishery products consumption for several decades now 
[229].
 
According to the December 2009 Food Outlook Report of the Food and 
Agriculture Organization (FAO), the annual per capita fish consumption in the world 
during the years 2007 - 2009 was estimated at ~ 17.1 kg. It is important to note that in 
the 1970s, 1980s and 1990s, these values were 11.5, 12.8 and 16.4 kg per capita 
respectively [230]. 
As indicated by recent estimates, there has been a net increase in the demand 
for seafood in countries around the world [231]. In the United Kingdom for instance, the 
seafood retail market has experienced a considerable increase between the years 2003 
and 2007, increasing from £2.4bn (retail price) to an estimated £3.25bn in 2007 [229].
 
A 
significant increase in seafood demand in developing countries has been observed, as 
well [231]. Millions of tons of seafood are caught each year worldwide to sustain the 
current demand. There has been a steady increase in the total world fish production 
since the 1950’s, from 19.3 million tons to about 134 million tons in 2002  [232]. 
According to a 2009 FAO report, the current world production (capture fisheries plus 
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aquaculture) is estimated at 144.1 million tons, divided into 98.8 million from capture 
fisheries and 54.3 million from aquaculture [230].   
 
Figure 5-1. Variation in the number of reported seafood-borne disease outbreaks 
since the 1990’s in the U.S.A. 
 
Unfortunately, seafood consumption is not without risks and food is an important 
vector of a wide range of health hazards (Figure 5-1). Foodborne illnesses are a serious 
public health concern and according to the Centers for Disease Control and Prevention 
(CDC) roughly 76 million foodborne illnesses corresponding to about 325,000 
hospitalizations and 5,000 deaths are recorded in the U.S. each year [233].
   
A recent 
survey conducted by the Center for Science for Public Interest (CSPI) [218], revealed 
that the food categories that were associated with the largest number of outbreaks in 
 183 
 
the United States during the period 1990-2006 were seafood, produce, poultry, beef and 
eggs. Seafood was responsible for 1,140 out of 5,778 outbreaks and therefore, was the 
most problematic food (Figure 5-2). Also reported was an increase in the number of 
seafood related outbreaks compared to the early 1990s (Figure 5-1). It is important to 
mention that the number of reported cases of seafood-borne illness has remained 
constant over the years. Though it ranked second as far as number of outbreaks, 
produce caused the largest number of cases of illness during that same time frame 
[218].  
 
Figure 5-2. Foodborne outbreaks reported during the years 1998 - 2007 by 
category of food in the U.S.A. 
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4. “Food safety hazards” associated with seafood 
Seafood-associated health hazards can be classified into two main categories: 
(1) biological contaminants (includes a long list of bacteria, viruses, parasites) and (2) 
chemical contaminants such as environmental pollutants (pesticides, heavy metals, 
approved or unapproved drug substances) and finally natural toxins from a variety of 
structural classes. According to the CSPI’s 2008 report, the latter category was 
associated with the largest number of seafood-borne outbreaks from 1990 through 2006 
(Figure 5-3) [218].
 
Currently known health hazards associated with seafood are either 
naturally occurring or from various anthropogenic activities. Seafood becomes 
contaminated either as a result of feeding on poisonous phytoplankton species or in 
sewage contaminated marine environments. Seafood contamination can also arise from 
inappropriate storage or accidental exposures during handling. Certain types of seafood 
are more likely vehicles of dangerous substances and pathogenic microorganisms than 
others.  
Categories of seafood that have been associated with greater public safety risks 
are considered a high priority in sampling and surveillance efforts by the Food and Drug 
Administration (FDA) [234].  At the top of the FDA’s seafood watch list are products 
such as molluscan shellfish from uncertified sources, refrigerated reduced oxygen 
packaged products, ready-to-eat seafood, seafood mixes containing cooked, raw or 
partially-cooked seafood components, as well as, scombrotoxin (histamine)-forming 
fish, aquaculture derived seafood  and finally salt-cured or dried uneviscerated finfish 
[234]. According to the 2008 CSPI report, based on the number of reported outbreaks, 
finfish (such as tuna and grouper) was the most dangerous type of seafood between the 
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years 1990 through 2006. Finfish was responsible for 61% of all reported seafood-borne 
outbreaks during this period, followed by molluscan shellfish (15%) (Figure 5-4). The 
largest number of cases of seafood-borne illness was attributable to molluscan shellfish 
(Figure 5-4)  [218].  
 
Figure 5-3. Specific health hazards that caused seafood-borne outbreaks reported 
during the years 1990 through 2006 in the U.S.A. 
 
4.1. Seafood associated toxins 
Seafood-associated toxins, especially scombrotoxin and ciguatoxin, have been 
linked to the majority of seafood-borne outbreaks that occurred during the last decade 
and as such, could be viewed as the most dangerous seafood-associated “food safety 
hazard” [218, 219].
  
Scombrotoxin and ciguatoxin alone were responsible for 57% of all 
seafood-related outbreaks in the United States reported from 1990 through 2006  [218].
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Seafood-associated toxins have been linked to a wide variety of intoxications. 
These include, poisoning associated with shellfish consumption, namely Diarrheic 
Shellfish Poisoning (DSP), Paralytic Shellfish Poisoning (PSP), Amnesic Shellfish 
Poisoning (ASP), Neurologic Shellfish Poisoning (NSP), AZaspiracid Shellfish Poisoning 
(AZP), and, poisonings associated with fish consumption. The latter include Ciguatera 
Fish Poisoning (CFP) and puffer fish poisoning [235].
  
It is necessary to point out that 
some seafood-associated biotoxins, namely ciguatoxin and toxins responsible for PSP, 
NSP and ASP can be lethal [236]. Seafood-associated toxins are generated either by 
bacterial contaminants that freely proliferate when seafood is improperly stored or by 
cyanobacteria and toxic microscopic algae (dinoflagellates and diatoms) on which the 
seafood feed. The blooms of these latter organisms, which occur from season to 
season, forming red tides (Harmful Algae Blooms (HAB) are a subject of public health 
and environmental concerns, affecting the tourism and fishing industries [237]. 
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Figure 5-4. Seafood-borne, outbreaks (A) and cases of illnesses, (B) reported in 
the U.S.A. during the years 1990 through 2006 (by category of seafood) 
 
4.1.1. Ciguatera fish poisoning 
Ciguatera fish poisoning has been reported in countries around the world 
(Europe, Africa, America, Asia, and Oceania). This form of poisoning is frequent 
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between the months of April through August and has been linked to the consumption of 
certain fish. Some examples are shark, barracuda, snapper, hogfish, horse-eye jack, 
red grouper, gray triggerfish, Spanish mackerel, narrowhead gray mullet, chinamanfish, 
swordfish and amberjack. Ciguatera fish poisoning is caused by a set of heat resistant 
polyether toxins known as ciguatoxins (Figure 5-5), which are the product of in situ 
gambiertoxin biotransformation [237, 238]. Ciguatoxin, maitotoxin, palytoxin, and 
scaritoxin are members of this group. These toxins are produced by a variety of 
organisms; these include Gambierdiscus toxicus, Gymnodinium sangieneum, G. 
polyedra, Ostreopsis lenticularis, Prorocentrum concavum, P. mexicanum, and P. 
rhathytum among others [235, 239]. Symptoms of ciguatera fish poisoning are mainly 
gastrointestinal and neurological. A few therapeutic approaches in case of poisoning 
include, but are not limited to, antihistamines, antiemetics (droperidol, prochlorperazin, 
metoclopramide), atropine, as well as, intravenous hydration [237].    
4.1.2. Scombrotoxic fish poisoning.  
Scombroid fish poisoning differs from other types of toxin mediated seafood 
poisonings because the responsible toxin is not produced by a microalgae. Instead, it is 
generated under improper storage conditions (temperature >20 ˚C). This toxin is the 
result of a catalytic reaction involving the conversion of in situ histidine into histamine (). 
The enzyme responsible for this conversion, histidine decarboxylase, can be produced 
by several types of bacteria. These include various Vibrio sp. Clostridium, 
Enterobacteriaceae (such as Morganella morganii and Klebsiella pneumoniae and 
Hafnia alvei) and Lactobacillus sp. [240]. Scombrotoxin is stable to both heat and cold 
conditions. Scombroid fish (fish containing a high level of free histidine) and non-
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scombroid fish have been implicated in this form of poisoning. These include fish such 
as amberjack, abalone, tunas, sardines, mackerel, bonito and bluefish, just to name a 
few [239]; associated symptoms rank from mild and self-limiting to severe. Groups at 
risk for developing the severe form of this disease are people with respiratory and 
cardiac conditions or those on medication such as isoniazid and doxycycline that slow 
histamine degradation [237, 239, 241].  Symptoms of scombrotoxic fish poisoning 
include headache, abdominal cramps, nausea, diarrhea and palpitations among others.  
As far as pathophysiology, bioamines other than histamine are believed to play a critical 
role; a few examples are spermine, cadaverine, agmatine and putrescine [239, 242]. 
There are several therapeutic approaches for this type of food poisoning. These include 
administration of activated charcoal, diphenhydramine, cimetidine and famodine [241].  
4.1.3. Other major seafoodborne poisonings. 
Paralytic shellfish poisoning (PSP) can be caused by a wide range of 
tetrahydropurine type toxins (carbamate, N-sulfo-carbamoyl, decarbamoyl and 
deoxydecarbamoyl) [238]
 
collectively called saxitoxins (Figure 5-5). These are 
neurotoxins that act by blocking sodium channels, causing symptoms like numbness, 
paralysis and disorientation. Saxitoxins are produced by dinoflagellates and blue-green 
algae. Dinoflagellates that have been linked to this form of poisoning include Pyrodinium 
bahamense, Gymnodinium catenatum, as well as several organisms belonging to the 
genus Alexandrium [235, 238, 243]. 
 
Various types of seafood can serve as vectors; 
these include clam, crabs, cockles, oysters, salmon, mackerels, scallops, and whales to 
name a few  [235, 237]. PSP has been reported on all continents. Regrettably, there is 
no antidote for PSP, and therapeutic approaches are mostly supportive and include 
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respiratory support in a life-threatening situation, gastric emptying, dialysis and 
enhancing renal clearance [237].   
Diarrheic shellfish poisoning (DSP) has also been reported worldwide. 
Diarrhea, nausea, cramps and vomiting are common signs of DSP. It is usually 
associated with consumption of contaminated clams, mussels, oysters and scallops. 
This syndrome is caused by a group of acidic (okadaic acid and related 
dinophysistoxins) and neutral toxins (pectenotoxin). Yessotoxins have also been 
reported to cause this form of poisoning (Figure 5-5) [238, 244]. These toxins are 
produced by a variety of marine dinoflagellates including Dinophysis spp (D. acuta, D. 
acuminate, D. caudate, D. mitra, D. norvegica) as well as Protoceratium spp., 
Prorocentrum spp. Gonyaulax spp. and Phalacroma spp [235].  
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Figure 5-5. Toxins involved in seafoodborne intoxications 
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Figure 5-5. (cont) Toxins involved in seafoodborne intoxications 
Amnesic shellfish poisoning (ASP) has been reported in various areas around 
the world including Europe, North, Central and South America, Asia and Oceania. 
Several types of seafood, including anchovies, clams, crabs, oysters, mussels, 
mackerels, lobsters, scallops and gastropods are potential vectors. ASP is caused by a 
marine biotoxin called domoic acid (Figure 5-5). This toxin is produced by a red-brown 
marine diatom called Pseudo-nitzschia pungens. Diarrhea, nausea and abdominal pain 
are examples of symptoms that indicate amnesic shellfish poisoning [235]. 
 
Neurotoxic shellfish poisoning (NSP) is caused by brevetoxins and its analogs 
(Figure 5-5). Occurrences have been reported in countries around the world. This form 
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of poisoning has been associated with the consumption of contaminated clams, mullets, 
mussels, oysters, tunas and whelks. Fibrocapsa japonica, Gymnodinium breve (Karenia 
brevis), Raphidophyceae sp., and Chattonella marina, among others, are examples of 
organisms that produce these toxins [235, 238].
 
Puffer fish poisoning has been linked to the most potent and lethal marine 
neurotoxin: tedrodotoxin (Figure 5-5). It is produced by a variety of animals including the 
California newt, trumpet shell, the blue ringed octopus and puffer fish, especially a 
species known as fugu (present in the liver). Puffer fish is a delicacy in Japan and is the 
main vector for this form of poisoning. Once again, there is no antidote. The first case in 
Europe occurred in 2009 and involved an individual that had consumed trumpet 
shellfish (Charonia sauliae) harvested from the Atlantic Ocean in Southern Europe 
[245]. The main therapeutic approach upon poisoning is supportive and includes 
respiratory support (life-threatening circumstances). Activated charcoal, atropine, 
anticholinesterase agents, and alpha agonists, among others, are also recommended 
[246]. 
AZaspiracid shellfish Poisoning (AZP). Mussels and oysters are known 
vectors of toxins responsible for azaspiracid shellfish poisoning. AZP has been reported 
in countries around Europe, namely Norway, Portugal, the U.K. and Ireland. AZP is 
caused by marine toxins known as azaspiracids (Figure 5-5), which are produced by 
Protoceratum crassipes and Protoperidinium. Nausea, vomiting and diarrhea, are a few 
symptoms of azaspiracid shellfish poisoning [235, 238]. 
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Figure 5-6. Structure of biotoxins produced by Karlodinium veneficum. (B) The 
absolute configuration of KmTx-2, 
 
Several other marine biotoxins not listed above have been reported. A few 
examples able to impair human health are gymnodimine, neosurugatoxin, 
prosurugatoxin, polycavernoside and debromoaplysiatoxin [235]. It is also important to 
note that a number of biotoxin producers (dinoflagellates) has been associated with 
massive fish mortality and thus represent a major issue to the seafood and tourism 
industry worldwide. Examples in this case are Pfiesteria piscicida and Karlodinium 
veneficum however there is growing evidence that P. piscicida associated fish kills in 
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the past may have been indeed have been K. veneficum derived. Blooms of K. 
veneficum have been linked to various episodes of massive fish kill around the world. In 
this particular case, a set of toxins, believed to be the etiological agents, and regrouped 
under the denomination karlotoxins or KmTxs, has been isolated [247, 248].  Examples 
of such toxins include the karlotoxin-1 (KmTx-1), the 10-O-sulfo-KmTx-1, the KmTx-3, 
the 64-E-chloro-KmTx-3, the 10-O-sulfo-KmTx-3, the 65-E-chloro-KmTx-1, and finally, 
the KmTx-2 (Figure 5-6) [249], for which the relative and absolute configurations were 
assigned only recently [250]. Ongoing work in this area actually began with research by 
Abbott and Ballantine in the 1940s and ‘50s  [251]. Karlotoxins kill fish by osmotic cell 
lysis, a result of the alteration of the ion transport system of the cell membrane. The fish 
dies as a result of damage to its vital gill epithelial tissues. These toxins are 
environmental pollutants and detectable in water during fish kill episodes. The 
ecological role of these toxins was investigated recently and because the toxins 
possesses an allelopathic inhibitory effect on competitors as well as a prey 
immobilization it was established that the organism produce these toxins in order to 
facilitate feeding and control of competition during a bloom [252, 253].  
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Figure 5-7. Specific health hazards that caused seafood-borne outbreaks reported 
during the years 1990 through 2006 in the U.S.A. 
 
4.2. Microbial pathogens  
Following chemical toxins, pathogenic microorganisms were the most likely 
cause of seafood-borne disease outbreaks throughout 1990-2006 (Figure 5-3). The 
CSPI’s survey associated bacteria to 24% of reported outbreaks during this period, 
trailed by norovirus (10%) [218].  
4.2.1. Pathogenic bacteria  
Seafood’s bacterial pathogens can be found either in their GI system (bivalve 
mollusks) or on their surface (crustaceans). These bacteria have been linked to various 
infections and intoxications. Pathogens accumulate in the digestive track of bivalve 
mollusks (cockles, mussels, oysters, clams) as a result of filter-feeding in heavily 
contaminated water. Seafood associated bacterial pathogens are either indigenous to 
the marine environment (case of Vibrionaceae, a source of greater concern) or 
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nonindigenous (resulting from fecal contamination). Members of the first category are 
pathogenic Vibrio spp. such as V. cholerae, V. parahaemolyticus, V. vulnificus, 
Clostridium botulinum (non-proteolytic types B, E, F), Aeromonas hydrophila, 
Plesiomonas shigelloides, and Listeria monocytogenes, just to name a few [236, 240, 
254]. Diarrhea is a common symptom of infection caused by several of these 
microorganisms.  V. parahaemolyticus, V. vulnificus, V. hollisae, and V. cholera non O-1 
have been also associated with more serious conditions such as septicemia. These 
microorganisms are most prolific during summer months as the water temperature rises. 
The second category includes bacteria such as Salmonella (nontyphoidal), Shigella, 
Campylobacter, Staphylococcus aureus, and Escherichia coli [218] 
Proper seafood storage is sufficient to protect against diseases caused by 
several of these bacteria. It has been established that their concentration in seafood is 
normally low (below the minimum infective dose) and will remain so providing that the 
seafood is stored in conditions that are not conducive to bacterial growth, multiplication 
or toxin production (refrigerated (4 ºC) and frozen (- 18 ºC)).  It is important to note that 
this does not apply to mollusks and their predators [242, 255]. While, in several cases, a 
low concentration in seafood is tolerated, FDA regulations become more stringent when 
it comes to bacteria such as L. monocytogenes, V. vulnificus, Salmonella, C. botulinum 
and toxigenic 01 V. cholera.  Current regulations require that these be undetectable in 
seafood requiring minimal cooking before consumption, for instance [217]. 
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4.2.1.1. Vibrio spp.  
Vibrio spp, especially V. parahaemolyticus and V. vulnificus, are a cause of 
significant concern in the U.S. and several Asian countries (Japan, Taiwan, India and 
China). V. parahaemolyticus (Vp), for instance, has been associated to the vast majority 
of seafood-borne gastroenteritis in the U.S. This bacterium has been associated with 
fewer outbreaks in Europe [254, 255]. The pathophysiology of Vp is centered on several 
virulence factors; a few examples in this case are the Thermostable Direct Hemolysin 
(TDH) and TDH-Related Hemolysin (TRH), which are encoded by tdh and trh genes 
respectively [256]. Healthy individuals are also at risk of developing Vp associated 
infection [239]. The FDA can take legal action when seafood products are found to 
contain a Vp count ≥ 1 x 104/g [217]. 
 
Raw or improperly cooked fish and shellfish are 
potential vectors [239]. The minimal infective dose for this pathogen is > 106/g [240]. 
 
V. 
vulnificus (Vv) infections can also result from consumption of raw or undercooked 
seafood. In addition, transmission can occur via wound infection. Though Vv is not a 
major issue in healthy individuals, in certain groups, Vv can cause serious infections or 
death. People suffering from alcoholic cirrhosis, hemochromatosis/cirrhosis, chronic 
hepatitis, post-necrotic cirrhosis, as well as diabetics and alcoholics are at higher risk. 
V. vulnificus is the second leading cause of seafood-related fatality in the U.S. [257-
259]. Vv infections that occur as a result of consumption of contaminated seafood 
(especially raw oysters) are primarily septicemia and gastroenteritis. One therapeutic 
approach is the use of antimicrobial agents (tetracycline and intravenous doxycycline 
with ceftazidime)  [258]. 
 
 199 
 
 2.2.1.2. Other seafood-associated bacteria  
Clostridium botulinum – This bacterium is responsible for a condition known as 
botulism, the responsible agent being a toxin. Lightly preserved, semi-preserved, and 
fully preserved smoked, fermented, salted and pickled fish products are likely vectors. 
Cold-smoked and fermented fish products are of greater risk. Chilling, autoclaving, and 
salting are approaches used to prevent botulism [240, 242].  
Listeria monocytogenes - Infections cause by this other bacterium can, at 
worst, result in septicemia spreading to several organs and even, in the case of 
pregnant women, to the fetus. This type of infection can be fatal. Groups most at risk 
are pregnant women, neonates, fetuses, and immuno-compromised patients. Shrimp is 
an important vector [240, 242, 260]. S. aureus has also been isolated from seafood. 
This bacterium is, as C. botulinum, a toxinogenic species. It produces toxins that are 
resistant both to enzymes degradation and heat. It is introduced in seafood as a result 
of environmental contamination or transferred from an infected worker involved in 
seafood handling
 
[240, 242]. 
Enterobacteriaceae such as Salmonella, Shigella and E. coli have been also 
reported in seafood. Enterobacteriaceae usually occurs in seafood as a result of fecal 
contamination. Salmonella is responsible for salmonellosis and is especially problematic 
for the shrimp industry [260]. Compared to other food categories, seafood is a less likely 
vector of Salmonella [239, 240]. The minimum infective dose for Salmonella sp has 
been estimated to be in the range of < 102 - >106. Non-bloody diarrhea, fever, 
abdominal pain and nausea, just to name a few, are indicators of infection by this 
pathogen. Symptoms of a Shigella infection, on the other hand, are bloody stools, 
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severe abdominal cramps, fever and dehydration. The minimum infective dose in this 
case has been estimated at 101- 102. This is similar to what has been reported for E. 
coli, for which the minimal infective dose is 101- 103 [240, 242]. 
Table 5-1. Safety levels set by FDA for several seafood associated bacteria 
 
 Compliance policy/programs  
a Sec 555.300 Compliance Policy Guide  [261] 
b
 Sec 560.600 Compliance Policy Guide [262] 
c 
 Compliance Program 7303.842 [263] 
 
4.2.2. Seafood associated viruses 
Seafood can also serve as a vector of viruses. Non A, non B enteral hepatitis 
viruses, Hepatitis A Virus (HAV), poliovirus, and norovirus, among others have been 
associated with seafood-borne outbreaks [239, 240, 264, 265]. Viruses end up in 
Hazards FDA & EPA 
thresholds  
Analytical 
approach  
Targeted  
seafood  
Higher risk 
populations 
  
Salmonella 
sp. 
Presence of 
organism a 
Conventional 
culture 
methods 
All fish Severe in the 
elderly, infants,   
AIDS patients 
E. coli  MPN of 230/100 
grams b 
APC - 
500,000/gram 
Hemorrhagic 
colitis agar- 
direct plating 
method 
Imported fresh 
and frozen 
clams and 
oysters  
All people – most 
susceptible are 
young children and 
the elderly 
S.aureus Presence of 
staphylococcal 
enterotoxin, or  a 
load ≥104/g 
(MPN) c 
Specific 
precipitation 
with antiserum 
All fish All people 
C. 
botulinum 
Presence of 
viable spores or 
vegetative cells 
or toxin c 
Mouse 
neutralization 
test 
All fish All people 
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seafood as a result of fecal contamination of the marine environment or when handled 
by an infected worker. Viruses are one of the most serious seafood-associated threats. 
So far, reports of seafood-borne infection outbreaks linked to viruses have emerged 
from countries around the world. HAV was associated with the largest seafood outbreak 
ever reported. This outbreak, which occurred in 1998, in the Chinese city of Shanghai, 
was linked to the consumption of contaminated clams and over 292,000 cases were 
reported [265, 266]. Another virus, namely norovirus, a single-stranded nonenveloped 
RNA virus, is currently responsible for roughly 50% of all foodborne outbreaks of 
gastroenteritis according to the CDC [267]. Norovirus was reported by CSPI as the most 
problematic seafood-associated virus during the period 1990 through 2006 (Figure 5-3) 
as it caused 10% of all reported seafood outbreaks during that time [218].  It is 
important to point out that of the five genogroups of norovirus, GII has been linked to the 
majority of infections. Filter feeding bivalve shellfish are important vectors [258]. 
Norovirus gastroenteritis-associated symptoms are vomiting, watery stools, non-bloody 
diarrhea with abdominal cramps, and nausea. It is a fairly resistant virus that can 
survive harsh conditions such as chlorine treatments (10 ppm), heating to 60 °C (4 
hours), or freezing [267].  
4.2.3. Seafood associated parasites 
Seafood (raw or undercooked) can also serve as a vector of pathogenic 
parasites. These include nematodes, cestodes and trematodes. Anisakis simplex, 
Pseudoterranova dicipiens, Gnathostoma sp., Capillaria sp., and Angiostrongylus sp. 
are examples of seafood-associated nematodes. Examples of tape worms that can be 
isolated from seafood include Diphyllobothrium latum and D. pacificum; Clonorchis sp., 
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Opisthorchis sp., Metagonimus yokagawai, Heterophyes sp., Paragonimus sp. and 
Echinostoma sp., on the other hand, are a few examples of seafood-associated 
trematodes [240].   
Several parasite-infected seafood dishes such as sushi, crab, sashimi, herring 
roe and undercooked grilled fish have been associated with illnesses [217].
 
Compared 
to bacteria and viruses, however, parasites are of lesser concern. Trematodes (such as 
Paragonimus westermani), cestodes (such as Diphyllobothrium latum, D. pacificum) 
and nematodes (such as Angiostrongylus cantonensis, Contraceacum osculatum) have 
been associated with domestic fish and shellfish. Several other organisms have been 
associated with imported products instead. These include Clonorchis sinensis, 
Heterophyes heterophyes, Metagonimus yokogawai, Opisthorchis felineus and 
Gnathostoma spinigerum. Some nematodes, cestodes, and trematodes are of greatest 
concern as far as seafood safety. These include Anisakis simplex, Pseudoterranova 
spp., Eustrongylides spp., Gnathostoma spp., Opisthorchis spp., Chlonorchis sinensis 
and Paragonimus spp, just to name a few [217, 264].   
4.3. Toxic heavy metals 
Heavy metals are a threat to the environment and public health and are 
problematic in regard to their long-term persistence. A variety of heavy metal 
contaminants has been reported in seafood. These elements originate from natural 
occurrences (marine volcanism, geological and geothermal events) and anthropogenic 
activities. Several categories of anthropogenic activities threaten the marine 
environment. These include, activities that take place in tanneries, steel plants, battery 
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industries, thermal power plants and farms, especially those farms using heavy metal 
containing fertilizers and pesticides. Runoff from roadways has also been recently cited 
as an important source of contamination [220, 268, 269].  
Heavy metals found in seafood include antimony, arsenic, cadmium, chromium, 
lead, mercury, nickel, copper, iron, manganese, selenium, zinc, aluminum, silver, 
strontium, thallium, and tin. Of these heavy metal contaminants, those of greatest 
concern are antimony, arsenic, cadmium, chromium, lead, mercury, and nickel. It is 
important to note that elements such as copper, selenium, iron and zinc (known 
essential micronutrients) are toxic only at high concentrations [220]. 
Arsenic can be present under a variety of forms: toxic (inorganic) and nontoxic 
(organic). Arsenic is an extremely potent poison in its trivalent form and can cause a 
wide range of acute and chronic illnesses. A few examples include cancer, nephritis, 
hepatomegaly, peripheral symmetrical neuropathy, and palmar hyperkeratosis, among 
others. In seafood, arsenic is mainly present in a nonpoisonous form known as 
arsenobetaine or arsenocholine [264]. A compilation of data (about 100,000 results) 
received from fifteen European countries revealed that seafood is among the food 
commodities with the highest arsenic levels [270]. 
Methyl mercury is a neurotoxic contaminant.  Due to its potential effects on the 
fetus, it is one of the most regulated seafood-associated toxic metals.  There are 
several related FDA recommendations to nursing/pregnant women, women of 
childbearing age, or children when it comes to seafood consumption. CH3Hg+ is present 
in nearly all seafood, but some types of fish such as shark, swordfish, king mackerel, 
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and tilefish are believed to have a higher content. The FDA and the U.S. Environmental 
Protection Agency (U.S.EPA) have recommended being very selective of the type of 
fish consumed, limiting uptake to ~ 12 ounces/week as a healthy approach for groups at 
risk [221]. This has been supported by scientific data [228, 271, 272]. Several reports 
have shown that moderate to high consumption of fish species containing only a low 
amount of CH3Hg+ during pregnancy, has a positive effect on fetal brain development. 
However, it is also important to note that several other studies, Myers et al. (2003) for 
instance, did not support the fact that exposure of pregnant women to methyl mercury 
through fish consumption could have deleterious effects on fetal development [228, 
273].  
Other toxic heavy metals include nickel, chromium, cadmium, selenium and 
lead. Cadmium tends to be bio-accumulated by crustacea and bivalves. Clinical signs of 
cadmium poisoning include osteoporotic and osteomalacic disease, as well as kidney 
damage. Lead poisoning, on the other hand, has been associated with anemia, 
convulsions, paralysis and proteinuria. This metal tends to accumulate in cortical and 
trabecular bone, kidney, lung, as well as the CNS. Edema, hepatitis, and hemorrhage 
are conditions that can result from selenium poisoning, which is also known, to result in 
congenital malformations and infertility. Arsenic (As), nickel (Ni) and chromium (Cr) are 
carcinogens [264].  
4.4. Other chemical environmental contaminants 
Organochlorine compounds. Until recently, organochlorine compounds were 
widely used. A wide range of polychlorinated substances can be found in seafood. 
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These include various insecticides, agrochemicals, industrial chemicals and byproducts. 
Examples of pesticides traceable to seafood include endrin, heptachlor, dieldrin, γ-1, 2, 
3, 4, 5, 6-Hexachlorocyclohexane, chlordane, dichlorodiphenyltrichloroethane and 
lindane. Polychlorinated biphenyls  and dioxins such as 2,3,7,8-tetrachlorodibenzo-p-
dioxin, are example of industrial chemicals that contaminate seafood. Prior to 1970, 
PCBs were widely used industrially [274]. Because they are non-biodegradable, toxic in 
nature and tend to bio-accumulate in seafood, organochlorine compounds now 
constitute a major environmental and public health concern. Several of these 
substances are known carcinogens (dioxins and polychlorinated biphenyls); but 
because seafood-associated health benefits outweigh potential risks, seafood 
consumption is recommended [228].  The level of these substances in fish is truly 
minimal.  However, it is important to note that people whose diet is predominantly made 
of seafood are still at risk [274]. Reports on farm raised salmon (especially European 
farms) containing higher levels of these contaminants compared to wild type salmon is 
believed to have had a serious impact on the consumer acceptance of this type of 
seafood [274, 275]. 
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Figure 5-8. Main causes of rejection or detention of seafood imports into Europe 
during the years 1999 – 2002. 
Antimicrobial drug contaminants of seafood.  This is a problem mainly 
associated with aquaculture, as farmers rely more and more on various drugs and 
antimicrobial agents to deal with specific seafood diseases (bacterial, fungal, viral), to 
improve the quality of water, and to manage pest-related issues.  
There are quite a few reasons why there are concerns over drug residues being 
present in seafood. Several antimicrobial agents used in aquaculture have been linked 
to various adverse health effects, such as hypersensitivity reactions. In vivo studies, in 
animals, have established several others as carcinogens; these include nitrofuran, 
malachite green, gentian violet, and fluoroquinolones. Fluoroquinolones have been also 
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associated with antibiotic resistance. There are several drugs used to this end in the 
U.S. that have been approved by the Center for Veterinary Medicine (CVM) (Table 5-2). 
Substances such as ciprofloxacin, erythromycin, tetracyclines, chloramphenicol, 
nitrofurans, malachite green, gentian (crystal) violet, and fluoroquinolones have been 
frequently reported in seafood imported into the U.S. in recent years [234]. A short, 
recent survey by the FDA has shown that imports from China test positive for the 
presence of a variety of unapproved substances, such as gentian violet, malachite 
green, nitrofuran, and fluoroquinolones. Consequently, these products are the subject of 
great concern and the focus of regulatory surveillance [276].   
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Table 5-2.  Aquaculture drugs approved in the U.S. and action levels 
FDA-approved aquaculture drugs 
Drug name Tolerance level in 
the flesh 
Type of seafood Purpose 
Unapproved drugs  No trace tolerated a  All fish            - 
Chorionic Gonadotropinb  Brood finfish Reproductive  
Formalin solutionc 
 
 Salmon trout, 
catfish, largemouth 
bass, and bluegill 
Antiparasitic 
and 
fungicidal/static  
Tricaine methanesulfonated  Catfish, salmon 
and trout, pike and 
perch 
- 
Oxytetracycline 2.0 ppme Salmonids, catfish, 
and lobster 
Disease control  
Sulfamerazine f Undetectable g  Trout - 
Sulfadimethoxine/ 
Ormetoprim combination h 
0.1 ppm i Salmonids and 
catfish. 
- 
 
Compliance policy/programs  
a Sec 615.200 Compliance Policy Guide [277] 
b
 21 CFR 522.1081 [278] 
c 21 CFR 529.1030 [279] 
d 21 CFR 529.2503 [280] 
e 21 CFR 556.500 [281] 
 
f21 CFR 558.582 [282] 
g21 CFR 556.660 [283] 
h21 CFR 558.575 [284] 
i21 CFR 556.640 [285] 
 
 
Similar issues have been reported in Europe. In fact, during the years 1999 
through 2002, the presence of residues of antimicrobial drugs, mainly nitrofuran and 
chloramphenicol, was one of the main reasons for detention or rejection of seafood 
imports into Europe (Figure 5-8) [242]. A handful
 
of
 
aquaculture drugs approved in 
Europe are presented in Table 5-3. 
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Table 5-3. Aquaculture drugs approved in Europe and action levels 
The Council of the European Communities approved aquaculture drugs 
 
Drug name Maximum Residue Limit (MRL) –
muscle and skin in natural portion 
Type of seafood 
Trimethoprim  50 µg/Kg * Finfish  
Flumequine 600 µg/Kg * Finfish  
Oxolinic acid 100 µg/Kg * Finfish  
Sarafloxacin 30 µg/kg * Salmonidae 
Tylosin A 100 µg/kg * Finfish  
Thiamphenicol 50 µg/kg * Finfish 
Colistin 150 µg/kg * Finfish 
Deltamethrin 10 µg/kg * Finfish 
Emamectin B1a 100 µg/kg * Finfish 
Oxolinic acid 300 µg/kg * Finfish 
Florfenicol 1 000 µg/kg * Fish 
Thiamphenicol 50 µg/kg * Finfish 
Deltamethrin 10 µg/kg * Finfish 
 
Compliance policy/programs  
* Council Regulation (EEC) No 2377/90 of 26 June 1990  [286] 
 
 
5. What are the approaches used to assure public safety? 
Regulatory authorities and the scientific community are two groups with 
complementary goals that play a key role in ensuring public safety against seafood-
associated health hazards. 
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5.1. Regulatory agencies 
Seafood regulatory agencies, via promulgation and enforcement of various laws 
and regulations, guidance, and recommendations are usually at the heart of protecting 
the public from seafood-associated hazards. Numerous programs have been designed 
over the years to this end. In the U.S., the primary responsibility of assuring seafood 
safety falls to the FDA, which is in charge of setting the maximum safe levels of 
unavoidable toxic substances in seafood [276]. The FDA has the authority to detain and 
even refuse import entries into the U.S. A recent related event was the June 28, 2007, 
decision of the FDA to detain Chinese farm-raised catfish, basa, shrimp and dace until 
they were cleared from containing unapproved drug substances [276]. 
  
As for domestic 
seafood, the FDA can recommend legal sanctions, which include “warning letters, 
seizure of products, injunction against further non-compliant practices, or prosecution of 
an individual or establishment” [234].  There are a few other regulatory agencies; these 
include the EPA (Environmental Protection Agency) in charge of chemical contaminants 
such as pesticides and the National Marine Fisheries Service for instance. In Europe, 
the E.U. parliament is at the heart of food safety control. This organization promulgates 
food safety related laws, regulations and directives, which are mandatory in all states of 
the European Union. The E.U. parliament works in close collaboration with the 
European Food Safety Authority, which was established by regulation (EC) 
No.178/2002. This latter organization, more science oriented, is in charge of risk 
assessment.  
There is a long list of guidance and regulations, mostly to seafood industries that 
protect the public from dangers associated with seafood consumption. Several of these 
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are preventive measures. A few examples in the U.S. are the National Shellfish 
Sanitation Program, the Salmon Control Plan, the Low-Acid Canned Food (LACF) 
Program, the Hazard Analysis & Critical Control Points (HACCP) Program and the 
Good Manufacturing Practice regulation. The latter is intended to assure that 
recommended processing conditions were used. The Salmon Control Program, on the 
other hand, was designed to assure the safety of salmon consumers and is a 
cooperative approach involving the FDA, industries, and various associations. As part of 
the Shellfish Sanitation Program in the U.S., the level of various pollutants in coastal 
water is to be monitored in order to classify each given area as suitable or unsuitable for 
shellfish harvest.  As for the HACCP, it applies to domestic as well as imported seafood. 
HACCP requires both domestic and foreign processors of fish and fishery products to 
understand all concepts behind food safety hazards and through a system of 
precautionary control measures to prevent hazards from occurring [234, 276]. The E.U. 
parliaments, as well as regulatory agencies of countries around the world, have issued 
several similar regulations and directives that apply to domestic and imported seafood. 
A few examples of seafood-related regulations promulgated by the European 
Parliament include regulations (EC) No. 852/2004 and No. 853/2004, which established 
some key hygienic rules for food (including seafood) business operators and regulation 
(EC) No. 854/2004 in which key exigencies related to the organization of seafood official 
control programs are determined. Several of these regulations elaborate on the 
“tolerance threshold” for contaminants present in seafood. Examples of “tolerance 
threshold” for seafood-associated health hazards, set by regulatory agencies around the 
world are presented in Table 5-1  Table 5-6.  
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Table 5-4. Seafood-associated marine biotoxins and action level set by regulatory agencies around the world 
Hazards Detection method (analytical 
methods for regulatory 
purposes)  
Tolerated thresholds  Targeted  seafood  
 
 
 
 
 
Paralytic shellfish 
poison  
USA-  mouse bioassay 0.8 ppm (80µg/100g) 
saxitoxin equivalent a 
800ug/Kg (live bivalve 
molluscs) 
All fish 
EU - mouse bioassay b 80 mg STX eq/100 g of 
meat c & d 
Bivalve molluscs 
Africa - mouse bioassay b 80 µg STX eq/100 g molluscs 
Canada - mouse bioassay b < 80 mg STX eq/100 g Molluscs 
Asia - mouse bioassay b 400 MU/100 g Shellfish 
Australia – mouse assay b 80 mg STX eq/100 g  Shellfish meat 
Amnesic shellfish 
poison    
  
USA - LC method 20 ppm domoic acid (in 
general) a 
30 ppm (in viscera of 
dungeness craba 
 
All fish 
 
Europe - LC method 20 mg/Kg of domoic acid c 
 
Live bivalve mollusks 
Canada - LC method 20 mg DA/kg    Mussel 
New Zealand - LC method 20 mg DA/kg    Shellfish 
Neurotoxic shellfish 
poison 
 0.8 ppm (20 mouse 
units/100 gram) (USA) 
Clams, mussels and 
oysters, fresh, frozen or 
canned 
Diarrheic shellfish 
poison  
EU - mouse bioassay b 160 ug of okadaic acid/Kg 
c
  
 
Molluscs, echinoderms, 
tunicates and marine 
gastropods  
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Asia (Japan) mouse bioassay 5 MU/100 g whole meat   Shellfish 
Australia  16 to 20 µg OA eq/100 g  Shellfish   
Azaspiracids USA - mouse or rat bioassay 
 
160 ug azaspiracid 
equivalents/Kg c  
 
Bivalve molluscs, 
echinoderms, tunicates 
and marine gastropods  
 
Europe - mouse or rat bioassay 
 
160 µg/kg 
 
Live bivalves 
Ciguatoxin 
 Presence c Fishery products 
Histamine   USA- extraction coupled to 
fluorescence spectroscopy 
50 ppm   Tuna, mahi mahi, and 
related fish  
Europe < 200 ppm e Scombridae, 
clupeidae, engraulidae 
and coryphaenidae 
 
Compliance policy/programs  
a  Compliance Program 7303.842 or Sec 540.250 Compliance Policy Guide [263] 
b
 FAO (2004) Marine Biotoxins Food and Agriculture Organization of the United Nations Rome, 2004 http://www.fao.org/docrep/007/y5486e/y5486e00.HTM 
available online, retrieved December 30, 2009 [238] 
c Regulation (EC) No 853/2004 (European standards)  [287] 
d EU Directive 91/492/EEC[288] 
e 
 council directives 91/493/EEC [289] 
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Table 5-5. Seafood-associated toxic heavy metals and action level set by the FDA 
Seafood Health Hazard Tolerance threshold  Targeted seafood 
Methyl mercury  1.0 ppm a All fish 
Arsenic 86 ppm (76 ppm for crustacea) b Clams, oysters, and 
mussels 
Cadmium 4 ppm (3 ppm for crustacean) b Clams, oysters, and 
mussels 
Chromium 13 ppm (12 ppm for crustacea) b Clams, oysters, and 
mussels 
Lead 1.7 ppm (1.5 ppm for crustacea) b Clams, oysters, and 
mussels 
Nickel 80 ppm (70 ppm for crustacean) b Clams, oysters, and 
mussels 
 
Compliance Policy/program  
aSec 540.600 Compliance Policy Guide  [262] 
b Appendix 5 - FDA & EPA Safety Levels in Regulations and Guidance [217] 
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Table 5-6. Seafood-associated environmental pollutants and action level set by 
the FDA 
 
Seafood Health Hazard Tolerance threshold  Targeted seafood 
Polychlorinated 
Biphenyls (PCBs) 
2.0 ppm (edible portion) a All fish 
DDT, TDE and DDE 5.0 ppm (edible portion) b All fish 
Chlordane -  0.3 ppm (edible portion) b All fish 
Chlordecone - 0.3 ppm  (0.4 ppm in 
crabmeat)b 
All fish 
Mirex  0.1 ppm b All fish 
Diquat   0.1 ppm c All fish 
Heptachlor and 
heptachlor epoxide   
0.3 ppm b All fish 
Glyphosate  0.25 ppm d 3.0 ppm (for 
Shellfish) 
Fin fish 
Fluridone 0.5 ppm e Fin fish and crayfish 
Simazine 12 ppm f Fin fish 
Aldrin and dieldrin -  0.3 ppm b Fin fish and shellfish 
Compliance Policy/program  
a  21 CFR 109.30 [290] 
b Sec 575.100 Compliance Policy Guide [291] 
c
 40 CFR 180.226 [292] 
d 40 CFR 180.364 [293] 
e 40 CFR 180.420 [294] 
f 40 CFR 180.213 [295] 
 
5.2. The Scientific community’s contribution in ensuring seafood safety 
Through the development of cutting edge technologies to solve problems at 
hand, science has also played a critical role in ensuring public safety against dangers 
associated with seafood. A simple literature search with a key word such as “seafood 
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safety” in ScienceDirect shows a significant and steady increase in seafood safety 
related research effort since 1991 (Figure 5-9). The international community relies on 
science, to develop cutting edge technologies and techniques that can rid seafood from 
associated biological and chemical contaminants in order to bring a safer product to the 
market. The development of cutting edge technologies for faster, cheaper, easier, and 
more accurate detection methods of seafood-associated health hazards is another way 
scientists have contributed in the protection of consumers against these dangers. 
 
Figure 5-9. Increased interest in seafood safety related research. 
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5.2.1. Detection tools for seafood associated health hazards 
Detection of biotoxins. Years of effort have yielded a wide range of approaches 
for toxin detection in seafood. These include various bioassays (in vivo and in vitro 
assays), biochemical techniques (immunoassays), and chemical techniques including 
fluorometric and colorimetric techniques, chromatographic techniques, electrophoretic 
techniques, mass spectrometry, and finally biosensor-based techniques (Table 5-7). In 
countries around the world, the mouse bioassay, despite its numerous shortcomings, 
and liquid chromatography are the two official methods recommended for biotoxin 
detection in seafood (Table 5-4).  
Chromatographic techniques are at the heart of several effective analytical 
approaches to biotoxin separation and detection. Compared to animal assays, analytical 
techniques present the advantages of higher accuracy and sensitivity. While with animal 
bioassays, it is impossible to clearly determine the nature of contaminants, these 
techniques, coupled with the appropriate detection methods, will permit not only 
separation and accurate identification of incriminated toxins, but also, using a standard 
curve, their quantification. A variety of analytical approaches is currently available for 
the detection of marine toxins. These include Gas Chromatography (GC), Thin-Layer 
Chromatography (TLC), Liquid Chromatography (LC), Liquid Chromatography–Mass 
Spectrometry (LC-MS), and Capillary electrophoresis [235, 296]. In addition to 
advantages listed above, with chromatography-based detection methods, several toxins 
can be monitored simultaneously. A new liquid chromatography–tandem mass 
spectrometry method was developed recently [297]. With this method, up to 28 marine 
lipophilic toxins can be monitored at the same time. In this case, toxins are separated 
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using a gradient of acetonitrile/water at alkaline pH on a new type of C18 column proven 
stable under these conditions: a Waters X-Bridge C18 (150 mm × 3 mm, 5 µm) [297]. 
Biosensor-based detection methods have also been investigated for application 
in seafood safety programs. They are not only economical, straightforward and easy to 
use, but offer the advantages of high sensitivities/low limit of detection, plus, these 
technologies are portable [235]. An example of a recent development in this field is a 
new planar interdigital sensor-based sensing system developed by Syaifudin et al. 
(2009). This approach involves simple monitoring of variations of reactive impedance of 
the planar interdigital sensors. Using this approach, as little as 12.6 µg/g of domoic acid 
in mussel meat, for instance, can be successfully detected [298].  
ELISA has also been investigated widely for application in seafood biotoxin 
detection. An example of a recent development in this field was made by Zhou et al. 
(2010), who reported a reliable ELISA-based approach to monitor brevitoxin in mollusks 
with reduce interference from the matrices. Oysters and cockles were used in this 
experiment. With such a method, the limit of detection of brevitoxin is improved. The 
main advantage of immunoassays, which are based on antibody-antigen interactions, is 
high specificity [299].  
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Table 5-7. Proposed methods for biotoxin detection in seafood [235, 238, 300] 
 PSP DSP ASP Ciguatera  NSP SFP 
Bioassays 
In vivo assays Mouse bioassay Mouse 
bioassay 
Suckling 
mouse 
assay 
Rat 
bioassay 
Daphnia 
magna 
assay 
Intestinal 
loop assays 
 
Mouse 
bioassay 
Mouse bioassay 
Chicken assay 
Mongoose and cat 
assay 
Brine shrimp assay 
Mosquito assay 
Diptera larvae assay 
 
Mouse bioassay 
Fish bioassay 
 
 
In vitro assays In vitro 
hippocampal 
slice assay 
Sodium channel 
blocking assay 
Cytotoxicity 
assays (rat 
hepatocytes, 
KB cells, 
fibroblasts) 
Receptor 
binding 
assays 
Hippocampal 
slice 
preparations 
 
Sodium channel 
binding assays for 
ciguatoxins 
 
Neuroblastoma 
cell assay 
Synaptosome 
binding assay 
Hippocampal 
slice assay 
 
 
Biochemical 
techniques  
Immuno assay 
(ELISA) 
Immunono 
assay (RIA 
or ELISA) 
Acid 
phosphatase 
assay 
Immuno 
assay 
(ELISA) 
Immuno assay 
(Radioimmunoassay 
Enzyme-linked 
immunosorbent 
assay ( ELISA ) 
Stick tests 
Immunoassays 
based on 
Immuno assay 
(ELISA) 
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monoclonal 
antibodies 
Solid-phase 
immunobead assay) 
 
Chemical/analytical 
techniques  
Fluorometric and 
colorimetric 
technique, MS 
Chromatographic 
and 
Electrophoretic 
techniques. 
TLC,GC, LC 
MEKC, MS 
Amino acid 
analysis 
TLC, LC, 
CE, MS 
 
 
Chromatographic 
detection 
Nuclear magnetic 
resonance 
(NMR)/mass 
spectrometry (MS) 
Mass spectrometry 
Capillary zone 
electrophoresis 
Micellar 
electrokinetic 
capillary 
chromatography 
detection 
Electrospray 
LC/MS 
Ionspray LC/MS 
LC/MS/MS 
 
Chromatography 
coupled with 
fluorimetric 
detection or  
derivatization 
techniques 
(TLC, GC,CE, 
HPLC) 
 
Biosensors based  
techniques 
Sodium channels 
based 
biosensors  
Immuno 
sensors 
 
Enzyme 
inhibition 
based 
biosensors  
Optical 
immuno 
sensors  
 
Molecularly 
imprinted 
polymer 
based 
biosensors  
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Drug residues in seafood. With the rise in demand of fish and shellfish, a large 
portion of seafood found in market places around the world comes from aquaculture, 
especially from China. As it is the case with any animal husbandry, veterinary drugs are 
often heavily used in aquaculture to control pests, infections, or to increase production. 
Unfortunately, drug residues, often molecules that have proven harmful to humans, are 
found in edible seafood tissues. As previously mentioned, lately in the U.S. as in 
Europe, there have been a significant number of alerts regarding seafood imports 
contaminated with unapproved drug residues (Figure 5-8). Over the years, through the 
dedication of the scientific community, better and more improved detection methods 
have been made available. An example in this case is liquid chromatography (LC) 
coupled with triple-quadrupole mass-spectrometry (LC–QqQ-MS). Until recently, in a 
single run, this sort of method could only analyze related molecular entities.  An 
upgraded and more robust version, a multi-component quantitative HRLC–ToF-MS, was 
reported recently. This new approach has proven effective at simultaneously monitoring 
a wide range of unrelated drugs generally used in aquaculture or found in seafood 
tissues [301]. Smith et al. (2009) also developed an LC-ion trap mass spectrometry 
approach, effective at detecting several types of veterinary drugs in fish samples. In this 
case, the extraction of drug residues from seafood matrixes is completed in acetonitrile 
and hexane followed by HPLC separation on a phenyl column. In certain cases, 
imidazoles, macrolides, fluoroquinolones for instance, very low concentrations 
(0.01 ppm) could be detected using this technique.  Other drugs involved in these 
studies included ionophores, macrolides, nitroimidazoles, benzimidazoles, 
anthelmintics, penicillines, quinolones, sulfonamides, tetracyclines, amphenicols, and 
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tranquilizers, among others [301, 302]. 
Detection of microbial pathogens in seafood. The best approaches for the 
detection of microbes in seafood are usually a combination of culture based and 
molecular based techniques; the latter being often used to assist in bacterial strain 
identification, while culture is required for enrichment purpose. The kind of medium used 
to this end is dictated by the type of microorganisms targeted. Over the years, a 
tremendous amount of effort has been dedicated to the conception of superior media. 
Recommended Standard Operating Protocols for use in microorganism detection, in 
seafood, are described in detail in the FDA’s 1998 Bacteriological Analytical Manual 
(BAM) [303]. Targets of quality control programs are numerous. These include various 
pathogenic bacteria such as Vibrio, Salmonella, S. aureus, L. monocytogenes and E. 
coli) as well as indicators of fecal contamination [240].
 
 
 
Several molecular and culture-based methods have been developed to assist in 
the detection of V. parahaemolyticus (Vp) and V. vulnificus (Vv), which are major issues 
as far as seafood safety is concerned. Commonly used culture-based approaches, 
which present the main disadvantages of being time consuming, laborious, and 
inaccurate, are the MPN and the ISO cultural methods [254].
  
Quite a few Vibrio-specific 
media has been developed to assist in the isolation of these bacteria from seafood 
matrixes; these include TCBS agar (for V. cholera and V. parahaemolyticus) and 
modified cellobiose polymyxin colistin (mCPC) and CC agar for V. vulnificus [303]. The 
MPN method, coupled with various techniques to assist in the identification of suspect 
isolates, is recommended for detection of Vv and Vp in seafood. Examples of 
approaches used for these identifications are the establishment of a biochemical profile, 
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DNA probes or PCR. In the case of PCR for instance, DNA primers targeting tdh and trh 
genes are used to detect virulent strains of V. parahaemolyticus. 
 
Until the advent of real-time PCR, this approach presented the main drawback of being 
limited to qualitative evaluation of food samples. Today, faster and quantitative 
assessment of Vibrio’s presence in food samples is possible [254]. More sophisticated 
methods have been introduced.  In 2009 for instance, Espiñeira et al. introduced a 
sequential multiplex PCR system for the detection of Vibrio sp that have been involved 
in fish and shellfish poisoning, namely V. cholerae, V. parahaemolyticus, V. vulnificus, 
V. alginoliticus and V. mimicus. This method, which has been validated, is not only able 
to detect problematic Vibrio species, but it can also, using a fragment analysis, confirm 
the viable-dead status of these microorganisms and most importantly, probe for the 
presence of important serogroups and virulence factors [304]. Genetic markers, a 
precious tool for PCR, have been identified for several other seafood-borne pathogens. 
These include cytotoxin-hemolysin (V. vulnificus), ctxAB (V. cholerae), oriC, 
chromosomal origin of replication (Salmonella spp.), listeriolysin O (hly) and the 16S 
rRNA (L. monocytogenes), polymerase gene (Hepatitis A virus) and polymerase gene 
for norovirus, just to name a few [303].
 
5.2.2. Examples of recent technological breakthroughs in efforts to free seafood 
from associated contaminants  
In recent years, outstanding breakthrough techniques and cutting edge 
technologies to aid in freeing seafood from associated contaminants have been 
developed. Molluscan shellfish and associated pathogens (especially V. vulnificus and 
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V. parahaemolyticus), scombrotoxin, fish safety (especially of cold-smoked salmon) and 
bio-preservation of seafood are a few examples of highly investigated topics.   
Molluscan shellfish and associated pathogens. Nowadays, seafood 
regulatory authorities face major issues with molluscan shellfish. For years now, 
molluscan shellfish has been classified as “high risk” seafood by the FDA. They were 
responsible for the largest number of seafood-borne illnesses during 1990-2006 (Figure 
5-4). Because of their filter-feeding habits, they tend to accumulate a wide range of 
etiological agents (pathogenic bacteria, parasites, and viruses) as well as biotoxins. The 
emergence of innovative FDA-approved Post-Harvest Processing (PHP) technologies 
such as Individual Quick Freezing (IQF), Heat-Cool Pasteurization (HCP), and High 
Hydrostatic Pressure (HHP), have revolutionized the industry of seafood, particularly in 
regard to oysters. These technologies, which are currently commercially available, have 
made it possible to bring raw and healthy products to consumers. An end product of 
high quality (fresh taste and superior appearance) is the major advantage of IQF, HCP 
and HHP. These processing techniques reduce the level of Vibrio bacteria to 
undetectable levels [304]. Though HHP is already approved by the FDA, several 
attempts to perfect this technology are currently on the way. In 2008 for instance, using 
a pressure resistant strain of Vp (MLT 403) to picture the worst-case scenario, Kural et 
al. proposed better pasteurizing conditions. Under such conditions, a 5-log reduction in 
the load of the pressure resistant Vp in live oysters could be achieved. These conditions 
were as follows: a two-minute treatment at pressure ≥ 350 MPa (1 °C to 35 °C) and a 
two-minute treatment at 40 °C (pressure ≥ 300 MPa) [305]. 
 
 
 225 
 
As far as seafood safety is concerned, HHP processing is an especially 
promising technology. Its inactivating effect on a variety of pathogenic agents isolable 
from seafood has been documented. These agents include viruses, parasites, and 
several other types of seafood-associated bacterial pathogens. The ability of HHP to 
inactivate oyster-associated viruses has been extensively studied [306-309]. A 5-min 
HHP treatment at pressure 400-MPa and 0 °C was established as an effective approach 
to bring murine norovirus-1 to undetectable levels in oysters [308]. HAV can also be 
effectively inactivated from oyster tissues using HHP. Calci et al. (2005) could achieve a 
PFU reduction >3 log10 with a one-minute treatment at 400 megapascals [306]. It is 
important to note that temperature, matrices’ pH, and salinity have a great effect on the 
efficiency of pressure mediated HAV inactivation [307].  
Another recent development in the field of molluscan shellfish safety is the 
application of super critical CO2 (scCO2), a known antibacterial substance widely used 
in the food industry to reduce the load of oyster-associated bacteria. Two conditions, 
100 bar and 37 °C for 30 minutes and at 172 bar and 60 °C for 60 minutes, were 
reported as able to induce 2-log and 3-log reductions in the oysters’ aerobic plate count 
respectively.  No significant change in the physical appearance, smell, or texture was 
recorded (Figure 5-10) [310]. 
As previously stated, V. vulnificus and V. parahaemolyticus are major seafood-
associated health concerns. In recent years, there has been a tremendous amount of 
effort to design approaches to reduce their load, especially in molluscan shellfish. One 
of the latest innovations in this field is the introduction of a “weak acidic electrolyzed 
water” based approach [311]. Quan et al. (2010) have demonstrated that weak acidic 
 226 
 
electrolyzed water possesses outstanding antibacterial potency against Vv and Vp, 
especially when compared to sodium hypochlorite (NaClO), a commercial sanitizer 
[311]. 
 
 
Figure 5-10. Appearance of oysters before and after a 40 minute exposure to 
scCO2.   
 
Oysters treated with scCO2 at 37 ˚C for 40 minutes  
Untreated oysters 
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A chlorine dioxide (ClO2) based approach was also recently introduced.  
According to Wang et al. (2010) a 6-hour treatment with 20 mg/L of ClO2 is enough to 
disinfect oyster tissues contaminated with Vp. These authors particularly recommend 
this method because it is cost-effective; it also has the potential of increasing seafood’s 
shelf life (~12 days)  [312]. In addition, E. coli O157:H7, S. typhimurium, and L. 
monocytogenes, other pathogens of importance regarding seafood safety, have proven 
sensitive to this type of treatment.  
Scombrotoxin. Because of the large number of associated outbreaks, 
scombrotoxin can be viewed as the most dangerous seafood-associated health hazard 
[218, 219]. To store fish at low temperatures is generally considered sufficient to 
prevent the growth of causative bacteria. Unfortunately, such conditions cannot always 
be respected, especially during retail processes. Phuvasate and Su (2010) proposed an 
alternative to low temperature storage applicable under these circumstances, namely 
the use of Electrolyzed Oxidizing (EO) water and ice. According to these authors, the 
load of several histamine-producing bacteria on food surfaces and fish skin can be 
significantly reduced simply by using electrolyzed oxidizing water and ice. Conditions 
reported as effective using salmon and tuna’s skin were, for EO water, 100 ppm 
chlorine for 120 minutes, and for EO ice, 100 ppm chlorine for 24 h [313]. Experts now 
agree, electrolyzed oxidizing water possesses a great potential as far as seafood safety. 
Its use is recommended not only because it is environmentally friendly, safe, and cost 
effective but also because its application is quite straightforward. Its antibacterial effects 
against several other seafood-associated bacteria have been reported. A few examples 
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are E. coli O157:H7, L. monocytogenes, as well as Salmonella enteritidis, 
Campylobacter jejuni, Enterobacter aerogenes, and S. aureus [314]
.
    
Bio-preservation of seafood.  To add various chemicals to seafood in order to 
reduce its bacterial load or inhibit the growth of unwanted bacteria is an option that 
many have proposed as a solution to some seafood safety issues. Regrettably, 
consumer acceptance of these products is not always guaranteed. As 
chemical/preservative-free, ready-to-eat seafood products are gaining in popularity 
alternatives to the use of chemicals have emerged, and an example is bio-preservation. 
Recently there have been a few innovations in this field. An example in this case is the 
proposed use of Carnobacterium divergens M35 and divergicin M35 in an effort to rid 
seafood from one of its most persistent bacterial contaminants, namely L. 
monocytogenes [315].
 
Matamoros et al. (2009) characterized several strains of lactic 
acid bacteria that can be used to this end as well. These bacteria (Lactobacillus 
fuchuensis, Leuconostoc gelidum, Lactococcus piscium, and Carnobacterium 
alterfunditum) showed inhibitory potential against seafood spoiling and pathogenic 
bacteria [316].
 
 Pinto et al (2009) also reported two bacteriocins produced by lactic acid 
bacteria (Enterococcus faecium and Pediococcus pentosaceus) that can be used to this 
end [317].   
Irradiation and other recent breakthroughs. Several other cutting edge 
technologies designed to help deal with seafood-associated health issues have been 
introduced in recent years. A few examples are X-ray, gamma ray, and electron beam 
irradiation based technologies.  Gamma irradiation (0.5, 1, 2, and 5 kGy) and electron 
beam irradiation have recently proven an effective non thermal approach to reduce the 
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load of V. parahaemolyticus as well as several other seafood-associated contaminants, 
namely L. monocytogenes and S. aureus, in a raw seafood dish (oyster Jeotkal). 
Organoleptic properties were not negatively affected by the irradiation. In this particular 
case, gamma irradiation appears a better alternative to electron beam irradiation [318]. 
The beneficial antibacterial effects of electron-beam irradiation applied to another 
seafood dish (salted and seasoned short-necked clam) were reported in 2009 by Kim et 
al. It is important to note that, in this case, no change in sensory qualities was observed. 
A significant microbial inactivation (coliform bacteria, aerobic bacteria, yeast and mold) 
was reported [319].
 
Similar results were achieved with cold-smoked salmon [320]. This 
technique appears to be a better alternative to HHP in regards to sanitization of cold-
smoked salmon. In fact, while both approaches (Irradiation at 2 kGy and HPP: 450 MPa 
for 5 min) yielded a safer final product, the visual aspect of HHP-treated, not Irradiation-
treated, salmon was negatively affected. The microbial load of both products did not 
exceed 6 log10 cfu/g after 35 days storage at 5 °C [320].  
X-ray irradiation has also been investigated for use in improving seafood 
microbiological quality. Several recent publications have demonstrated its beneficial 
effects on V. parahaemolyticus, V. vulnificus (shrimp contaminants). It is important to 
note that several other shrimp-associated bacterial contaminants, namely E. coli, 
Salmonella  enterica, and Shigella flexneri, were inactivated as well [321, 322].
 
High Hydrostatic Pressure (HHP) was also reported as an excellent alternative to 
reduce the level of Listeria in fish. According to Gudbjornsdottir et al. (2010), a 700–
900MPa treatment of 10 s is sufficient to reduce the load of L. innocua to undetectable 
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levels. This experiment was completed with cold-smoked salmon. In this case, though 
there was no lipid oxidation, some variations in color and microstructure of the final 
product were noted [323]. The potential of HHP to rid mackerel from parasites, such as 
the nematode Anisakis simplex, was also recently reported. In this particular case, a 
complete inactivation of the larvae in the fish tissue was achieved at 300 MPa after a 
five-minute exposure [324].
 
Another recent report has proposed using CO2 in packaging fish. Schirmer et al. 
(2009) proposed using CO2 combined with various organic acids: citric acid (3% w/w, 
pH 5) and acetic acid (1% w/w, pH 5) in packaging fresh fish, as an effective way to 
improve its quality and shelf life. This combination has proven efficient at completely 
inhibiting bacterial growth in naturally contaminated salmon stored at 4 °C for 14 days. 
Monitored bacteria were Enterobacteriaceae, lactic acid bacteria, and sulphur reducing 
bacteria. Sensory analysis was not completed by these authors [325].
 
A better alternative to rid shrimp from V. parahaemolyticus was recently 
introduced. The use of chlorine is the current approach to reduce the level of shrimp-
associated pathogenic bacteria. Unfortunately, health issues such as bronchitis and 
pulmonary edema in workers have been reported. Norhana et al. (2009) proposed an 
even simpler approach to deal with shrimp-associated bacterial pathogens. These 
authors show that washing shrimp with acidic fruit juice, namely bilimbi (Averrhoa 
bilimbi) or tamarind (Tamarindus indica L.) was also an effective way to significantly 
reduce its load of bacteria [326]. In 2007, Chaiyakosa et al. reported another safer 
alternative to reducing the load of V. parahaemolyticus in shrimp, namely the use of 
Chitosan [327]. Another author reported this same substance as an effective means of 
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bringing safer salmon to consumers. Packing cold-smoked salmon in chitosan-coated 
plastic films containing 4.5 mg/cm2 sodium lactate or either a combination of 4.5 mg/cm2 
sodium lactate plus 0.6 mg/cm2 potassium sorbate or 2.3 mg/cm2 sodium lactate plus 
500 IU/cm2 nisin was found to be beneficial. It was established that for seafood 
conditioned using this approach and stored at low temperature (~ 4 ºC), L. 
monocytogenes’ growth was inhibited for at least six weeks [328].
 
6. Future directions and conclusions  
From pathogenic bacteria, parasites, and viruses of all sorts, to life threatening 
biotoxins, the range of chemical and biological contaminants present in seafood is 
broad in scope and challenging to manage. Despite years of efforts from regulatory 
authorities and the scientific community, the public at large is still at risk of dangers 
associated with seafood consumption. For several years now, seafood has ranked 
foremost as the most significant source of food-borne disease outbreaks of known 
origin. Contributing factors are numerous and represent key points upon which urgent 
action, from regulatory authorities and the scientific community is required. Special 
attention should be paid to deleterious agents that have been associated with the 
largest number of outbreaks in the past years. In the U.S. for instance, major threats 
were scombrotoxin, responsible for 36% of all reported seafood-borne outbreaks from 
1990 to 2006, followed by ciguatera (responsible for 21% of outbreaks), bacteria 
(especially Vibrio spp) responsible for 24% and finally noroviruses, which cause about 
10% of all outbreaks reported during this same period [218]. It is important to note that 
these same agents pose serious problems in other parts of the world, as well. 
Scombroid fish poisoning, for instance, is also a serious problem in countries like Japan 
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and the U.K.  [242].
 
Vibrio spp, especially V. parahaemolyticus, have been reported as a 
major problem in several Asian countries [254].
 
A recent study, a 2005 – 2008 survey of 
shellfish (mussels, clams and oysters), showed that norovirus is a problem in Italy, as 
well [329].  
The task of ensuring consumers protection against the dangers of seafood is 
shared by several groups.  These include (1) regulatory authorities, which depend 
heavily on the scientific community, and are in charge of the promulgation and 
enforcement of laws and regulations, (2) establishments involved in the harvest, 
processing, storage, and retail of seafood, and (3) consumers themselves. Failures and 
flaws at various levels of the current safety management system explain why seafood 
has been a persistent issue for the past few years. A certain number of defects in the 
seafood regulatory system of the U.S. for instance are presented in a 2008 report of the 
Center for Science in the Public Interest (CSPI). Mentioned shortcomings are the 
“voluntary recall” approach currently in place, added to financial issues. CSPI sees in 
the limited budget allocated to the FDA (Figure 5-11), a serious hindrance to its 
efficiency. This can be a serious hindrance, for instance, when it comes to law 
enforcement. CSPI reports an extremely low inspection rate of food processing 
companies by the FDA, a rate that is insignificant compared to the USDA’s [218]. 
Currently, in the U.S., there are approximately 13,400 seafood-processing 
establishments. The FDA reports having inspected only 3,066, 2,830, and 2,456 during 
the fiscal years 2004, 2005 and 2006 respectively. 
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Figure 5-11. Graphical representation of some limitations in the current federal 
food safety regulatory system with signficant impact on seafood safety 
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Financial limitations are not the only obstacle to full efficiency of regulatory 
agencies. The unavailability of effective technological tools that could either help rid 
seafood from hazardous entities/substances, or assist regulatory authorities in effective 
risk assessment and management during various control programs is also critical. 
Without effectual detection methods, efficient law enforcement is nearly impossible. 
Though numerous approaches applicable to virtually all seafood-associated health 
hazards have been proposed so far, several gaps remain.  
This is the case of biotoxins for instance, which alone were responsible for 63% 
of all reported seafood-borne diseases from 1990 to 2006. Because they are extremely 
resistant to various post-harvest processing techniques, as far as assuring seafood 
safety, preventive measures are a better option.  More effective detection tools are thus 
critically needed in order to reduce the current incidence of biotoxin-linked seafood-
borne illnesses. Presently, in this field, there is still a need for cost-effective, rapid, 
sensitive, specific, and straightforward methods that can be operated by untrained 
personnel on a routine basis. 
Though several approaches to toxin detection in seafood have been proposed so 
far, and even significant progress made recently (Table 5-7), animal-based assays and 
liquid chromatography, techniques that have their share of shortcomings, are still the 
official   methods (Table 5-4) 
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Animal bioassays for instance, are fit to assess the overall toxicity of a sample 
but cannot give insight on the nature of the toxin(s) involved. Moreover, these assays 
are time consuming, of limited accuracy and controversial (ethics). As stated previously, 
liquid chromatography, on the other hand, when coupled with effectual detection 
methods, is valuable at accurately identifying the nature and concentration of the 
incriminated toxin(s). However, it is important to note that, chromatography-based 
methods are lengthy and not cost-effective; heavy equipments and trained specialists 
are needed. Better methods have been proposed, but, to our knowledge, none has 
been approved by regulatory authorities for routine use. Though these new methods 
present some clear advantages, it is important to point out that they also possess some 
weaknesses. Among these are difficulty of application on a routine basis, the necessity 
for heavy equipment, and the complexity of protocols and generated data, just to name 
a few.  
There are flaws in current approaches to control scombroid fish poisoning and 
ciguatera.  In the case of scombroid fish poisoning for instance, there is still a need for 
more effective alternatives to control Histamine-Producing Bacteria (HPB). Current 
recommendations of the FDA involve rapid cooling (≤ 40 ˚F) after visceration (for larger 
fish) upon death. Unfortunately, this approach possesses a few shortcomings. It is 
important to note that not all HPB are mesophiles. Several studies showed that 
histamine can be produced even at low temperature by physchrophilic HPB [242, 330].  
Ciguatera was second to scombrotoxin as the most likely cause of seafood-borne 
disease outbreak from 1990 to 2006. Though ciguatera is such an issue in the U.S., 
“there are neither standards, nor an official method” that applies to Ciguatera Fish 
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Poisoning (CFP) in this country [238].  Innovations, regulation-wise, in this regard are 
obviously critical. Current efforts with respect to CFP prevention involve various toxin-
monitoring programs, education, alongside with bans on the sale and capture of fish 
most likely to cause poisoning (Europe, Australia).  
Bacteria were next to toxins as the most prevalent cause of seafood-borne 
illnesses during the past decade. Fortunately, in this case, there are currently several 
approved Post-Harvest-Processing (PHP) approaches aimed at reducing their load in 
seafood. These included IQF (Individually Quick Frozen), HCP (Heat Cold 
Pasteurization), and HHP (High Hydrostatic Pressure). Though these techniques have 
revolutionized the industry of oysters, for instance, there is still room for improvement, 
especially because oysters do not survive such processing [331]. In terms of shelf life, 
this can be an issue. To store, HHP-, IQF- and HCP-treated oysters at low temperatures 
is, unfortunately, not enough to solve the issue. Prapaiwong et al. (2009), studying 
variations in the bacterial load (total aerobic bacterial counts) of HHP-treated oysters 
stored at 4 °C for instance, determined that the bacterial count of processed products 
can rise quickly during storage and can even reach ~ 107 CFU/g in just 7 days [332]. 
Moreover, long-term storage presents the disadvantage of increasing the final 
production cost. Post-harvest-processing techniques non lethal to oysters would be, 
without the shadow of a doubt, a better alternative. Mahmoud and Burrage (2009c) 
reported X-ray irradiation as a better approach for reducing the load of oysters-
associated V. parahaemolyticus because oysters are able to survive even extremely 
high X-ray doses [333].
 
Oysters have also been shown to be able to survive scCO2 
exposure, making it an attractive tool for further exploration [310]
. 
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Norovirus is another major seafood-associated health hazard. Major gaps in the 
current system are regulatory and scientific. Despite the clear threat posed by this virus, 
not much effort has apparently being exerted regulation-wise. As mentioned by Terio et 
al. (2010), “there is no virological standard for bivalve shellfish in European legislation” 
[329].
 
 Though several approaches to the detection of norovirus in seafood have been 
proposed so far, much still needs to be done; an area in need of improvement is the 
development of more efficient methods of viral RNA extraction. RNA extraction is a 
critical step in several virus detection protocols. RNeasy Kit was recently presented by 
Husman et al. (2009) as a most useful alternative for viral RNA extraction after 
comparing five such approaches side by side. A modified paramagnetic silica-based 
guanidium extraction based technique was also developed recently [334, 335]. 
Other challenges faced in norovirus detection are related to the virus’ genetic variability 
and scarcity in samples. Interferences of seafood matrix, mainly, the presence of 
inhibitory substances, also represents a serious obstruction [335].
   
An effective TaqMan 
RT-PCR based approach for quantification of genogroups I and II norovirus, which 
presents the advantage of overcoming background inhibitory effects, was introduced 
recently by Gentry et al. (2009) [336]. An effective and more sensitive multiplex RT–
PCR-based approach to norovirus and rotavirus detection in oysters was also 
introduced recently [337]. 
  
There is no doubt that the development of effective technologies able to 
surmount each and every one of these challenges will aid efforts to reduce outbreak 
incidents of seafood-borne infections attributable to viruses. 
 
 238 
 
 
 
Chapter 6 : REDUCING OYSTER-ASSOCIATED 
BACTERIA LEVELS USING SUPERCRITICAL FLUID 
CO2 AS AN AGENT OF WARM PASTEURIZATION 
 
Running Title: SUPERCRITICAL CO2 EFFECTS ON OYSTER’S BACTERIAL 
CONTAMINANTS          
 
Published in the International Journal of Food Microbiology, 2010, 138 (1-2):63-70 
 
Authors: Meujo DA, Kevin DA, Peng J, Bowling JJ, Liu J, Hamann MT 
                                    
 
ABSTRACT - An innovative approach to Post-Harvest Processing (PHP) of oysters is 
introduced focusing on the effects of supercritical carbon dioxide (scCO2) on bacterial 
contaminants trapped in the digestive system of oysters. Oysters were exposed to 
scCO2 under two conditions: (1) 100 bar and 37 °C for 30 min and (2) 172 bar and 60 
°C for 60 min. Using FDA standard guidelines for food analysis, variations in the Aerobic 
Plate Count (APC) were assessed. It was established that exposing oysters to CO2 at 
100 bar and 37 °C for 30 min and at 172 bar and 60 °C for 60 min induced 2-log and 3-
log reductions in the APC respectively. The decrease in the microbial load as a result of 
treatment with scCO2 was found to be significant (P=0.002). A release of adductor 
muscles from the shell was noted in oysters treated at 172 bar and 60 °C for 60 min; 
this was not the case for oysters treated at 100 bar and 37 °C for 30 min. A blind study 
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allowing sensory analysis of treated vs. untreated oysters was also completed and no 
significant change in the physical appearance, smell, or texture was recorded. In this 
paper, we also report the effect of scCO2 on several bacterial isolates, including a 
referenced ATCC strain of a non-pathogenic Vibrio (Vibrio fischeri) as well as several 
other bacterial isolates cultured from oyster' tissues and found to share biochemical 
features common to pathogenic Vibrio strains. A complete inactivation (minimum 7-log 
reduction) was achieved with these latter bacterial isolates. A 6-log reduction was 
observed with V. fischeri. 
 
1. Introduction  
As a direct consequence of filter-feeding in often heavily contaminated water, 
oysters can be loaded with pathogenic microorganisms. These microorganisms are 
absorbed concomitantly with nutrients and accumulate in the gastrointestinal (GI) 
system of oysters. Hepatitis viruses (A and E), Salmonella, Shigella spp., Escherichia 
coli, Vibrio spp., Clostridium perfringens, C. botulinum and Yersinia enterocolitica are 
some of the microbes that have been reported as part of this pathogenic microflora 
[265, 338, 339]. Since oysters are often consumed raw, these pathogens are a serious 
concern. These microorganisms have been associated with a wide range of mild to 
severe foodborne illnesses. Of pathogens that contaminate the GI system of oysters, 
Vibrio spp (especially V. parahaemolyticus (Vp) and V. vulnificus (Vv)) are of greater 
concern [338, 340, 341]. Among immunocompromised patients, especially those with 
chronic liver disease, V. vulnificus strains have been strongly associated with severe 
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and life-threatening conditions.V. vulnificus is the second leading cause of seafood-
related fatality in the US [257, 259].  
Pathogenic microorganisms are not the only concern associated with oyster 
consumption. Other risks include toxic metals, biotoxins and chemical environmental 
contaminants. These also accumulate in the GI system and tissues of oysters and have 
been associated with food poisoning outbreaks [235].  
Until recently, all attempts to reduce the incidence of oyster-related foodborne 
illnesses were centered on consumer education. Other efforts to minimize consumer 
exposure to oyster-associated pathogens included natural depuration and harvesting 
restrictions. Despite these efforts, in 2002, Potasman et al. reported a worrisome 
increase in the number of outbreaks of bivalve-associated infections primarily from 
oysters, from 3 reports in the 1970s to 22 during the 1990s. The large majority of these 
outbreaks were due to raw oyster consumption [265]. 
The emergence of innovative FDA approved Post-Harvest Processing (PHP) 
technologies such as Individual Quick Freezing (IQF), introduced in 1989, Heat–Cool 
Pasteurization (HCP), introduced in 1995, and High Hydrostatic Pressure (HHP), 
introduced in 1999, have revolutionized the industry of seafood, particularly in regard to 
oysters. These technologies, which are currently commercially available, have made it 
possible to bring safer raw products to consumers. An end product of high quality (fresh 
taste and superior appearance) is the major advantage of Individual Quick Freezing 
(IQF), Heat–Cool Pasteurization (HCP) and High Hydrostatic Pressure (HHP) 
processing. These processing techniques also reduce the level of V. vulnificus to non-
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detectable levels (i.e., < MPN/g). The level of spoilage bacteria is significantly reduced 
aswell. Unfortunately, oysters cannot survive any of the above PHP technologies [331].  
In terms of shelf life, this can be an issue and thus it is mandatory to store HHP-, 
IQF- and HCP-treated oysters at low temperature; long term storage is expensive. 
Several other methods are under development including approaches using X-ray and 
Gamma radiation as cold pasteurizing agents.  
In the present paper, we introduce an original and promising approach to post-
harvest processing of oysters: warm pasteurization of oysters using scCO2 (CO2 at a 
temperature and pressure above its critical point). The antimicrobial potential of dense 
CO2 was first reported in 1951 by Fraser while working with E. coli [342]. Extensive work 
has since been completed and currently, the bactericidal potential of scCO2 is well-
established over a wide range of pathogenic microorganisms. ScCO2 has been 
documented to effectively inactivate viruses (HIV-1, Sindbis virus, polio Sabin type I 
virus, and pseudorabies virus [PRV]), yeast (Saccharomyces cerevisiae), as well as 
vegetative and sporal forms of various bacteria (Salmonella, S. aureus, listeria, E. coli, 
Pseudomonas fluorescens, etc.) [343-346]. So far, however, there has been no report 
on the effect of scCO2 on Vibrio spp.  
There are also several reports of studies related to the kinetics of inactivation of 
bacteria in food products (e.g., milk, fruit juice, herbs, ground beef, etc.) using scCO2 
[345-347]. However there is no reported attempt to assess whether treating oysters with 
scCO2 could have a positive impact on the wide range of pathogenic bacteria which 
populate their GI system. 
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The present studies address several key questions in regards to oyster 
pasteurization by scCO2. First, the effects of scCO2 was evaluated in vitro on bacterial 
cultures of a non-pathogenic strain of Vibrio used here as a model for Vibrio spp (Vibrio 
fischeri ATCC® 7744™) and several bacterial isolates from an oyster homogenate. 
Second, the effect of scCO2 on the bacterial community trapped in the oyster GI system 
was studied. Finally, using a panel of thirteen participants, a sensory analysis of fresh 
untreated oysters versus scCO2-treated oysters was completed in a blind survey. 
2. Material and Methods  
2.1. Bacterial strains 
Referenced bacterial strains used to assess the effect of scCO2 on bacteria in 
vitro were V. fischeri (ATCC® 7744™) and E. coli (Migula) Castellani and Chalmers 
(ATCC® 25922™). V. fischeri was grown and maintained on either Luria Bertani Salt 
(LBS) medium (1% [wt./vol.] bacto tryptone [DB], 0.5% [wt./vol.] bacto yeast extract [BD, 
Franklin Lakes, NJ], 2% [wt./vol.] NaCl, 0.3% [vol./vol.] glycerol, 50 mM Tris–HCl [pH 
7.5]) [348], or BOSS medium (3% [wt./vol.] NaCl [Fisher Scientific], 0.1% [wt./vol.] 
Glycerol [Sigma Aldrich], 1% [wt./vol.] bacto peptone [DB], 0.3% [wt./vol.] beef extract, 
[pH 7.3]; [349].  E. coli was grown and maintained in Bacto nutrient broth [Difco 
Laboratories, Detroit, MI], 23 g/L. 
2.2. Oysters 
Oysters were purchased from a seafood distributor in Memphis, TN, USA. These 
oysters were harvested on 04/13/09, properly maintained and delivered to our facility on 
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4/20/09. After arrival, the oysters were stored whole on ice overnight and our 
experiments were carried out the following day. Oysters were presumed alive unless the 
shell's adductor muscles were permanently released, in which case the oysters were 
discarded. Concerning morphology and size, the oysters were a mixture of “banana-
shaped” and “good-quality shaped” oysters; “goodquality shaped” oysters constituted 
the majority. The morphology classification was performed according to procedures 
previously published by Lee et al., 2004 [350]. The length of the oysters varied from 
small (7.5 cm) to large (13 cm). 
2.3. Supercritical unit and treatment of oysters using supercritical CO2  
The SFT-150 SFE system (Supercritical Fluid Technologies, Inc.) (Figure 6-1) 
was used for all scCO2 treatments. The internal surfaces of the SFT-150's treatment 
chamber were sterilized with a 70% ethanol solution and allowed to dry at room 
temperature. The samples prepared for treatment were placed into the chamber which 
was then hermetically sealed. The liquid carbon dioxide source was opened filling the 
chamber and venting for 5 s to purge the chamber of any air. An external air source was 
utilized to supply the SCT-150's pneumatic compressor which increases the chamber's 
internal pressure. An external air pressure gauge was utilized to control the pneumatic 
compressor. The SCT-150's internal pressure was maintained and monitored via the 
fine-control valves and internal pressure displays located on the SCT-150 unit. Oysters 
were sampled in groups of 10–13 and placed in porous bags (Filter Specialists, Inc., 
[FSI] Michigan City, IN) which were placed into a 4 L capacity chamber. The oysters 
were exposed to scCO2 under two different conditions: 100 bar for 30 min at 37 °C and 
172 bar for 60 min at 60 °C. After treatment, the chamber was carefully vented, the 
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oysters removed, and their microbial load (APC) was assessed alongside untreated 
oysters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1. Standard bench-top SFT-150 (bottom) and schematic of supercritical 
sterilization apparatus (top). 
(1) Filter. (2) Bulkhead. (3) Relieving Regulator. (4) CO2 Pre-chiller. (5) Liquid CO2 pump. (6) 
Preheater. (7) Vessel. (8) Sterilization unit. 
 
2.4. Microbiological analysis of treated vs. untreated oyster samples   
For microbiological analysis, each group of oysters was divided into three sub-
samples which were analyzed independently. Each oyster's surface was carefully 
Julabo chiller 
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cleaned with 70% ethanol solution and dried under a bacteriological hood using a paper 
towel. Oysters were opened aseptically in order to separate the flesh and interstitial fluid 
from the shell. The flesh and interstitial fluids were macerated in a sterilized blender for 
about a minute in an equal volume of Butterfield's phosphate-buffer to yield an oyster 
homogenate (dilution 1:2). A dilution of 1:10 was prepared by transferring 20 g of this 
homogenate into 80 mL of Butterfield's phosphate-buffered dilution water. Subsequent 
10-fold dilutions were prepared. One mL of each dilution was pipetted into separate, 
duplicate, appropriately marked Petri dishes. About 12–15 mL plate count agar (cooled 
to about 45 ± 1 °C) was added to each plate and the agar was allowed to solidify. The 
plates were incubated promptly for 48 ± 2 h at 35 °C. 
As a positive control a group of 12 oysters was split into three subgroups, placed 
in self-sealing sterilization pouches, and autoclaved (30 min at 121 °C and 18–20 psi). 
At the end of the sterilization process using the same procedure described above, the 
APC was assessed and confirmed to be zero. 
2.5. Statistical analysis 
All oysters' experiments were replicated twice and assessments of APC counts 
were run in triplicate for each replicate (n = 2 × 3). Mean values ± standard deviations 
were used to plot the corresponding graph. 
The test of the hypothesis that the bacterial load in treated vs. untreated oysters 
was significantly different was done by application of the Mann–Whitney U test to 
groups of log means of each set of two within sample replicates. The difference 
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between the set of treatment group log means and the set of untreated group log means 
was found to be significant when P < 0.05. 
2.6. Biochemical characteristics of bacteria isolated from oyster tissue   
Several bacterial colonies were isolated from the oysters' tissues (treated 
oysters); Gram staining, catalase tests, oxidase tests, mobility tests and fermentation 
profiles were completed for each isolate. The catalase reaction was completed with 3% 
H2O2. The ability of isolates to ferment specific carbohydrates was determined using 
phenol red broth (enzymatic digest of casein [1%], supplement sugar [0.5%–1%], 
sodium chloride [0.5%], phenol red [0.0018%], final pH: 7.4 ± 0.2 at 25 °C) to which 
specific carbohydrates (glucose, sucrose, lactose or mannitol) were added. Oxidase 
reagent droppers [0.5 mL of a 1% aqueous solution of N, N, N′, N′-tetramethyl-p 
phenylenediamine dihydrochloride] were used for the oxidase test. Some isolates  were 
also cultured on the Vibrio selective thiosulfate-citrate-bile salts-sucrose (TCBS) agar 
(yeast extract [0.5%], proteose peptone No. 3 [0.1%], sodium citrate [1%], sodium 
thiosulfate [1%], oxgall [0.8%], saccharose [2%], sodium chloride [1%], ferric 
ammoniumcitrate [0.1%], bromothymol blue [0.004%], thymol blue [0.004%], and agar 
[1.5%]) (Table 6-2). 
2.7. Effects of scCO2 on bacteria isolated of oysters tissues  
Four bacteria isolates possessing basic biochemical characteristics common to 
pathogenic Vibrio sp (i.e., Gram negative, catalase positive, oxidase positive and growth 
on TCBS agar) were cultured overnight at 35 ± 2 °C in ISP2. Ten milliliters of each 
culture was pipetted into 50 mL Sterile Corning® centrifuge tubes. A hole was made in 
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the cap of these tubes to allow the flow of scCO2 into the tube. Dry sterilized filtered 
paper was used to cover the hole. Two such culture tubes were prepared for each of the 
four isolates. These were placed together in the 100 mL vessel of the unit of the 
Supercritical Fluid Technologies, Inc., SFT-150 SFE system and treated with scCO2 at 
100 bar and 37 °C for 30 min. Bacterial counts were estimated by plate spread 
technique using ISP2 or plate count agar; serial dilutions were completed in each case 
and these plates were seeded with 100 µL of treated or untreated culture 
2.8. Kinetics of inactivation of two ATCC referenced Gram negative bacteria V. 
fisheri and E. coli by scCO2 
For each experiment, 2 mL of a freshly grown culture of E. coli and V. fischeri 
contained in a 15 mL Sterile Corning® Centrifuge tube (Corning Incorporated, Big Flats, 
NY), was introduced in the 100 mL vessel of the unit; a hole was also generated in the 
plug-sealed cap of the centrifuge tube to allow the flow of scCO2 into the tube. The 
experiment was completed under three different pressures (100, 150, and 200 bar) at 
37 °C with the purpose of evaluating the effects of pressure variation on the sterilization 
potential of CO2; exposure times were 5, 10, 15 and 20 min. The initial load was 
estimated by plate count (E. coli) or by using a calibration curve (V. fischeri). At the end 
of each experiment, the number of surviving bacterial cells was counted by plate spread 
techniques [351]. Briefly, a fourfold serial dilution of each test culture was made in a 96 
well-plate format. A few wells were selected for the bacterial count process via 
spreading 25 µL of the content of the given wells or dilution on the surface of a plate 
containing BOSS or nutrient agar; the bacterial count per well was repeated twice and 
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the average value was considered as the final count. The experiment was repeated to 
confirm the previously observed trend (n = 4).  
2.9. Sensory assessment 
The sensory analysis of oysters treated by scCO2 was assessed by a panel of 13 
people. The features evaluated included physical appearance, smell, and texture of 
oysters; the oysters were not tasted. Because they were not trained panelists, these 
panelists were presented with standards (Figure 6-4) that would assist them in the 
grading process. There were two such standards; the first was labeled as “fresh” and 
the second as “spoiled.” The first standard was a freshly shucked, untreated oyster 
while the second was an oyster that was left at room temperature for about two days 
(enough to allow it to develop the mild odor associated with spoiled oysters). Each 
panelist was asked to comparatively examine the physical appearance, smell, and 
texture of these standards after what they were led to the oyster stations where five 
groups of oysters were aligned side by side. One of these groups included untreated 
oysters while the rest included oysters treated under a variety of conditions ([20 min, 
100 bar, 37 °C], [50 min, 100 bar, 37 °C], [50 min, 200 bar, 37 °C], and [20 min, 200 bar 
37 °C]). These oysterswere labeled using simple codes: X1, X2, X3, X4 or X5 (blind 
study). The panelists were informed that one out of these five groups was made of 
standard/untreated oysters. The panelists were then asked to evaluate the physical 
appearance, smell, and texture of the oysters as closely resembling our standard for 
“fresh” or our standard for “spoiled”. A third option, “intermediate” was also offered. A 
score of two (2) was allocated for the adjective “fresh” (the most desirable). A score of 
zero (0) was allocated for the adjective “spoiled” (the least desirable). Finally, a score of 
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one (1) was allocated for “intermediate.” (Table 6-1) The overall “freshness score” for 
each given oyster was the sum of scores it received for its texture, physical appearance, 
and smell. This freshness score varied from 0 to 6. To be judged acceptable, an oyster 
must have obtained an overall score ≥ 3. 
Data from all the 13 panelists were pooled for each group of oysters and an 
overall scorewas assigned per the group; this was the mean value of scores achieved 
by individual oyster of each particular group. 
Table 6-1. Guide used in grading oysters (treated and untreated): blind study 
 
3. Results 
3.1. Microbiological analysis of treated and untreated oyster samples  
Oysters sampled in groups of 10–13 oysters were treated with scCO2 under the 
following two conditions: 100 bar, 30 min, 37 °C and 60 min, 172 bar, 60 °C. After 
exposure, the effect of scCO2 on the aerobic microbial load (APC) that contaminates the 
GI system of these oysters was assessed using the FDA recommended approach to 
food analysis (n = 6). The microbial load (Aerobic Plate Count) present in the GI system 
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of untreated oyster samples was determined using this same approach and estimated 
to be 1.8 × 107 CFU/g of oyster meat (EAPC).   
It was estimated that exposure of oysters to CO2 (100 bar, 30 min, 37 °C) led to a 
significant decrease (P = 0.002) in the load of oysters' bacterial contaminants. This 
treatment induced a 97.6% reduction in the microbial load that contaminated their GI 
tract corresponding to a 2-log reduction. A similar result was observed in previous 
experiments with oysters exposed to scCO2 at 100 bar, 40 min, and 37 °C (data not 
shown). The residual load of bacteria in these scCO2-treated oysters was estimated to 
be about 4 × 105 CFU/g (EAPC) (Figure 6-2). 
A greater bacteria inactivation level was observed with oysters exposed to 172 
bar, 60 min and 60 °C. In this case the APC reduction was estimated to be 99.9%, 
which corresponds to a 3-log reduction. This translates into reducing the initial load of ~ 
1.8×107 CFU/g (EAPC) of oyster meat to 3.3×104 CFU/g. 
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Figure 6-2. Inactivating effect of scCO2 on bacterial contaminant of oyster. 
Oysters were thoroughly cleaned and treated at 100 bars, 30 mins and 37 ˚C. The oysters were 
separate in 3 groups shucked in aseptic environment; the amount of APC was then estimated 
using FDA recommended approach to food analysis. This whole experiment was repeated twice 
for an “n = 6 (that is 2 * 3). Untreated Oysters were processed in a similar manner. The APC was 
estimated twice also for an n = 6 that is (2 * 3) 
*** Statistically significant difference  
 
3.2. Effects of scCO2 on bacteria in vitro 
As mentioned previously, V. parahaemolyticus and V. vulnificus are key players 
in quality control programs for raw oysters. We anticipate assessing the effect of scCO2 
on these microorganisms (in vitro and in vivo) in future studies. In the present 
document, we have evaluated the effect of scCO2 on a non-pathogenic strain, namely 
V. fischeri which we used as a model for Vibrio sp. The kinetic of inactivation of V. 
fischeri by scCO2 was studied under three different pressures conditions (100 bar, 150 
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bar, and 200 bar at 37 °C); exposure times were 5, 10, 15 and 20 min. The effects of 
scCO2 on oyster bacterial isolates possessing several key biochemical features 
common to pathogenic Vibrio spp (namely V. parahaemolyticus and V. vulnificus) was 
assessed as well. 
 
 
 
Figure 6-3. Comparative Effects of scCO2 on V. fisherii and another Gram negative 
bacterium (E. coli) in vitro 
The kinetic of inactivation of two Gram negative bacteria by scCO2 was studied. Cultures of (A) V. 
fisherii (3 x 106 CFU/mL) and (B) E. coli (5 x 108 CFU/mL) were exposed to sc CO2 at 100 bar, 
150 bar and 200 bar for 5, 10, 15 and 20 minutes.   
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3.2.1. Effect of scCO2 on bacterial isolates possessing some basic biochemical 
characteristics common to pathogenic Vibrio sp (in vitro).  
Ten milliliters of overnight cultures of oysters' bacterial isolates (Table 6-2) was 
exposed to scCO2 (100 bar, 37 °C) for 30 min. The initial microbial load was estimated 
to be higher than 2 × 107 CFU/mL of broth. A complete (100%) inactivation was 
obtained for all cultures. No growth was observed even in plates seeded with 100 µL of 
the undiluted sample (pipetted directly from the test tube) (Table 6-3).   
This experiment was replicated and the number of survivals in each case was 
estimated in triplicate. This corresponds, at a minimum, to a 7-log reduction. 
Subsequent experiments helped to establish that a 30 minute-long exposure is not 
required to achieve this level of inactivation; similar results were achieved with cultures 
treated for only 10 min. 
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Table 6-2. A few biochemical features of bacterial isolates obtained from treated oyster tissues 
Isolate code Gram  
Type 
Catalase 
reaction 
Oxidase 
reaction 
On TCBS Mobility  
    
Growth Colonies  Colonies’ 
Color 
conversion 
 
 
Isolate #13*  - + + + Green 
centered 
colonies 
- + AF 
Isolate #18*   - + + + Green +y +* AF 
Isolate #30* - + + + Green +d +* AF 
Isolate #36* - + + + Green +d +* AF 
 
        
y: conversion to yellowish color ; d: conversion to darker (blackish) colonies ; +: Positive ; -: Negative ; * did not ferment glucose, lactose or mannitol 
, +* poor growth, AF: anaerobie facultative  
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Table 6-3. Effect of scCO2 on bacterial isolates possessing some basic 
biochemical characteristics common to pathogenic Vibrio sp (bacteria count 2E + 
07 CFU/mL a) 
 
 
Figure 6-4. Standards used for sensory analysis of untreated vs. treated oysters 
A sensory analysis of untreated vs. scCO2 - treated oysters was completed. To grade the physical 
appearance, smell, and texture of oysters, a panel of 13 people used two standards; the first standard 
was that for “fresh” oysters and the second standard was that for “spoiled” oysters.  (A) Standard for 
“fresh” (B) Standard for “spoiled”  
3.2.2.. Comparative effects of scCO2 on two ATCC referenced Gram-negative 
bacteria: V. fisherii and E. coli - kinetic of bacterial inactivation   
V. fischeri was reduced to a non-detectable level (6-log reduction) after only 5 
min of exposure to scCO2; this occurred independently of pressure. V. fischeri appeared 
far more sensitive to the effect of scCO2 when compared to E. coli, for instance. E. coli 
is considered one of the most sensitive bacteria to this treatment [352]. The complete 
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inactivation of E. coli (8-log reduction), under these same conditions, was achieved only 
after 20 min of exposure to scCO2. Dillow et al. (1999) and also Smelt and Rijke (1992) 
reported similar results [353, 354]. Along with this decrease in bacterial viability came a 
decrease in the pH of the culture. This decrease in pH can suggest a possible 
mechanism for the bacterial inactivation. 
3.3. Sensory assessment 
Treated and untreated oysters were evaluated side by side by a panel of 13 
volunteers in a blind study. A score was assigned to oysters individually and as a group. 
To be judged acceptable, an oyster or a group of oysters must have achieved an overall 
score ≥ 3. From the data collected, it was concluded that oysters remain acceptable, as 
far as their physical appearance, texture and smell, after exposure to CO2 ([100 bar for 
20 min at 37 °C], [100 bar for 50 min at 37 °C], [200 bar for 50 min at 37 °C] and [200 
bar for 20 min at 37 °C]). The group of treated oysters that received the best rating were 
those treated at 100 bar for 20 min at 37 °C (score = 4.4). Ratings for the other groups 
were also ≥ 3. The group of untreated oysters achieved a score of 4.9. 
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Figure 6-5. Appearance of oysters before and after a 40 minutes exposure to 
scCO2. 
The effect scCO2 on the physical appearance of oysters is presented.  Oysters were sampled in 
small groups and introduced in a supercritical unit (SFT-150 SFE system -Supercritical Fluid 
Technologies, Inc.) where they were exposed to scCO2 for 40 minutes. They were then shucked 
and photographed.  Temperature and pressure conditions were 37°C and 100 bar.  
4. Discussion  
Herein, we report that the level of bacterial inactivation (Aerobic Plate Count) 
achieved with scCO2 (100 bar for 30 min at 37 °C or 172 bar for 60 min at 60 °C), is 
comparable to that achieved with several FDA approved PHP for oysters, namely, HHP 
(High Hydrostatic Pressure) and QF (Quick Frozen). In 2009, Prapaiwong et al. reported 
 
 
Untreated Oysters (group 1) 
Oyster treated at  100bar, 37°C 
for 40minutes (Group2)  
Oyster treated at  100bar, 37°C 
for 40minutes (Group1)  Untreated 1  
Untreated 2  
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a comparable residual amount of bacteria in HHP- and QF-treated oysters. Oysters 
included in their study were sampled from batches of treated oysters on their way to the 
market. These authors reported a Total Aerobic Plate Count (TAPC) of 1.4 × 104 CFU/g, 
1.6×104 CFU/g, and 3.3 × 104 CFU/g in HHP-treated oysters harvested during summer, 
winter, and fall, respectively. They reported similar amounts of residual bacteria in QF-
treated oysters. Untreated oysters harvested during these same periods reportedly 
contained 3.5 × 105, 2.8 × 105, and 1.4 × 109 CFU/g for oysters harvested during winter, 
fall, and summer, respectively [332]. Bacteria that survived these scCO2 treatments 
were mostly Gram negative similar to what has been reported for HHP-treated and QF-
treated oysters [332].  
Twenty-four out of thirty isolates were identified as catalase positive, and 
eighteen as oxidase positive. Once in culture however, these isolates (a random 
selection of four) appeared to be extremely sensitive to the effect of scCO2. According 
to Lin et al. (1994) [355], the complex physicochemical environment of food products 
especially a high fat content can increase the resistance of vegetative cells to the effect 
of scCO2 by limiting the penetration of CO2. 
Each of the current three FDA approved PHP for oysters, namelyHHP, HCP, and 
IQF, has its advantages and disadvantages. One of the major selling points of High 
Hydrostatic Pressure (HHP), for instance, is the fact that it induces a release of 
adductor muscles from oysters' shells. Whether the release of these adductor muscles 
is truly a desirable effect is somewhat controversial. While it makes shucking oysters 
afterwards easier, it is important to note that the permanent release of such muscles is 
a clear indication that oysters did not survive the process which in terms of shelf life 
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could be an issue. Prapaiwong et al. (2009) [332] studying variations in the bacterial 
load of HHP-treated oysters stored at 4 °C, determined that the bacterial count can go 
from an initial 1.6 × 104– 3.3×104 CFU/g (post-treatment residual load) to about 107 
CFU/g in just 7 days. 
Based on the Cold Storage Chart of the FDA [356], the quality of such oysters 
can be maintained for a longer period of time (~ up to 3 – 6 months) provided they are 
stored at ~ −17 °C. We were able to verify that such long term storage does not affect 
the quality of oysters. In fact treated and untreated oysters used for our sensory study 
were stored at ~ −17 °C before analysis.  
The scCO2 approach stands out in this regard because the release of adductor 
muscles from oysters can be monitored. Oysters in this case were treated under two 
conditions, one that can be considered as mild (100 bar, 30 min and 37 °C) and another 
that can be considered harsher (172 bar, 60min and 60 °C). Contrary to what was 
observed at milder conditions (100 bar, 30 min and 37 °C), treating oysters at 172 bar 
for 60 min at 60 °C, caused a release of adductor muscles from the shell. Oysters 
exposed to the milder condition however did not release their adductor muscles and 
retained their fresh-like appearance closely resembling the untreated ones (Figure 6-5). 
On the other hand, the oysters treated at 172 bar, for 60 min at 60 °C though still watery 
appeared slightly cooked or steamed—certainly a direct consequence of the high 
temperature. This effect was most pronounced in another group of oysters treated at 
this same condition and left in the scCO2 unit afterwards for about 45 min; this set of 
oysters was excluded from our analysis. 
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After processing, oysters that remain alive are undoubtedly a better alternative. 
This is, for instance, the major selling point of several emerging PHP techniques, 
namely those using X-ray and gamma irradiation as cold pasteurizing agents [357]. X-
ray and gamma irradiation are believed to exert their bactericidal effect by damaging the 
bacterial DNA. Because of the high probability that oysters' DNA could sustain the same 
damage, concerns have been raised concerning the shelf life of X-ray and gamma 
irradiation-treated oysters. As mentioned previously, treating oysters at 100 bar for 30 
min at 37 °C did not release the adductor muscles. We have good reasons to believe 
that oysters can survive mild scCO2 treatments, such as 100 bar for 30 min at 37 °C. 
During trial experiments, a few oysters treated under similar pressure and temperature 
conditions for 40 min (Figure 6-5) and afterwards put in a flask filled with water were 
actually able to open and close their shells (on contact with a hard object) for several 
days. This was a clear indication that they had survived the treatment. The ability of 
individual oyster to survive such high pressure and CO2 concentration varies with 
individual health. The LD50 of scCO2 on oysters will be addressed in future studies. 
The sensory experiments revealed that oysters treated at milder conditions retain 
their acceptability. It is important to note that of all the groups of oysters included in this 
analysis, none received a perfect score of 6 (not even the group of untreated oysters). 
Two oysters from this group were graded as “spoiled.” Because of current facility 
limitations, the only feature used to decide whether any given oyster is alive or healthy 
(thus qualifying for inclusion into the study) is whether or not their shell is tightly closed. 
While it is true that this feature is shared by live oysters when brought out of the water, it 
is also true that some oysters, unhealthy or even dead, could share this feature. This 
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constitutes a source of bias and explains why two spoiled oysters were found in the 
group of untreated oysters. This justifies why, as stated above, at this point, it is difficult 
to clearly assess the LD50 of scCO2 on oysters. Another difficulty and possibly a source 
of bias, especially when it comes to sensory analysis studies, is the way our scCO2 unit 
is built; this instrument was designed for scCO2 extraction; the lack of uniformity in the 
treatment chamber could result in some oysters being overexposed. 
Although the exact mechanism of the bactericidal action of CO2 is still unknown, 
it has been proposed that the bacterial inactivation might occur as a result of 
acidification of the medium or product being sterilized. This acidification occurs as a 
result of CO2 interaction with water, an interaction which ultimately results in the 
generation of H2CO3. H2CO3 exists in equilibrium with HCO3- this equilibrium is 
responsible for the release of protons in the bacterial environment, thus decreasing pH. 
.
  ([353]) 
Low pH can then induce structural changes in the membrane of bacterial cells. 
These changes, in turn, will increase the permeability of the membrane to CO2, which 
then can freely diffuse and accumulate in the bacterial cell, interfering with the normal 
metabolism of these living cells and ultimately resulting in the death of the bacteria [347, 
353]. There have been several other proposed mechanisms of bacterial inactivation by 
scCO2, such as removal of vital constituent from cell membrane, induction of 
intracellular electrolytes imbalance, and direct effect of CO2 on bacterial metabolism, 
among others [345, 346].  
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In conclusion, the scCO2 based approach to warm pasteurization of oysters is a 
promising PHP technique. In the present document, it is established that scCO2 is as 
effective as several current FDA approved standard approaches to PHP of oysters (e.g., 
HHP and QF) aimed at reducing the microbial load (aerobic flora) present in the GI 
system of oysters. We believe that the scCO2 approach will also be as effective in 
reducing the load of most problematic oysters-associated bacteria, namely, V. 
parahaemolyticus and V. vulnificus. The bacteria used as a model for Vibrio sp., namely 
V. fischeri showed an extremely high sensitivity to scCO2 and bacterial isolates cultured 
from oysters' tissues and sharing common biochemical characteristics of V. 
parahaemolyticus and V. vulnificus showed an extremely high sensitivity to scCO2, as 
well. 
As a PHP approach, the scCO2 based approach provides quite a number of 
advantages over other emerging oyster PHP technologies. Large scale scCO2 based 
technologies for food processing are already available commercially and used 
industrially for processes such as coffee decaffeination. This represents a serious 
advantage over gamma and/or X-ray based PHP techniques. The use of scCO2 in food 
industry is well-established and safe; it can thus be predicted that acceptance by the 
public will be easier. We have also completed a sensory analysis, and no significant 
change was noted as a result of oysters having been treated with scCO2.  
Finally, as mentioned in the introduction, microbial contaminants are not the only 
health hazard associated with oysters. Other risks include biotoxins, toxic metal, and 
chemical environmental contaminants. None of the currently proposed PHP treatments 
(e.g., HHP, IQF, HCP, X-ray based approach, and gamma-based approach) can reduce 
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the load of toxic metal, biotoxins, and chemical environmental contaminants in oysters. 
Though it is beyond the scope of this paper, it is important to note that the ability of 
scCO2 to remove such contaminants from various biological substrates is well-
established [358, 359] 
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